gemcitabine has been researched along with Carcinoma, Ductal, Pancreatic in 790 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 48 (6.08) | 29.6817 |
| 2010's | 504 (63.80) | 24.3611 |
| 2020's | 238 (30.13) | 2.80 |
| Authors | Studies |
|---|---|
| Kuang, Y; Ljungman, M; Neamati, N; Nurra, S; Sechi, M | 1 |
| Ahmed, AA; Andrade, ACG; Balasubramanian, S; Besser, RJ; Di Vita, G; Diocou, S; Evans, TRJ; Gunaratnam, M; Haider, SM; Laughlin-Toth, S; Marchetti, C; Marsico, G; Morton, JP; Neidle, S; Ohnmacht, SA; Pazitna, I; Pedley, RB; Pike, JA; Robson, M; Tannahill, D; Vo, T; Wilson, WD; Zyner, KG | 1 |
| Bai, C; Chen, J; Chen, Y; Chong, C; Ding, Y; Gao, Y; Geng, Y; Li, J; Wang, M; Wu, L; Yu, J; Zhang, Q | 1 |
| Bergonzini, C; Carbone, D; Cascioferro, S; Cirrincione, G; Dekker, H; Diana, P; Funel, N; Geerke, D; Giovannetti, E; Mantini, G; Parrino, B; Peters, GJ; Petri, GL | 1 |
| Che, Q; Li, D; Li, J; Liu, X; Shah, M; Sun, C; Sun, N; Zhang, G; Zhang, X; Zhu, T | 1 |
| Fan, G; Hu, Q; Ji, S; Liu, M; Liu, W; Qin, Y; Xu, W; Xu, X; Ye, Z; Yu, X; Zhang, Z; Zhuo, Q | 1 |
| Chen, C; Cui, F; Lin, K; Peng, L; Sun, L; Yao, Y; Yu, Q; Zhang, Y; Zhuang, L | 1 |
| Jensen, E; Nalluri, H; Staley, C | 1 |
| Hua, J; Liang, C; Liu, J; Meng, Q; Shi, S; Tan, Z; Wang, W; Xu, J; Yang, J; Yu, X; Zhang, B | 1 |
| Ding, L; Hang, Y; Oupický, D; Sil, D; Tang, S; Tang, W; Xie, Y; Yu, A; Zhang, C | 1 |
| Fujii, T; Gyoten, K; Hayasaki, A; Iizawa, Y; Isaji, S; Kishiwada, M; Komatsubara, H; Kuriyama, N; Maeda, K; Mizuno, S; Murata, Y; Nakagawa, Y; Noguchi, D; Sakurai, H; Shinkai, T; Tanemura, A | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Chen, Q; Gao, G; Go, VLW; Guo, J; Li, K; Li, N; Liu, J; Pan, Y; Tao, X; Xiao, GG; Zhao, Y | 1 |
| Barrera, LN; Brumskill, S; Calcraft, P; Costello, E; Phillips, C | 1 |
| Besselink, MG; Bonsing, BA; Bouwense, SAW; de Jong, EJM; de Meijer, VE; de Vos-Geelen, J; Geurts, SME; Homs, MYV; Janssen, QP; Koerkamp, BG; Simons, TFA; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; van der Geest, LG; van Laarhoven, HWM; Wilmink, JW | 1 |
| Andrén, PE; Atkinson, J; Barnes, J; Barry, ST; Brais, R; Bunch, J; Dunlop, CR; Goodwin, RJA; Gopinathan, A; Hamm, G; Jodrell, DI; Johnson, TI; Kaistha, BP; Lau, A; Ling, S; Maglennon, G; Nilsson, A; Race, AM; Richards, FM; Sansom, OJ; Serra, MP; Smith, A; Strittmatter, N; Sutton, D; Takats, Z; Wallez, Y; Wilson, J; Wong, E | 1 |
| Bates, SE; Hur, C; Ingram, MA; Kastrinos, F; Kong, CY; Lauren, BN; Lim, F; Manji, GA; Park, J; Pumpalova, Y | 1 |
| Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H | 1 |
| Alemany, R; Álvarez, R; Bazan-Peregrino, M; Blasco, C; Blasi, E; Capella, G; Cascallo, M; Garcia-Carbonero, R; Gimenez-Alejandre, M; Ginestà, MM; Gornals, JB; Hidalgo, M; Laquente, B; Maliandi, MV; Mato-Berciano, A; Moreno, R; Morgado, S; Perea, S; Perez-Carreras, M; Prados, S; Riesco, MC; Rodríguez-García, A; Salazar, R | 1 |
| Carson, JA; Chaib, M; Glazer, ES; Hayes, DN; Kansal, R; Makowski, L; Morrrison, M; Rana, M; Shibata, D; Stanfill, AG; Teng, B | 1 |
| Cutillas, PR; de Luxán-Delgado, B; Dormann, C; Drake, RJG; Géraud, C; Gómez-Escudero, J; Hodivala-Dilke, K; Maiques, O; Meng, YM; Newport, E; Rajeeve, V; Reynolds, LE; Richards, FM; Roy-Luzarraga, M; Sanz-Moreno, V; Saur, D; Vermeulen, PB; Weller, C; Wisniewski, L; Wong, PP | 1 |
| Kawano, R; Kondo, N; Murakami, Y; Okada, K; Otsuka, H; Seo, S; Sumiyoshi, T; Takahashi, S; Uemura, K | 1 |
| Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Kang, FP; Liao, CY; Lin, CF; Tian, YF; Wang, ZW | 1 |
| Du, H; Epps, J; Johnson, S; Karki, K; Safe, S; Shrestha, R; Suva, L; Vaziri-Gohar, A; Yu, Z; Zarei, M | 1 |
| Boeck, S; Engel, J; Gil, L; Guenther, M; Heinemann, V; Mayerle, J; Ormanns, S; Palm, MA; Surendran, SA; von Bergwelt-Baildon, M; Werner, J | 1 |
| Andolfo, A; Latiano, TP; Orsenigo, F; Panebianco, C; Pazienza, V; Perri, F; Pisati, F; Potenza, A; Terracciano, F; Tripodo, C; Ulaszewska, M; Villani, A | 1 |
| Chen, Y; Liu, M; Lu, P; Niu, N; Shen, X; Shi, J; Sun, Y; Tang, Y; Xu, D; Xue, J; Yang, X; Yao, H | 1 |
| Chen, G; Liu, Y; Qiu, J; Su, D; Tao, J; Yang, G; You, L; Zhang, T; Zhao, F; Zhao, Y; Zheng, L | 1 |
| Chen, T; Geng, Y; Gu, Y; Li, Y; Liu, K; Sun, L; Wang, L; Wu, S; Xu, F; Xu, H; Zhao, Z; Zou, M | 1 |
| Ananda, S; Burge, M; Chee, CE; Clarke, K; Cooray, P; Fox, A; Gibbs, P; Harris, M; Knowles, B; Lee, B; Lipton, L; Mclachlan, SA; Nagrial, A; Nikfarjam, M; Pattison, S; Shapiro, J; Tebbutt, N; Thomson, B; Usatoff, V; Walpole, I; Wong, R; Zielinski, R | 1 |
| Elia, A; Kraev, I; Miralles, F; Rashid, S; Rimmer, E | 1 |
| Fujii, K; Fujiwara-Tani, R; Kishi, S; Kuniyasu, H; Mori, S; Nishiguchi, Y; Ohmori, H; Sasaki, T; Takagi, T | 1 |
| Hattori, N; Hayashi, M; Inokawa, Y; Kanda, M; Kodera, Y; Kurimoto, K; Nakayama, G; Otsu, T; Shimizu, D; Takami, H; Tanaka, C; Tanaka, H; Tanaka, N | 1 |
| Chang, A; Gao, S; Ge, Y; Hao, J; Huang, C; Li, H; Liu, J; Sun, H; Wang, X; Wang, Y; Wu, L; Xu, C; Yuan, Y; Zhao, T | 1 |
| Chang, JS; Chen, HA; Chiu, CF; Hsu, TW; Lin, CY; Park, JM; Peng, JM; Saengboonmee, C; Shan, YS; Shen, YS; Su, YH | 1 |
| Hou, X; Li, JH; Li, SJ; Li, YX; Ni, X; Wu, X; Yin, XY; Zhao, W; Zhu, XX | 1 |
| Artru, P; Assenat, E; Bauguion, L; Ben Abdelghani, M; Biagi, JJ; Bouché, O; Castan, F; Conroy, T; Evesque, L; Hammel, P; Lambert, A; Lecomte, T; Lopez, A; Mitry, E; Monard, L; Turpin, A; Wei, AC; Ychou, M | 1 |
| Algül, H; Braren, RF; Crone, B; Harder, FN; Heid, I; Jungmann, F; Kaissis, G; Karst, U; Liotta, L; Lohöfer, F; Makowski, MR; Mayer, M; Siveke, JT; Steiger, K; Topping, GJ; Trajkovic-Arsic, M; Weichert, W; Wildgruber, M; Yen, HY | 1 |
| Chang, Q; Chen, Q; Huang, X; Jiang, H; Li, K; Li, R; Liu, G; Liu, X; Shi, P; Tu, Q; Xu, G; Yao, X; Zhao, B; Zhu, H | 1 |
| Cao, R; Chen, H; Li, L; Li, R; Li, Y; Liu, X; Shao, R; Shi, Y; Song, W; Wang, J; Yao, H; Ye, C; Zhang, L; Zhou, X | 1 |
| Jiang, Y; Sohal, DPS | 1 |
| Chiao, PJ; Fu, J; Furukawa, K; Ling, J; Lu, YU; Marukuchi, R; Sun, Y | 1 |
| Deng, J; Du, J; Fu, D; Gu, J; Guo, Y; Hu, X; Kong, L; Li, J; Tao, B; Ying, T | 1 |
| Bai, C; Cheng, Y; Dai, M; Guo, J; Lu, J; Qiao, C; Tang, H; Wang, Y; Zhang, T | 1 |
| Chen, S; Cortez, NE; Hong, BV; Hwang, CI; Mackenzie, GG; Matsukuma, K; Müller, M; Pontifex, MG; Ramsey, JJ; Rodriguez Lanzi, C; Vahmani, P; Vauzour, D; Wang, F; Xu, J | 1 |
| Huang, CS; Lai, JM; Liu, Q; Liu, ZD; Shi, YH; Su, Q; Wang, JQ; Wang, XY; Xu, QC; Xu, X; Yin, XY; Zhao, GY; Zhu, YQ | 1 |
| Chen, Y; Lin, L; Lin, X; Ou, G; Pan, L; Su, M; Tan, Y; Tian, Z | 1 |
| Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A | 1 |
| Azizian, A; Cawley, H; Gaedcke, J; Ghadimi, BM; Hanna, N; Hussain, SP; Lal, T; Ohara, Y; Rupin, E; Sinha, S; Ströbel, P; Tang, W; Valenzuela, P; Wang, L; Yang, S; Zhang, L | 1 |
| Fujiwara, T; Fushimi, T; Kagawa, S; Kajiwara, Y; Kanaya, N; Kikuchi, S; Kuroda, S; Noma, K; Ohara, T; Tazawa, H; Umeda, Y; Urata, Y; Yamada, M; Yoshida, R | 1 |
| Banavath, HN; Gupta, S; Tejavath, KK | 1 |
| Balconi, F; Berardi, R; Cimbro, E; Donisi, C; Giampieri, R; Lai, E; Lupi, A; Murgia, S; Pecci, F; Persano, M; Pozzari, M; Pretta, A; Pusceddu, V; Puzzoni, M; Scartozzi, M; Spanu, D; Ziranu, P | 1 |
| Chang, A; Chen, Y; Feng, Y; Hao, J; Huang, C; Huang, Z; Li, MJ; Li, S; Li, X; Liu, W; Qi, L; Shi, L; Tang, B; Wang, Z; Wu, C; Xie, P; Yu, X; Yuan, Y | 1 |
| Amir, SS; Behrens, A; Khan, OM; Kohil, A | 1 |
| Beutel, AK; Halbrook, CJ | 1 |
| Betts, C; Bridge, M; Chen, B; Cheung, A; Coussens, LM; Crocker, M; Dragomanovich, H; Fahlman, A; Fong, L; Griffith, MJ; Lerner, K; Liu, E; Lopez, CD; Marquez, J; Pener, D; Rajagopalan, B; Sinha, M; Sivagnanam, S; Solman, I; Stultz, J; Sudduth-Klinger, J; Taber, E; Tamaki, W; Tempero, M; Todd, K; Vaccaro, G; Vo, J; Ware, C; Zhang, L | 1 |
| Ahn, E; Ahn, T; Bang, S; Choi, J; Han, JM; Hwang, GS; Kim, K; Kim, Y; Lee, HS; Luo, E; Min, DS; Park, SJ; Sung, Y; Yoo, HC; Yu, YC | 1 |
| Arlen, P; Basu Mallick, A; Beg, MS; Cleary, JM; Horick, NK; Hosein, PJ; Huffman, BM; Lacy, J; Manz, C; Mavroukakis, S; Morse, MA; Murphy, JE; Sanoff, H; Schlechter, BL; Wang-Gillam, A; Wolpin, BM; Zaki, A | 1 |
| Hu, Q; Huang, Y; Li, B; Liang, T; Ping, Y; Shao, S; Tang, H; Wang, M; Yao, Z; Zhang, F | 1 |
| Araujo, R; Dallaston, M; Jenner, AL; Kelly, W; Kim, PS; Parfitt, I; Pooladvand, P; Steinitz, D; Vine, KL; Wade, SJ | 1 |
| Aprile, G; Bergamo, F; Bernardini, I; Bozzarelli, S; Cardellino, GG; Cavanna, L; Cordio, S; De Simone, I; Di Marco, MC; Ghidini, M; Giommoni, E; Macchini, M; Maiello, E; Milella, M; Orsi, G; Pinto, C; Porcu, L; Reni, M; Rulli, E; Spada, M; Torri, V | 1 |
| Huang, X; Jin, C; Li, H; Wang, W; Yang, C; Yu, X | 1 |
| Amano, H; Dash, S; Honda, M; Kawazu, M; Komuro, A; Okada, H; Ueda, T | 1 |
| Hasegawa, R; Imaizumi, H; Ishizaki, A; Ishizaki, J; Iwai, T; Kaneko, T; Kida, M; Kurosu, T; Kusano, C; Okuwaki, K; Watanabe, M; Yamauchi, H | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Marukawa, D; Noda, T; Sasaki, K; Takahashi, H; Tanemura, M; Tomimaru, Y; Yamada, D | 1 |
| Bolm, L; Braun, R; Busch, H; Castven, D; Drenckhan, M; Färber, B; Gorantla, SP; Hael, AAM; Honselmann, KC; Keck, T; Konukiewitz, B; Künstner, A; Lapshyna, O; Marquardt, JU; Spielmann, M; Ungefroren, H; Watzelt, J; Wellner, UF | 1 |
| Alemanno, F; Barra, A; Cavo, M; D'Amone, E; Del Mercato, LL; Delle Cave, D; Fachechi, A; Gigli, G; Lonardo, E; Rizzo, R | 1 |
| Chen, Y; Huang, K; Xia, C; Xu, D; Yang, F; Yang, H | 1 |
| Aronson, A; Cohen, DJ; Fulop, DJ; Labiner, AJ; Lucas, AL; Sigel, KM; Wisnivesky, J; Wu, YL; Zylberberg, HM | 1 |
| Furuya, N; Hamada, T; Ito, T; Kato, N; Kido, M; Kohno, H; Kouno, H; Kuraoka, K; Kusunoki, R; Kuwai, T; Mizumoto, T; Sugata, S; Tamaru, Y; Yamaguchi, A | 1 |
| Hu, Q; Huang, J; Liang, T; Shao, S; Wang, M; Yao, Z; Zhang, F; Zhao, X | 1 |
| Guo, Z; Huang, Y; Lai, S; Li, T; Lin, C; Wang, Y; Weng, S; Zhang, X | 1 |
| Bai, Y; Dal, E; Li, K; Li, X; Lin, R; Liu, N; Liu, Z; Qi, R; Shi, B; Wang, H; Wang, X; Wang, Y; Xu, Y | 1 |
| Bhambhvani, H; Collisson, EA; Fountzilas, C; Hendifar, A; Johansen, JS; Joshi, A; Krishna, V; Makawita, S; Mehta, A; Musher, B; Nimgaonkar, V; Rajpurkar, P; Singhi, A; Smith, K; Sohal, D; Tiu, E; Vrabac, D; Wainberg, Z | 1 |
| Brender, JR; Chandramouli, GVR; Devasahayam, N; Kishimoto, S; Krishna, MC; Mitchell, JB; Otowa, Y; Saida, Y; Yamamoto, K; Yamashita, K | 1 |
| Bresalier, RS; Hafley, MA; Liu, Y; Lorenzi, PL; Tan, L; Wang, L; Wei, D; Yang, P; Zuo, X | 1 |
| Fujisawa, T; Fukuma, T; Fukumura, Y; Isayama, H; Ishii, S; Ito, K; Nagahara, A; Suzuki, A; Takahashi, S; Takasaki, Y; Tomishima, K; Ushio, M; Yao, T | 1 |
| Cho, YJ; Han, BS; Hong, SS; Jung, KH; Kim, DK; Kim, SE; Ko, S; Lee, JE; Lee, P; Lee, YJ; Lim, JH; Park, MS; Ryu, JK; Shim, S; Yoon, YC | 1 |
| Bhawal, UK; Fujiwara-Tani, R; Ikemoto, A; Kishi, S; Kuniyasu, H; Luo, Y; Mori, S; Nishiguchi, Y; Ogata, R; Ohmori, H; Sasaki, R; Sasaki, T; Sho, M; Takagi, T | 1 |
| Baba, H; Inoue, Y; Ito, H; Kitano, Y; Oba, A; Ono, Y; Ozaka, M; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Takeda, T | 1 |
| Boeck, S; Engel, J; Guenther, M; Haas, M; Heinemann, V; Ormanns, S; Surendran, SA; von Bergwelt-Baildon, M; Werner, J | 1 |
| Bai, W; Chang, A; Fu, D; Gao, S; Hao, J; Hou, X; Huang, C; Jiang, W; Li, X; Liu, J; Liu, Z; Man, Q; Sun, H; Sun, J; Wang, H; Wang, X; Wang, Y; Xie, Y; Yan, J; Yang, S; Zhang, X; Zhang, Z; Zhao, T; Zhou, T | 1 |
| Bhoopathi, P; Das, SK; Emdad, L; Fisher, PB; Mannangatti, P | 1 |
| Cooper, SJ; Gordon, ER; James, M; Wright, CA | 1 |
| Bajwa, A; Bisunke, B; Fang, J; Glazer, ES; Kansal, RG; Rana, M; Shibata, D; Yang, J | 1 |
| Beaman, C; Hurtado de Mendoza, T; Ishfaq, M; Joshi, S; Lowy, AM; Madheswaran, S; Park, IH; Patel, J; Pham, TV; Rohila, D; Sun, S; Tamayo, P; Tapia, E; Weitz, J | 1 |
| Niu, J; Qian, S; Qu, J; Shen, S; Straubinger, RM; Wang, X | 1 |
| Beebe, J; Dong, Z; Hao, Y; He, Z; Huang, C; Liu, H; Liu, JY; Liu, Y; Qin, L; Subramaniyan, B; Zhang, JT | 1 |
| Bai, R; Chen, R; Chen, Z; Deng, S; He, X; Huang, X; Li, M; Li, R; Lin, D; Liu, J; Liu, S; Su, J; Xu, Z; Xue, C; Zeng, L; Zhang, J; Zhang, S; Zhao, H; Zhao, S; Zheng, J; Zhou, Q; Zhou, Y; Zhuang, L | 1 |
| Chang, A; Ding, J; Feng, Y; Fu, D; Gao, C; Gao, S; Hao, J; Huang, C; Liu, J; Liu, Y; Ma, X; Ma, Y; Tang, B; Wang, H; Wang, X; Yan, J; Yang, S; Zhang, Z; Zhao, R; Zhao, T | 1 |
| Doi, M; Endo, M; Furuya, K; Hasegawa, N; Hashimoto, S; Hoshiai, S; Kobayashi, M; Makishima, H; Mathis, BJ; Miyazaki, Y; Mizumoto, M; Mori, K; Moriwaki, T; Nakai, K; Nakajima, T; Niisato, Y; Numajiri, H; Oda, T; Saida, T; Saito, T; Sakurai, H; Shimomura, O; Takahashi, K; Tsuchiya, K; Yamada, T; Yamamoto, Y | 1 |
| Agirman, F; Arsenijevic, T; Azurmendi Senar, O; Bellahcène, A; Crake, R; D'Haene, N; Dehaye, J; Gasmi, I; Koopmansch, B; Lambert, F; Lardinois, F; Maloujahmoum, N; Peiffer, R; Peulen, O; Van Laethem, JL | 1 |
| Baar, K; Chen, S; Cortez, NE; Crone, R; Gomes, AV; Hong, BV; Mackenzie, GG; Pathak, S; Rodriguez Lanzi, C; Sule, R; Wang, F | 1 |
| Anttila, M; Arias, V; Basnet, S; Cervera-Carrascon, V; Clubb, JHA; Grönberg-Vähä-Koskela, S; Havunen, R; Haybout, L; Heiniö, C; Hemminki, A; Jirovec, E; Kudling, TV; Pakola, S; Quixabeira, DCA; Santos, JM | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Nishi, H; Noda, T; Sasaki, K; Takahashi, H; Tanemura, M; Tomimaru, Y; Yamada, D | 1 |
| Hu, H; Ma, Y; Xiong, S; Zhu, C; Zhu, D | 1 |
| Besselink, MG; Busch, OR; Doppenberg, D; Farina, A; Kazemier, G; Mebius, RE; Meijer, LL; van Ee, T; van Kooyk, Y; Versteijne, E; Wilmink, JW; Zwart, ES | 1 |
| Alves, F; Feldmann, C; Ischyropoulou, M; Napp, J; Niemeyer, CM; Sabljo, K; Schneider, L | 1 |
| Nagaraju, GP; Natu, J | 1 |
| Bartkeviciene, A; Dambrauskas, Z; Gulbinas, A; Jasukaitiene, A; Jaudzems, K; Maimets, T; Matthews, J; Stukas, D; Teino, I | 1 |
| Cao, P; Chang, A; Feng, Y; Guo, W; Hao, J; Li, H; Li, S; Liu, W; She, C; Wang, X; Wu, C; Xie, Y; Xu, C; Yang, Y | 1 |
| Hayashi, H; Kubota, K; Masuo, H; Miyazaki, S; Notake, T; Sakai, H; Shimizu, A; Soejima, Y; Yoshizawa, T | 1 |
| Characiejus, D; Janiulioniene, A; Jasiunaite, E; Matuzeviciene, R; Radzevicius, M; Sileikis, A; Tulyte, S; Zvirblis, T | 1 |
| Dai, C; Gong, T; Guo, Y; Huang, Y; Pan, H; Wu, D; Yan, J; Yang, Y; Zhao, Y; Zhu, S | 1 |
| Bouchekioua-Bouzaghou, K; Chen, J; Griera, JB; Jiang, X; Kong, X; Meng, YM; Qin, H; Wang, M; Wong, PP; Xu, Q | 1 |
| Chen, Q; He, J; Liu, L; Lou, W; Pu, N; Shi, C; Wang, W; Wu, W; Xie, Y; Xu, H; Yin, H; Yu, J; Zhang, L | 1 |
| Chen, X; Liu, X; Liu, Z; Lu, J; Song, W; Yang, Y | 1 |
| Fang, S; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, MJ; Lee, BE; Lee, DE; Lee, KJ; Lee, YS; Park, JS; Yoo, J | 1 |
| Dutta, M; Kar, S; Minz, AP; Mishra, S; Mohapatra, AP; Mohapatra, D; Parida, D; Sasmal, PK; Senapati, S; Sethi, M | 1 |
| Baines, AT; Bialkowska, AB; Graves, LM; Ingle, K; LaComb, JF | 1 |
| Chen, H; Gan, L; Han, L; Jiang, L; Jiang, Y; Lin, X; Shen, B; Shi, M; Wang, T; Wu, Z; Xiong, C; Xue, M; Zhu, Y | 1 |
| Agostini, A; Alfieri, S; Arena, S; Bizzozero, L; Bria, E; Caggiano, A; Carbone, C; Corbo, V; De Sanctis, F; Esposito, A; Guerriero, I; Larghi, A; Lucchetti, D; Musella, M; Piro, G; Priori, L; Quero, G; Rizzatti, G; Roberto, L; Scaglione, G; Sgambato, A; Sistigu, A; Tortora, G; Ugel, S | 1 |
| Feng, X; Gong, S; Guo, J; Ma, X; Ren, Z; Wu, N; Xu, L; Zhang, C; Zhang, P; Zhang, X; Zhang, Y; Zhao, M | 1 |
| Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y | 1 |
| Cao, Z; Feng, M; Liu, Y; Luan, J; Luo, W; Qiu, J; Yang, G; You, L; Zhang, T; Zhang, Y; Zhao, F; Zhao, Y; Zheng, L | 1 |
| Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H | 1 |
| Dalin, S; Fenoglio, S; Grauman-Boss, B; Hemann, MT; Kreidl, E; Lau, AN; Lauffenburger, DA; Lees, JA; Luengo, A; Mueller, HS; Sullivan, MR; Vander Heiden, MG | 1 |
| Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A | 1 |
| Bansal, R; Bijlsma, MF; De Geus, SWL; Kuninty, PR; Kuppen, PJK; Mardhian, DF; Metselaar, JM; Östman, A; Prakash, J; Schnittert, J; Sier, CFM; Storm, G; Vahrmeijer, AL; van Baarlen, J; van Laarhoven, HW | 1 |
| Iyikesici, MS | 1 |
| Alekhina, O; Billadeau, DD; Ding, L; Dube, J; Dutta, SK; Giles, FJ; Kiers, S; Kozikowski, AP; Madamsetty, VS; Mazar, AP; Mukhopadhyay, D; Schmitt, DM; Ugolkov, A; Wang, E; Zhang, JS; Zhang, Y | 1 |
| Haan, L; Hankemeier, T; Joore, J; Kramer, B; Lanz, HL; Olivier, T; Vermeer, M; Vulto, P | 1 |
| Cardoso, ACF; Florez Bedoya, CA; Fogelman, D; Katz, MHG; Kim, MP; Ngo-Huang, A; Park, M; Parker, N; Petzel, MQ; Romero, SG; Schadler, KL; Wang, H | 1 |
| Berkenstam, A; Dai, B; DiLorenzo, S; Fleming, J; Hases, L; Ibrahim, A; Jafferali, MH; Jose Augustine, J; Kang, Y; Kim, M; Lin, CY; Mesmar, F; Wang, J; Williams, C; Zhao, Y | 1 |
| Chen, HY; Chou, CJ; Hsieh, YY; Lee, KH; Liu, TP; Yang, PM | 1 |
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Chen, ZM; Huang, H; Ji, B; Jiang, CX; Mukaida, N; Song, Y; Yao, NH | 1 |
| Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Chen, J; Chen, ZH; Huang, JL; Ma, XK; Wei, L; Wen, JY; Wu, DH | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Kubo, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y | 1 |
| Boeck, S; Crispin, A; D'Haese, JG; Gebauer, L; Haas, M; Heinemann, V; Ilmer, M; Kirchner, T; Kobold, S; Kruger, S; Kunz, WG; Mayerle, J; Ormanns, S; Ricke, J; Schirle, K; Schirra, J; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Eguchi, H; Kubo, M | 1 |
| Ahmad, S; Hasan, B; Hussain, I; Jain, AG; Jehanzeb, S; Khan, AK; Khetpal, N; Rahman, AU; Rashid, MU; Sarvepalli, D; Ullah, W | 1 |
| Hashimoto, M; Hikichi, T; Irie, H; Konno, N; Nakamura, J; Ohira, H; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T | 1 |
| Chikhladze, S; Fichtner-Feigl, S; Kousoulas, L; Lederer, AK; Reinmuth, M; Sick, O; Wittel, UA | 1 |
| Fu, CX; Li, HM; Liu, W; Peng, WJ; Tang, W; Wang, QF; Wang, XH; Zhou, LP | 1 |
| Asch, D; Beatty, GL; Domchek, SM; Nathanson, KL; O'Dwyer, PJ; Reiss, KA; Rosen, MA; Siegelman, ES; Wattenberg, MM; Yu, S | 1 |
| El Hassouni, B; Giovannetti, E; Immordino, B; Mantini, G; Peters, GJ | 1 |
| Abou Ali, E; Batteux, F; Bordacahar, B; Camus, M; Chouzenoux, S; Jeljeli, M; Lafon, C; Leenhardt, R; Mestas, JL; Nicco, C; Prat, F | 1 |
| Akita, H; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Mori, M; Nagano, H; Noda, T; Tomimaru, Y | 1 |
| Caffrey, TC; Clement, EJ; Cook, LM; Costanzo-Garvey, D; DiMaio, DJ; Fisher, KW; Grandgenett, PM; Grem, JL; Hollingsworth, MA; Krieger, KL; Lagundžin, D; Law, HC; Qiao, F; Wagner, ZS; Woods, NT; Yu, F | 1 |
| Brunetti, O; Silvestris, N | 1 |
| Anders, R; Batukbhai, B; Begum, A; De Jesus-Acosta, A; de Wilde, RF; Laheru, DA; Maitra, A; McAllister, F; O'Dwyer, PJ; Rajeshkumar, NV; Ramanathan, RK; Rasheed, Z; Sahin, I; Sugar, EA; Von Hoff, DD; Yabuuchi, S; Zheng, L | 1 |
| Blanco, A; Li, J; Norgard, RJ; Stanger, BZ; Yamazoe, T; Yan, F; Yuan, S | 1 |
| Bjånes, TK; Cros-Perrial, E; Jordheim, LP; Kamceva, T; Kotopoulis, S; Langer, A; McCormack, E; Riedel, B; Ruiz de Garibay, G; Schjøtt, J | 1 |
| Chen, X; Li, T; Wan, J; Wang, H; Wang, Y; Wu, L; Zhang, F | 1 |
| Adiseshaiah, PP; Burgan, W; Goswami, D; Guerin, TM; Kozlov, SV; McCormick, F; Mukhopadhyay, S; Nissley, DV; Yi, M | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Caprioli, R; Dai, X; Dosch, AR; Kashikar, N; Kwon, D; Mehra, S; Merchant, NB; Nagathihalli, NS; Reyzer, ML; Srinivasan, S; Willobee, BA | 1 |
| Jia, Y; Liu, B; Ma, J; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xue, L; Yin, X | 1 |
| Besselink, MG; Creemers, GJ; de Groot, JWB; de Vos-Geelen, J; Haj Mohammad, N; Homs, MYV; Latenstein, AEJ; Mackay, TM; Molenaar, IQ; Ten Tije, BJ; van der Geest, LGM; van Eijck, CHJ; van Laarhoven, HWM; Wilmink, JW | 1 |
| Chen, X; Gao, M; Han, H; Hou, Y; Ji, J; Jin, Q; Kang, M; Zhang, P | 1 |
| Gibbs, SL; King, D; Solanki, A; Thibault, G; Wang, L | 1 |
| Akkermans-Vogelaar, JM; Besselink, MG; Bonsing, BA; Buijsen, J; Busch, OR; Creemers, GM; de Groot, JWB; de Hingh, IH; de Vos-Geelen, J; Eskens, FALM; Festen, S; Groot Koerkamp, B; Groothuis, K; Homs, MYV; Kerver, ED; Luelmo, SAC; Neelis, KJ; Nuyttens, J; Paardekooper, GMRM; Patijn, GA; Punt, CJ; Suker, M; van Dam, RM; van der Sangen, MJC; van Eijck, CH; van Hooft, JE; van Tienhoven, G; Versteijne, E; Wilmink, JW; Zwinderman, AH | 1 |
| Drexler, R; Feyerabend, B; Kleine, M; Küchler, M; Oldhafer, KJ; Wagner, KC | 1 |
| D'Haese, JG; Maisonneuve, P; Miksch, RC; Weniger, M; Werner, J | 1 |
| Antico, G; Blauer-Petersen, C; Doleh, Y; Lal, LS; Pishvaian, M | 1 |
| Gao, S; Hao, J; Huang, C; Jin, F; Liu, J; Wang, H; Wang, X; Xiao, D; Yang, S; Zhao, T | 1 |
| Dorman, MJ; Fishel, ML; Grippo, PJ; Hwang, RF; Kamath, SD; Kumar, S; Munshi, HG; Narbutis, M; Park, A; Principe, DR; Rana, A; Thummuri, D; Trevino, JG; Underwood, PW; Viswakarma, N | 1 |
| Damarla, V; Dobrosotskaya, I; Khan, G; Kwon, D; Li, J; Raoufi, M; Seixas, T; Siddiqui, F; Thanikachalam, K; Winters, K; Wollner, I | 1 |
| Chiba, M; Honma, S; Imazu, H; Ito, M; Shimamoto, N; Sumiyama, K | 1 |
| Kimura, S; Kurioka, Y; Matsumoto, T; Matsuo, Y; Miura, K; Morishita, H; Okazaki, U; Takagi, S; Takatani, M; Tsuduki, T | 1 |
| Cui, M; Dai, M; Gao, J; Guo, J; Kleeff, J; Li, T; Li, Y; Liao, Q; Liu, J; Liu, Q; Lu, Z; Pan, B; Wang, W; Wu, H; Wu, W; Zhang, R; Zhang, T; Zhang, X; Zhao, Y; Zhou, L | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH | 1 |
| Anthoney, A; Arif, S; Basu, B; Bax, L; Brais, R; Bridgewater, J; Bundi, P; Chhabra, A; Corrie, PG; Cummins, S; Dalchau, K; Dayim, A; Ellis, R; Evans, J; Falk, S; Gillmore, R; Gopinathan, A; Isherwood, C; Jodrell, DI; Lwuji, C; Ma, YT; Machin, A; McAdam, K; Neesse, A; Palmer, D; Propper, D; Qian, W; Scott-Brown, M; Skells, R; Tuveson, D; Valle, JW; Wadsley, J; Wall, L; Wasan, H | 1 |
| Barone, D; Bekaii-Saab, T; Flaherty, KT; Krause, S; Mahalingam, D; O'Reilly, EM; Richards, DA; Roach, JM; Rosano, M; Ryan, DP; Shao, SH; Wolf, J; Yu, KH | 1 |
| Chen, ZN; Jiang, JL; Liu, Z; Tang, J; Yang, H; Zheng, M; Zhou, Y; Zhu, P | 1 |
| Chen, D; Chen, J; Hao, Q; Huag, Y; Jiang, L; Kong, Y; Li, W; Liu, R; Lu, Y; Tang, Y; Tao, W; Yang, X; Yu, H; Zhang, H; Zhang, Y; Zhu, X; Zou, H | 1 |
| Babu, S; Biankin, AV; Chang, DK; Escobar-Hoyos, LF; K Bai, JD; Kawalerski, RR; Leiton, CV; Otsuka, Y; Pan, CH; Scampavia, L; Shroyer, KR; Spicer, T; Sridharan, B; Torrente Gonçalves, M; Woo, M | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Bullock, A; Chiorean, EG; Oestreicher, N; Rowan, CG; Yeganegi, H | 1 |
| Balourdas, DI; Berger, BT; Cheung, PF; Hahn, SA; Hamdan, FH; Joerger, AC; Johnsen, SA; Knapp, S; Ladigan, S; Liffers, ST; Lucas, R; Scheffler, B; Siveke, JT; Trajkovic-Arsic, M; Weiser, T; Zegar, T; Zhang, X | 1 |
| Chen, R; Chen, Y; Feng, H; Fung, FKC; Li, CH; Li, G; To, KF; Tong, JH; Wong, CH; Xia, T; Zhu, YX | 1 |
| Capacio, BA; Carr, MJ; Chai, LF; Cox, BF; Erdem, S; Jaroch, DB; Katz, SC; Ray, P; Shankara Narayanan, JS; Vicente, DA; White, RR | 1 |
| Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF | 1 |
| Cao, D; Cheng, K; Guo, F; Li, J; Li, S; Li, X; Peng, Y; Shui, L; Shui, P; Yi, C | 1 |
| Abolmaali, N; Baumann, M; Blum, S; Distler, M; Folprecht, G; Grützmann, R; Jentsch, C; Polster, H; Saeger, HD; Troost, EGC; Weitz, J; Zimmermann, C; Zöphel, K | 1 |
| Moir, JAG; Severs, GR; Tingle, SJ; White, SA | 1 |
| Fogelman, D; Herman, J; Ikoma, N; Javle, M; Katz, MHG; Kim, M; Koay, EJ; Lee, JE; Overman, M; Pant, S; Perri, G; Prakash, L; Qiao, W; Tzeng, CW; Varadhachary, GR; Wolff, R | 1 |
| Du, J; Gu, J; Li, J | 1 |
| Cao, J; Chen, J; Diao, F; Huang, P; Qiu, F | 1 |
| Ahmad, SA; Beg, MS; Chiorean, EG; Duong, M; Gandhi, NS; Guthrie, KA; Hochster, HS; Lowy, AM; Philip, PA; Sohal, DPS; Wade, JL; Wang-Gillam, A | 1 |
| Bernaldo de Quirós Fernández, S; Cadogan, EB; Dunlop, CR; Durant, ST; Jodrell, DI; Johnson, TI; Lau, A; Richards, FM; Wallez, Y | 1 |
| Dash, AK; Deodhar, S; Hulce, M; North, EJ | 1 |
| Agarwal, C; Agarwal, R; Bagby, SM; Dhar, D; Kumar, D; Messersmith, WA; Orlicky, DJ; Pitts, TM; Raina, K; Wempe, MF | 1 |
| Cui, C; Feng, Y; Hao, C; Kong, D; Su, H; Tian, X; Xue, J; Yan, L; Yao, Q; Yao, Y; Zhou, T | 1 |
| Hatano, H; Imura, S; Johira, H; Kagajo, Y; Kashu, N; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Watanabe, R; Yunoki, S | 1 |
| Bakhtiyari, S; Gheysarzadeh, A; Mofid, MR | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA | 1 |
| Bulanadi, JC; Gill, AJ; Gong, X; Hugh, T; Julovi, SM; Moghaddam, MJ; Phillips, L; Proschogo, N; Rye, KA; Smith, RC; Smith, SF; Xue, A | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Adachi, T; Eguchi, S; Harada, H; Miyazaki, Y; Nagai, K; Sugiyama, H | 1 |
| Arcucci, S; Barentin, C; Ben-Mériem, Z; Delanoë-Ayari, H; Delarue, M; Guillermet-Guibert, J; Hatzikirou, H; Mascheroni, P; Prunet, A; Rivière, C; Rizzuti, IF | 1 |
| Jiang, W; Li, H; Li, T; Liu, L; Liu, X; Yu, X; Zhang, J; Zhang, W | 1 |
| Abushahin, L; Chakravarti, A; Cruz-Monserrate, Z; Hegazi, A; Jacob, JR; Palanichamy, K; Robb, R; Shyu, DL; Trevino, JG; Williams, TM; Wolfe, AR; Yang, L | 1 |
| Arai, T; Fukumura, Y; Hirabayashi, K; Kawanishi, A; Kojima, M; Matsuda, Y; Mino-Kenudson, M; Nakano-Narusawa, Y; Ohkubo, S; Sahara, Y; Takahashi, S; Yamaguchi, H | 1 |
| Batra, SK; C Caffrey, T; Chhonker, YS; Chirravuri, R; Chugh, S; Grandgenett, PM; Gupta, R; Hollingsworth, MA; L Grem, J; Lele, SM; Leon, F; Mallya, K; Marimuthu, S; Murry, DJ; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Prajapati, DR; Rachagani, S; Rauth, S; Shailendra, GK | 1 |
| Beck, A; Gravekamp, C; Lara, O; Meena, K; Meheus, L; Rooman, I; Selvanesan, BC | 1 |
| Capone, A; Capurso, G; de Latouliere, L; Di Agostino, S; Manni, I; Montori, A; Naro, C; Panzeri, V; Piaggio, G; Pilozzi, E; Sacconi, A; Sette, C | 1 |
| Chen, HA; Chiu, CF; Chuang, TH; Hsieh, CL; Hsu, TW; Huang, MT; Leo Su, J; Su, CM; Su, YH | 1 |
| Armenoult, L; Arsenijevic, T; Augustin, J; Ayadi, M; Bachet, JB; Bigonnet, M; Blum, Y; Cros, J; Dahan, L; de Reyniès, A; Duconseil, P; Dusetti, NJ; Elarouci, N; Emile, JF; Gayet, O; Gilabert, M; Giovannini, M; Grandval, P; Hammel, P; Iovanna, J; Moutardier, V; Nicolle, R; Puleo, F; Roques, J; Svrcek, M; Van Laethem, JL; Vanbrugghe, C | 1 |
| Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
| Gao, S; Xu, Y; Zhang, Z; Zhao, C | 1 |
| Caires, HR; Castro, I; Cavadas, B; Ferreira, D; Oliveira, MJ; Pereira, L; Santos, LL; Vasconcelos, MH; Xavier, CPR | 1 |
| Banerjee, S; Banerjee, SK; Dutta, D; Haque, I; Jain, P; Kale, N; Kambhampati, S; Mallik, S; Mohammed, J; Nair, G; Orr, M; Parmer, M; Quadir, M; Ray, P; Reindl, KM | 1 |
| Azevedo-Pouly, AC; Brekken, RA; Girard, L; Huang, H; Kantheti, HS; Layeghi-Ghalehsoukhteh, S; MacDonald, RJ; Niederstrasser, H; Ocal, O; Pal Choudhuri, S; Pashkov, V; Posner, BA; Wilkie, TM; Zolghadri, Y | 1 |
| Abdel Hadi, N; Borge, L; Carrier, A; Cormareche, L; Diémé, B; Dou, S; Dusetti, N; El Kaoutari, A; Garcia, J; Gayet, O; Gicquel, T; Iovanna, J; Lac, S; Masoud, R; Pasquier, E; Reyes-Castellanos, G; Shintu, L; Tranchida, F | 1 |
| Chen, Y; Huang, C; Kong, X; Liu, C; Meng, Q; Meng, YM; Qiu, X; Su, L; Wang, M; Wong, PP; Wu, S; Zhao, X | 1 |
| Hua, YQ; Meng, ZQ; Ning, ZY; Shen, YH; Sheng, J; Wang, P; Xu, LT; Yan, X; Zhu, ZF; Zhuang, LP | 1 |
| Che, G; Chen, Y; Huang, C; Li, T; Li, Y; Lin, Y; Luo, L; Peng, S; Ren, T; Yang, P; Zeng, L | 1 |
| Fukutomi, A; Furuse, J; Hashimoto, Y; Honda, G; Ioka, T; Miyamoto, A; Mizuno, N; Morinaga, S; Nakamori, S; Okusaka, T; Saiura, A; Sasahira, N; Seyama, Y; Shimizu, S; Shimizu, Y; Sugiyama, M; Takadate, T; Takahashi, H; Ueno, H; Ueno, M; Umemoto, K; Unno, M | 1 |
| Bogeski, I; Ellenrieder, V; Gaedcke, J; Gibhardt, CS; Hamdan, FH; Hessmann, E; Johnsen, SA; Kopp, W; Kutschat, AP; Najafova, Z; Ströbel, P; Wang, X; Wixom, AQ | 1 |
| Betancourt, O; Cazes, A; Esparza, E; Gymnopoulos, M; Jaquish, D; Lowy, AM; Mose, ES; Tiriac, H; Wascher, AA; Wong, E | 1 |
| Caffrey, TC; Clausen, H; Hollingsworth, MA; Leiphrakpam, PD; McAndrews, KL; Radhakrishnan, P; Sagar, S; Swanson, BJ; Thomas, D; Wandall, HH | 1 |
| Beatty, GL; Carpenter, EL; Giannone, MA; Gladney, WL; Herrera, VM; Wattenberg, MM | 1 |
| Cheng, K; Li, G; Li, Y; Lin, CY; Liu, Y; Staveley-OCarroll, KF; Zhao, Z | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Akahori, T; Ikeda, N; Kunishige, T; Nagai, M; Nakagawa, K; Nakamura, K; Nishiwada, S; Sho, M; Takagi, T; Terai, T | 1 |
| Bendell, J; Greil, R; Gueorguieva, I; Hecht, JR; Hozak, RR; Lin, Y; Lonardi, S; Lopez, CD; Macarulla, T; Muñoz Martin, AJ; Park, JO; Rao, S; Ryoo, BY; Sim, HW; Van Cutsem, E; Wang, H | 1 |
| Gao, W; Li, X; Liu, Y; Luo, D; Yu, L; Yu, X; Zhu, H | 1 |
| Furukawa, T; Higuchi, R; Izumo, W; Matsunaga, Y; Shiihara, M; Uemura, S; Yamamoto, M; Yazawa, T | 1 |
| Abdul-Ahad, A; Boeck, S; Dechow, T; Fischer von Weikersthal, L; Freiberg-Richter, J; Frickhofen, N; Haas, M; Heinemann, V; Held, S; Illerhaus, G; Kaiser, F; Kanzler, S; Kruger, S; Kubicka, S; Mahlberg, R; Malfertheiner, P; Reinacher-Schick, A; Seufferlein, T; Snijder, R; Stahl, M; von Bergwelt-Baildon, M; Waldschmidt, DT; Westphalen, CB | 1 |
| Baba, H; Goel, A; Nishiwada, S; Okada, Y; Sho, M; Takayama, T; Yamamura, K | 1 |
| Goel, A; Okada, Y; Takahashi, N; Takayama, T | 1 |
| Albores-Saavedra, J; Álvarez-Hilario, LG; Ávila-López, PA; Cedillo-Barrón, L; Guerrero, G; Hernández-Montes, G; Hernández-Rivas, R; Herrera-Goepfert, R; Montes-Gómez, AE; Nuñez-Martínez, HN; Peralta-Alvarez, CA; Recillas-Targa, F; Schnoor, M; Vargas, M; Villegas-Sepúlveda, N | 1 |
| Liu, B; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xu, G; Yin, X; Zou, X | 1 |
| Einama, T; Fujii, Y; Fukai, M; Hatanaka, Y; Kamachi, H; Kawamata, F; Kobayashi, N; Matsuzawa, F; Mizukami, T; Taketomi, A | 1 |
| Dedonyte, V; Kurlinkus, B; Schemmer, P; Sileikis, A; Valius, M; Zalyte, E | 1 |
| Han, HS; Hwang, JH; Kim, H; Kim, J; Lee, JC; Shin, DW; Yoon, YS | 1 |
| Beg, MS; Brekken, RA; Du, W; Huang, H; Lorens, JB; Phinney, NZ; Toombs, JE; Wang, Z; Westcott, J; Wilkie, TM; Zhang, Y | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| Aoki, T; Iso, Y; Kubota, K; Matsumoto, T; Mori, S; Park, KH; Sakuraoka, Y; Shimizu, T; Shiraki, T; Yamaguchi, T | 1 |
| Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG | 1 |
| Brown, ZJ; Cloyd, JM | 1 |
| Burdio-Pinilla, F; Casasola-Sánchez, LE; Pereira-Rodríguez, JA; Radosevic, A; Sánchez-Velázquez, P; Visa, L | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Alig, S; Bararia, D; Boeck, S; Haas, M; Haebe, S; Heinemann, V; Kobold, S; Kruger, S; Metzger, P; Ormanns, S; Rataj, F; Sams, L; von Bergwelt-Baildon, M; Weigert, O; Werner, J; Westphalen, CB; Zhang, D | 1 |
| Bahra, M; Bischoff, S; Kruger, S; Kurreck, A; Modest, DP; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Weckwerth, J | 1 |
| Barth, DA; Djanani, A; Gantschnigg, A; Gerger, A; Greil, R; Horvath, L; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Schlick, K; Schwarzenbacher, E; Stöger, H; Stotz, M | 1 |
| Eurola, A; Haglund, C; Hagström, J; Mustonen, H; Nurmi, AM; Ristimäki, A; Seppänen, H | 1 |
| Liu, A; Tang, X; Xu, J; Zhao, T; Zhou, B; Zhou, Y | 1 |
| Fukahori, M; Kakuma, T; Miwa, K; Murotani, K; Nagasu, S; Naito, Y; Okabe, Y; Sakaue, T; Suga, H; Tanaka, T; Torimura, T; Ushijima, T | 1 |
| Bhutkar, S; Dukhande, V; Patel, K; Patki, M; Saraswat, A | 1 |
| Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK | 1 |
| Hashimoto, D; Hirooka, S; Inoue, K; Ishida, M; Ryota, H; Sakaguchi, T; Satoi, S; Sekimoto, M; Yamaki, S; Yamamoto, T | 1 |
| Minomi, K; Tamura, Y; Yoneda, A | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H | 1 |
| Li, Y; Paxton, JW; Wu, Z; Xu, H | 1 |
| Cao, Y; Jiang, L; Jin, G; Ju, X; Liu, W; Ye, Y; Zhang, H; Zhao, X; Zhu, X | 1 |
| Attri, KS; Auwerx, J; Chaika, NV; Chaudhary, S; Fu, X; He, C; High, RR; Hu, T; Jha, K; King, RJ; Lan, P; Lazenby, A; Mai, A; Mehla, K; Mulder, SE; Mullen, NJ; Murthy, D; Pacheco, CG; Rotili, D; Shukla, SK; Siddhanta, K; Singh, PK; Steegborn, C; Tafani, M; Thakur, R; Tuveson, D; Valente, S; Verdin, E; Vernucci, E; Wang, D; Yu, F | 1 |
| Baydogan, S; Dong, W; Fogelman, DR; Hasanov, M; Javle, MM; Katz, MHG; Kim, MP; Lotze, MT; McAllister, F; Mizrahi, JD; Mohindroo, C; Overman, MJ; Pant, S; Prakash, LR; Rogers, JE; Tzeng, CD; Varadhachary, GR; Wolff, RA | 1 |
| Gao, S; Hao, J; Huang, C; Li, X; Liu, J; Liu, W; Ma, Y; Wang, H; Wang, X; Wang, Z; Wu, L; Yang, S; Yu, X; Zhao, T | 1 |
| Arscott, WT; Bear, A; Ben-Josef, E; Drebin, J; Lee, MK; Loaiza-Bonilla, A; Lukens, JN; Metz, J; Nead, KT; O'Hara, M; Plastaras, JP; Reiss, KA; Shabason, J; Shroff, SG; Teitelbaum, U; Venigalla, S; Wojcieszynski, A | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Abuelafia, AM; Bigonnet, M; Chuluyan, E; Cros, J; Dusetti, N; Fraunhoffer, NA; Gayet, O; Iovanna, J; Nicolle, R; Palazzo, L; Teyssedou, C | 1 |
| Bapiro, TE; Bautista, W; Chen, V; Gilbert, DJ; Guerin, TM; Jodrell, DI; Kim, SJ; Kozlov, S; Kumar, P; Li, D; Mehta, M; Ock, CY; Palena, C; Pate, N; Richards, FM; Rudloff, U; Schaub, N; Schlomer, JJ; Sorber, R; Talsania, K; Teper, Y; Zhao, Y | 1 |
| Akshinthala, D; Clohessy, JG; Gaglia, G; Gray, NS; Hidalgo, M; Ke, S; Kibe, S; Kim, N; Koikawa, K; Lee, TH; London, N; Lu, KP; Manz, TD; Muthuswamy, SK; Nakamura, M; Nezu, Y; Oda, Y; Ohuchida, K; Pinch, BJ; Qiu, C; Santagata, S; Sekino, N; Suizu, F; Verma, A; Wegiel, B; Wulf, GM; Zhou, XZ | 1 |
| Croagh, D; Deswaerte, V; Gao, H; Gearing, LJ; Hertzog, PJ; Jenkins, BJ; Lundy, J; McLeod, L; Pajic, M; Porazinski, S; West, AC; Yu, L | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Chen, H; Deng, X; Fang, Y; Huo, Z; Li, H; Lu, X; Peng, C; Shen, B; Shi, M; Tang, X; Wang, X; Wen, C; Xie, J | 1 |
| Li, W; Yao, J; Zhang, C; Zhang, L | 1 |
| Jia, L; Li, H; Li, L; Liu, X; Sun, Y; Wu, J; Zhao, L; Zhou, W | 1 |
| Baechmann, S; Boeck, S; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Modest, DP; Ormanns, S; Remold, A; Werner, J | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Bentrem, DJ; Cho, CS; Ethun, CG; Hanseman, DJ; Kooby, DA; Maithel, SK; Salem, A; Stocker, SJ; Talamonti, MS; Weber, SM; Xia, BT | 1 |
| Adamska, A; Domenichini, A; Falasca, M | 1 |
| Abraham, T; Adair, JH; Butler, PJ; Clawson, GA; Fox, T; Gigliotti, CM; Kester, M; Linton, SS; Loc, WS; Martin, JA; Matters, GL; McGovern, CO; Smith, JP; Tabakovic, A; Tang, X; Wilczynski, ZR | 1 |
| Alexander, JF; Borsoi, C; Elganainy, D; Ferrari, M; Godin, B; Kai, M; Kang, Y; Koay, EJ; Lee, Y; Leonard, F; Liu, X; Liu, YT; Yokoi, K; Zaid, M | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Aloia, TA; Cloyd, JM; Das, P; Egger, ME; Fleming, JB; Fogelman, D; Herman, JM; Javle, M; Katz, MHG; Kim, MP; Koay, EJ; Lee, JE; Maitra, A; Overman, MJ; Prakash, LR; Shroff, R; Tzeng, CD; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Cheng, H; Guo, M; Jin, K; Liu, C; Lu, Y; Luo, G; Ni, Q; Yu, X | 1 |
| Billadeau, DD; Huang, H; Jin, X; Ma, T; Pan, Y; Tang, AH; Wang, L; Wu, H; Zhang, L | 1 |
| Bahra, M; Bischoff, S; Bläker, H; Denkert, C; Jöhrens, K; Jühling, A; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Striefler, JK; Wislocka, L | 1 |
| Algül, H; Azoitei, N; Bohnenberger, H; Frappart, PO; Gaedcke, J; Gieldon, L; Hampp, S; Hessmann, E; Hohwieler, M; Ihle, M; Kleger, A; Lechel, A; Lesina, M; Liebau, S; Lin, Q; Perkhofer, L; Reinhardt, HC; Romero Carrasco, MC; Ruess, DA; Russell, R; Schmitt, A; Schröck, E; Seufferlein, T; Sipos, B; Wagner, M; Wiesmüller, L | 1 |
| Abrego, J; Berim, L; Chaika, NV; Grem, J; Gunda, V; King, RJ; Lazenby, AJ; Sasson, AR; Shukla, SK; Singh, PK; Tadros, S; Vernucci, E; Yu, F | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Dörken, B; Gellert, K; Ghadimi, M; Grützmann, R; Jacobasch, L; Liersch, T; Maschmeyer, G; Messmann, H; Oettle, H; Pelzer, U; Rau, BM; Riess, H; Sinn, M; Stieler, JM; Striefler, JK; Waldschmidt, D; Weinmann, A; Wilhelm, M | 1 |
| Chen, Y; Cui, X; Lin, Y; Qin, C; Wang, X; Wang, Z; Xian, G; Zhang, Z | 1 |
| Anders, RA; Che, X; Chen, J; Jaffee, EM; Kleponis, J; Muth, S; Rucki, AA; Sharma, R; Xiao, Q; Zheng, L | 1 |
| Avraham, R; Barshack, I; Barzily-Rokni, M; Bhatia, SN; Brandis, A; Bu, J; Chatman, K; Cooper, ZA; Danino, T; Ferrone, CR; Flaherty, KT; Fleming, J; Frederick, DT; Fuks, G; Garrett, WS; Gavert, N; Geller, LT; Gevers, D; Golan, T; Golub, TR; Gopalakrishnan, V; Gurbatri, C; Hurd, MW; Huttenhower, C; Johnston, SE; Jonas, OH; Katz, M; Kim, M; Ligorio, M; Livny, J; Maitra, A; Mandinova, A; Michaud, M; Mosher, CM; Nejman, D; Reuben, A; Sandbank, J; Shee, K; Shental, N; Skalak, M; Smith, DA; Straussman, R; Thaiss, CA; Thayer, SP; Trauger, SA; Wargo, JA; Zwang, Y | 1 |
| Coppola, L; D'Andrea, MR; Di Raimo, T; Giordano, G; Olivieri, N; Pancione, M; Parcesepe, P; Toffoli, G; Velocci, M | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Iida, T; Ju, H; Lee, H; Li, H; Ling, J; Lu, Y; Sun, Y; Wu, M; Zhuang, Z | 1 |
| Furukawa, K; Kagawa, S; Miyazaki, M; Nishino, H; Ohtsuka, M; Shimazaki, R; Shimizu, H; Suzuki, K; Takano, S; Yoshitomi, H | 1 |
| Chang, A; Gao, S; Hao, J; Huang, C; Li, N; Li, Y; Li, Z; Ren, H; Wang, H; Wang, X; Yang, S; Zhao, T | 1 |
| Ji, S; Liang, C; Liang, D; Meng, Q; Ni, Q; Qin, Y; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| An, MJ; Cha, YH; Gee, HY; Han, JW; Jeung, HC; Jun, I; Jung, J; Lee, MG; Park, HS; Park, JS; Piao, H; Shin, YK; Yook, JI; Yoon, DS; Yun, BG; Zhang, X | 1 |
| Goel, A; Han, H; Ravindranathan, P; Toden, S; Yoshida, K | 1 |
| Andersson, B; Andersson, R; Ansari, D; Hilmersson, KS; Urey, C | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Cox, TF; Deakin, M; Dervenis, C; Ghaneh, P; Glimelius, B; Goldstein, D; Halloran, CM; Izbicki, JR; Jackson, R; Jones, O; Kleeff, J; Lerch, MM; Mayerle, J; McDonald, AC; Melling, J; Neoptolemos, JP; O'Reilly, DA; Oláh, A; Padbury, R; Palmer, DH; Raraty, M; Rawcliffe, CL; Scarfe, AG; Shannon, J; Smith, CJ; Strobel, O; Tebbutt, NC; Valle, JW | 1 |
| Attwood, K; Balachandar, S; Chandra, D; Chaudhary, AK; Hochwald, S; Inigo, JR; Kumar, R; Kumar, S; O'Malley, J; Wang, J; Wang, X; Yadav, N | 1 |
| Baldwin, G; He, H; Huynh, N; Nikfarjam, M; Wang, K; Wang, X | 1 |
| Bielli, P; Capurso, G; Farini, D; Fave, GD; Panzeri, V; Passacantilli, I; Pilozzi, E; Sette, C | 1 |
| Deshmukh, SP; Epstein, JD; Keith, SW; Kozak, GM; Lavu, H; Scott, BB; Winter, JM; Yeo, CJ | 1 |
| Allen-Petersen, BL; Amery, TS; Crawford, HC; Egbukichi, N; Farrell, AS; Heiser, LM; Hoffman, MT; Jenny, ZP; Joly, MM; Kendsersky, ND; Lanciault, C; Link, J; Manning, SL; Morton, JP; Murphy, DJ; Muthalagu, N; Pelz, C; Pratt, ED; Rhim, AD; Sansom, OJ; Sauer, D; Sears, RC; Sheppard, BC; Thoma, MC; Worth, PJ | 1 |
| Brekken, RA; Cruz, VH; Du, W; Lorens, JB; Ludwig, KF; Maitra, A; Rajeshkumar, NV; Sorrelle, NB; Toombs, JE; Topalovski, M; Wnuk-Lipinska, K; Yabuuchi, S | 1 |
| Armbrecht, N; Bernhardt, G; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Fleischmann-Mundt, B; Gürlevik, E; Kubicka, S; Kühnel, F; Manns, MP; Niemann, J; Peters, K; Ribback, S; Smyth, MJ; Wirth, TC; Woller, N | 1 |
| Puls, TJ; Tan, X; Voytik-Harbin, SL; Whittington, CF | 1 |
| Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Cheng, K; Han, X; Hao, J; Lang, J; Lin, Y; Miao, QR; Nie, G; Qin, H; Ren, H; Shi, J; Sun, W; Wang, X; Wang, Y; Zhao, R; Zhao, X; Zhao, Y; Zheng, X | 1 |
| Gourd, E | 1 |
| Kondo, N; Murakami, Y; Nakagawa, N; Okano, K; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Altomare, DA; Copik, AJ; Gitto, SB; Hogan, FC; Oyer, JL; Pandey, V; Phanstiel, O | 1 |
| Cai, H; Chen, J; Chen, Q; Guo, Q; Huang, S; Jiang, B; Kang, M; Li, P; Lu, W; Qin, W; Rao, J; Wan, D; Wang, L; Wu, Y; Zheng, W; Zhou, Y | 1 |
| Brenner, R; Capanu, M; Chen, AP; Dhani, N; Do, RK; Epstein, AS; Estrella, H; Golan, T; Kelsen, DP; Kindler, HL; Lee, JW; Lowery, MA; Maynard, H; Moore, MJ; O'Reilly, EM; Salo-Mullen, EE; Segal, A; Segal, M; Stadler, ZK; Tang, LH; Yu, KH | 1 |
| Hayashi, K; Inoue, T; Joh, T; Kato, A; Kondo, H; Naiki-Ito, A; Naitoh, I; Nakazawa, T; Nishi, Y; Okumura, F; Shimizu, S; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Egawa, S; Eguchi, H; Fujiki, F; Homma, S; Ishii, J; Ishikawa, T; Ito, K; Kanno, Y; Koido, S; Kokura, S; Kon, M; Kumanogoh, A; Morimoto, S; Morita, S; Nagano, H; Nishida, S; Oba, MS; Oka, Y; Sato, M; Shimada, H; Sugiyama, H; Unno, M; Yanagimoto, H; Yasuda, H | 1 |
| Head, R; Jiang, H; Li, L; Li, Q; Lim, KH; Liu, J; Ruzinova, MB; Wang-Gillam, A; Yu, J; Zhang, D | 1 |
| Capurso, G; Delle Fave, G; Panzeri, V; Passacantilli, I; Sette, C; Terracciano, F | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Ichikawa, Y; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Takeyari, M; Tatsumi, M; Wada, H; Yamada, D | 1 |
| Colby, AH; Grinstaff, MW; Liu, K; Lu, C; Oberlies, NH; Pearce, C; Sabbatini, ME; Yang, D | 1 |
| Anthoney, DA; Basu, B; Cook, N; Evans, J; Farmer-Hall, H; Gopinathan, A; Halford, S; Hampson, LV; Hategan, M; Jodrell, D; McLeod, R; Nebozhyn, M; Palmer, D; Propper, D; Smith, DM; Steward, WP; Turner, H; Tuveson, D; Venugopal, B | 1 |
| Chie, EK; Choi, SH; Han, Y; Heo, JS; Jang, JY; Kim, SH; Kim, SW; Koh, YH; Kwon, W; Lee, H; Lee, IJ; Lee, JM; Lee, KH; Lee, WJ; Lim, DH; Oh, DY; Park, JO; Park, JS; Park, SJ; Yoon, DS | 1 |
| Adamberg, K; Adamberg, S; Andriulli, A; Copetti, M; Fontana, A; Jaagura, M; Kolk, K; Panebianco, C; Pazienza, V; Vilu, R | 1 |
| Cheng, JX; Li, J; Qu, X; Tian, J; Zhang, JT | 1 |
| Anthoney, A; Aughton, K; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Elander, NO; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Lerch, MM; Mackey, JR; Mayerle, J; McDonald, AC; Neoptolemos, JP; Oláh, A; Palmer, DH; Scarfe, AG; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Chen, H; Chen, Z; Hua, YQ; Huang, L; Meng, ZQ; Ming, LL; Na, L; Wang, F; Wang, L; Yu, J | 1 |
| Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Boichard, A; Bush, KT; Tsigelny, IF | 1 |
| Feng, M; Hu, Y; Huang, H; Xiong, G; Yang, G; You, L; Zhang, T; Zhao, Y; Zheng, L; Zheng, S | 1 |
| Bauer, N; Gladkich, J; Gretz, N; Gross, W; Hackert, T; Herr, I; Liu, L; Nwaeburu, CC; Sticht, C; Strobel, O; Yin, L; Yin, Y; Zhao, Z | 1 |
| Kim, DU | 1 |
| Adham, M; Boschetti, G; Castel-Kremer, E; Charlois, AL; Chopin-Laly, X; Comte, B; De Talhouet, S; Graillot, E; Lombard-Bohas, C; Walter, T | 1 |
| Gao, H; Itkin-Ansari, P; Jakubison, BL; Konieczny, SF; Liu, Y; Moser, SE; Schweickert, PG; Scully, K; Yang, Y | 1 |
| Chung, FF; Er, JL; Goh, PN; Hii, LW; Lee, CY; Leong, CO; Mai, CW; Tan, YJ | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Yamada, D | 1 |
| Devasahayam, N; Gillies, RJ; Hart, CP; Kishimoto, S; Krishna, MC; Matsumoto, S; Mitchell, JB; Munasinghe, JP; Saito, K; Takakusagi, Y | 1 |
| Huang, M; Huang, Q; Lin, X; Liu, C; Liu, Z; Meng, F; Wang, C; Xie, F | 1 |
| Esumi, H; Fujioka, R; Ikeda, M; Kishino, S; Mochizuki, N; Nomura, S; Owada, S; Sato, A; Tsuchihara, K; Yomoda, S | 1 |
| Absil, J; Bali, MA; Chao, SL; Marechal, R; Matos, C; Metens, T; Peerboccus, BM; Pullini, S; Van Laethem, JL | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Bernaldo de Quirós Fernández, S; Dunlop, CR; Fornari, C; Jodrell, DI; Johnson, TI; Koh, SB; Lau, A; Richards, FM; Wallez, Y; Yates, JWT | 1 |
| Cheng, L; Li, X; Yang, F; Zhang, L | 1 |
| Hua, J; Liang, C; Liang, D; Meng, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Halldén, G; Nattress, CB | 1 |
| Ji, L; Ke, M; Li, Y; Liu, G; Ou, Z; Tang, N | 1 |
| Álvarez, R; Carrato, A; Díaz, R; García, A; Hidalgo, M; Laquente, B; Macarulla, T; Muñoz, A; Sastre, J | 1 |
| Delpero, JR; Ewald, J; Gilabert, M; Marchese, U; Turrini, O | 1 |
| Ben David, G; Binenbaum, Y; Fridman, E; Gil, Z; Milman, N; Schroeder, A; Shlomi, T; Yaari, Z | 1 |
| Cao, J; Chen, K; Cheng, L; Duan, W; Jiang, Z; Li, J; Ma, Q; Qian, W; Yan, B; Zhou, C | 1 |
| Chang, S; Choi, EA; Choi, YS; Kim, I; Kim, SC; Lee, EJ; Park, S; Rhee, JK; Song, JH | 1 |
| Barbie, D; Chaves, J; Fuchs, CS; Hahn, WC; Hendifar, A; Koh, B; Ng, K; Starodub, A; Yang, Y | 1 |
| Cabeza-Morales, M; Garcia-Carbonero, N; Garcia-Foncillas, J; Li, W; Martinez-Useros, J | 1 |
| Bhowmick, NA; Boros, LG; Chheda, C; Edderkaoui, M; Habtezion, A; Hu, RW; Lewis, M; Madhav, A; Murali, R; Pan, X; Pandol, SJ; Ramanujan, VK; Soufi, B; Tajbakhsh, J; Tuli, R; Wang, Q; Zayou, F | 1 |
| Akita, H; Asukai, K; Ishikawa, O; Matsunaga, T; Miyata, H; Nakanishi, M; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shirayanagi, M; Sugimura, K; Takahashi, H; Takahashi, Y; Tomokuni, A; Wada, H; Yamamoto, K; Yamamoto, T; Yamasaki, T; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S | 1 |
| Cheon, MJ; Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, SJ; Kim, YS; Lee, JE; Lim, JH; Park, JH; Shin, SM; Son, MK; Woo, MG; Yan, HH | 1 |
| Chiou, SH; Dorsch, M; Grüner, BM; Koong, AC; Kozak, MM; Kusch, E; Naranjo, S; Winslow, MM | 1 |
| Bahra, M; Neumann, CCM; Pratschke, J; Reutzel-Selke, A; Sauer, IM; Schmuck, RB; Seidel, E; von Hörschelmann, E | 1 |
| Bruno, S; Butera, G; Conti, P; Donadelli, M; Margiotta, M; Mullappilly, N; Pacchiana, R; Riganti, C | 1 |
| Arlt, A; Deisinger, F; Helm, O; Hesse, L; Kha, ML; Röcken, C; Schäfer, H; Sebens, S; Sipos, B | 1 |
| Bhosale, P; Fogelman, D; Gulhati, P; Javle, M; Katz, MHG; Koay, EJ; Lee, JE; Lee, JH; Maitra, A; Prakash, L; Shroff, R; Tamm, E; Tzeng, CD; Varadhachary, GR; Wang, H; Wang, X; Weston, B; Wolff, RA | 1 |
| Biondi, M; Botti, G; Fusco, S; Iaffaioli, RV; Mayol, L; Quagliariello, V; Serri, C | 1 |
| Chen, R; Li, G; Li, Z; Lin, Q; Liu, Y; Lu, Y; Wei, L; Ye, H; Zheng, S; Zhou, Q | 1 |
| Arumugam, T; Chiao, P; Curran, MA; Deng, D; Hung, MC; Husted, H; Hwang, RF; Lee, JE; Ling, J; Liu, Y; Logsdon, CD; Lu, M; Maitra, A; Moore, T; Niehrs, C; Ramachandran, V; Wang, H; Zhou, L | 1 |
| Chiorean, EG; Gu, D; Jia, Y; Wan, J; Wang, Y; Xie, J; Yu, B; Zhang, X | 1 |
| D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Braiteh, FS; Chen, LT; Chiu, CF; Cunningham, D; de Jong, FA; Dean, AP; Hubner, RA; Jameson, GS; Lee, KH; Li, CP; Macarulla, T; Mamlouk, K; Schwartsmann, G; Shan, YS; Siveke, JT; Wang-Gillam, A | 1 |
| Cao, XY; Hu, LP; Huo, YM; Jiang, SH; Jiang, YS; Li, J; Li, Q; Sun, YW; Tao, LY; Tian, GA; Wang, YH; Xiao, GG; Yang, MW; Yang, Q; Yang, XM; Zhang, XX; Zhang, YL; Zhang, ZG; Zhu, LL | 1 |
| Kumar, L; Tiwari, A | 1 |
| Amundadottir, L; Clarke, WR; James, MA | 1 |
| Arima, K; Baba, H; Chikamoto, A; Fukuzawa, K; Hashimoto, D; Hirata, T; Hirota, M; Inomata, M; Maehara, Y; Nakagawa, S; Negoro, Y; Ohga, T; Oki, E; Saeki, H; Yamashita, YI | 1 |
| Abraham, RG; Dedi, B; Krucher, NA; Thomas, NA | 1 |
| Bartsch, JW; Bronsert, P; Conrad, C; Hoeppner, J; Kulemann, B; Lopatta, P; Maurer, J; Nyström, A; Oria, VO; Preca, BT; Schilling, O; Schmitz, T | 1 |
| Cao, D; Chen, X; Feng, Y; Gong, C; Haydon, RC; He, TC; Huang, B; Huang, S; Lei, Y; Liu, B; Liu, W; Liu, X; Luo, W; Luu, HH; Ma, C; Peng, B; Shen, Y; Tang, S; Wang, X; Wu, T; Wu, X; Yang, L; Ye, Z; Yuan, C; Zeng, Z; Zhang, B; Zhang, L; Zhang, Z; Zhao, L | 1 |
| Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Abou Ali, E; Batteux, F; Bordacahar, B; Camus, M; Lafon, C; Mestas, JL; Prat, F | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Azumi, Y; Fujii, T; Hayasaki, A; Iizawa, Y; Isaji, S; Kato, H; Kishiwada, M; Kuriyama, N; Mizuno, S; Murata, Y; Sakurai, H; Takeuchi, T; Tanemura, A; Usui, M | 1 |
| Bates, SE; Chabot, JA; Manji, GA; Raufi, AG | 1 |
| Du, G; Fan, Z; Ma, L; Wang, H | 1 |
| Ho, TTB; Honda, M; Kaneko, S; Kawaguchi, K; Komura, T; Miyazawa, M; Mizukoshi, E; Nasti, A; Okuzono, M; Sakai, Y; Takabatake, H; Wada, T; Yamada, T; Yamashita, T; Yamato, M; Yoshida, K | 1 |
| Thoma, C | 1 |
| Bronich, TK; Caffrey, T; Hollingsworth, MA; Lei, F; Lele, SM; Mehla, K; O'Connell, KA; Radhakrishnan, P; Sagar, S; Soni, KS; Thomas, D | 1 |
| Laczkó, D; Marchand, B; Pitarresi, JR; Reichert, M; Rustgi, AK; Suzuki, K | 1 |
| Brunner, M; Ellenrieder, V; Gaedcke, J; Goetze, RG; Gruetzmann, R; Hamdan, FH; Hessmann, E; Jodrell, DI; Johnsen, SA; Kari, V; Kitz, J; Knösel, T; Neesse, A; Patil, S; Patzak, MS; Pilarsky, C; Richards, FM; Rümmele, P | 1 |
| Wang, C; Xin, B; Zhang, X; Zhao, P | 1 |
| Ahn, DH; Bekaii-Saab, T; Goldstein, D; Li, CP; Macarulla, T; O'Neil, B; Okusaka, T; Reni, M; Sonbol, MB; Tabernero, J; Van Cutsem, E | 1 |
| Fang, L; Guan, X; Li, Q; Li, Z; Lian, J; Liu, C; Lou, C; Shi, J; Wang, B; Wang, Y; Yao, Y; Zhan, F; Zhang, Y; Zhao, Q; Zhou, B; Zhu, Y | 1 |
| Biankin, A; Chang, D; Crawford, HC; Dreyer, S; Frankel, TL; Halbrook, CJ; Hong, HS; Kemp, S; Kovalenko, I; Kremer, DM; Lapienyte, L; Lazarus, J; Lee, HJ; Lyssiotis, CA; Morton, JP; Nelson, BS; Pasca di Magliano, M; Pontious, C; Sajjakulnukit, P; Shi, J; Thurston, G; Zhang, L; Zhang, Y | 1 |
| Baldwin, GS; He, H; Nikfarjam, M; Wang, K | 1 |
| Cole, G; Gabrail, NY; James, D; Khorana, AA; Ramanathan, RK; Shah, S; Thomas, GW; Wong, S; Zhou, C | 1 |
| Billig, AM; Jordan, VC; Medarova, Z; Pantazopoulos, P; Ross, A; Sheedy, P; Yoo, B | 1 |
| Cheng, SH; Cheng, YJ; Jin, ZY; Xue, HD | 1 |
| Alcalá, S; Alonso-Nocelo, M; Carrato, A; Cassiano, C; D'Errico, G; Earl, J; Feliu, J; García, CP; García-Bermejo, L; Hermann, PC; Lombardia, L; Martin-Hijano, L; Martinelli, P; Monti, MC; Sainz, B; Seufferlein, T; Valle, S; Vallespinos, M | 1 |
| Angelini, G; Ciferri, E; Cornacchia, C; Filauro, M; Rutigliani, M; Serventi, A | 1 |
| Fukushima, T; Kaneko, T; Maeda, S; Oka, H; Okada, K; Okazaki, H; Sugimori, K; Tozuka, Y | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Chen, Q; Chen, X; Guo, Q; Jiang, C; Li, C; Liang, C; Lu, Y; Shi, S; Sun, T; Yu, X; Zhang, Y; Zhou, W | 1 |
| Alhothali, M; Chellappan, S; Iyer, G; Lawrence, HR; Mathew, M; Padmanabhan, J; Yang, S | 1 |
| Chang, S; Khawar, IA; Kuh, HJ; Nam, S; Park, JK | 1 |
| Awasthi, N; Hassan, MS; Kronenberger, D; Schwarz, MA; Schwarz, RE; Stefaniak, A; von Holzen, U | 1 |
| Branstrom, A; Cao, L; Decker, AR; Eberle-Singh, JA; Hu, J; Kim, MJ; Maurer, HC; Mollin, A; Olive, KP; Palermo, CF; Sagalovskiy, I; Sastra, SA; Sheedy, J; Weetall, M | 1 |
| Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
| Akita, H; Asai, A; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Ishii, H; Iwagami, Y; Kasahara, Y; Kawamoto, K; Kobayashi, S; Konno, M; Koseki, J; Matsushita, K; Mori, M; Mori, S; Morihiro, K; Noda, T; Obika, S; Okuda, T; Satoh, T; Yamada, D | 1 |
| Aasrum, M; Amrutkar, M; Gladhaug, IP; Verbeke, CS | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Kocher, HM; North, B; Sasieni, P | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nagashima, F; Nakajima, TE; Ohkawa, S; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Castellanos, K; Cordoba-Chacon, J; Dawson, D; Dorman, MJ; Grimaldo, S; Grippo, PJ; Hirsch, E; Kumar, S; Mancinelli, G; McKinney, R; Munshi, HG; Principe, D; Rana, A; Torres, C; Viswakarma, N | 1 |
| Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
| Bhattacharya, S; Caplette, JR; Dutta, SK; Gong, X; Mukhopadhyay, D; Nguyen, FT; Son, M; Strano, MS; Wang, E | 1 |
| Collisson, EA; Fer, N; Galeas, J; Kim, SE; McCormick, F; Sharib, J; Wang, MT | 1 |
| Büchler, MW; Hackert, T; Heger, U; Hinz, U; Klaiber, U; Liu, B; Michalski, CW; Sachsenmaier, M; Springfeld, C; Sun, H; Tanaka, M | 1 |
| Dvorak, P; Ehrlichova, M; Flasarova, D; Hlavac, V; Kocik, M; Mohelnikova-Duchonova, B; Ojima, I; Oliverius, M; Soucek, P; Strouhal, O | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Korangath, P; Maitra, A; Pai, SG; Rajeshkumar, NV; Rasheed, ZA; Streppel, MM; Yabuuchi, S | 1 |
| An, Y; Cai, B; Chen, J; Jiang, K; Lv, N; Miao, Y; Sun, J; Tu, M; Wei, J; Wu, P | 1 |
| Abe, Y; Asaka, M; Eto, K; Fukuoka, M; Kawahata, S; Kawakami, H; Kudo, T; Kuwatani, M; Matsuno, Y; Sakamoto, N; Takasawa, A | 1 |
| Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Chen, G; Cui, QC; Du, X; Shi, J; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Alvarez, E; Campos, MD; Cavaliere, V; Costantino, S; Kaiser, CM; Lombardo, T; Papademetrio, DL; Simunovich, T | 1 |
| Cheng, X; Ji, Z; Lu, M; Mei, F; Ou, Y; Peng, Z | 1 |
| Maréchal, R; Van Laethem, JL | 2 |
| Giese, N; Giese, T; Gladkich, J; Hage, C; Herr, I; Labsch, S; Mattern, J; Nwaeburu, C; Rausch, V; Schönsiegel, F | 1 |
| Hiraoka, N; Ikeda, M; Kondo, S; Kosuge, T; Morizane, C; Nara, S; Okusaka, T; Otsuka, T; Shimada, K; Ueno, H | 1 |
| Ai, Y; Brody, JR; Burkhart, RA; Cozzitorto, JA; Gehrmann, M; Lal, S; Liang, Q; Miller, K; Napper, A; Norris, ZA; Peng, Y; Sawicki, JA; Talbott, VA; Tholey, RM; Winter, JM; Witkiewicz, AK; Yeo, CJ; Zhuang, Z | 1 |
| Baines, AT; Baldwin, AS; Bednarski, BK; Cobb, MG; Gavilano, L; Kim, HJ; Taverna, P; White, CD; Williams, D; Witherspoon, SM; Xu, D | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Bakker, A; Balic, A; Garcia, E; Hahn, SA; Heeschen, C; Hermann, PC; Hidalgo, M; Sahoo, SK; Sainz, B; Trabulo, SM; Tunici, P; Vandana, M | 1 |
| Bapiro, TE; Frese, KK; Jodrell, DI; Nakagawa, T; Neesse, A; Pilarsky, C; Seeley, TW; Spong, SM; Sternlicht, MD; Tuveson, DA | 1 |
| Akada, M; Egawa, S; Fujishima, F; Ishida, K; Katayose, Y; Motoi, F; Nakagawa, K; Oikawa, M; Okada, T; Ono, F; Ottomo, S; Shimamura, H; Takemura, S; Unno, M | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Ducreux, M; Heinemann, V; Macarulla, T; Reni, M; Richel, DJ; Ychou, M | 1 |
| Cheng, AL; Hsu, CH; Kuo, SH; Lee, JC; Tien, YW; Yang, SH | 1 |
| Asuthkar, S; Cines, DB; Estes, N; Gondi, CS; Holterman, AL; Lebedeva, T; Rao, JS; Stepanova, V | 1 |
| Barth, PJ; Bartsch, DK; Brendel, C; Ebert, MP; Endlicher, E; Fass, J; Fensterer, H; Gress, TM; Hofheinz, R; Kornmann, M; Lindig, U; Märten, A; Michl, P; Müller, HH; Schade-Brittinger, C; Schmidt, WE; Settmacher, U; Tebbe, S | 1 |
| Abood, GJ; Bahary, N; Bartlett, DL; Krasinskas, AM; Lembersky, BC; Moser, AJ; Potter, DM; Ramanathan, RK; Shuai, Y; Smith, RP; Van Buren, G; Zeh, HJ; Zureikat, AH | 1 |
| Alavi, A; Beatty, GL; Brothers, A; Chiorean, EG; O'Dwyer, PJ; Saboury, B; Sun, W; Teitelbaum, UR; Torigian, DA; Troxel, AB; Vonderheide, RH | 1 |
| Bartsch, DK; Buchholz, M; Fendrich, V; Fichtner-Feigl, S; Kesselring, R; Knoop, R; Plassmeier, L; Waldmann, J | 1 |
| Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q | 1 |
| Avan, A; Boggi, U; Campani, D; Caretti, V; Fuchs, D; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Lagerweij, T; Maftouh, M; Peters, GJ; Schuurhuis, GJ; Van Tellingen, O; Verheul, HM; Würdinger, T | 1 |
| Dwinell, MB; Hauser, AD; Roy, I; Williams, CL; Wilson, JM; Zimmerman, NP | 1 |
| Avan, A; Boggi, U; Funel, N; Giovannetti, E; Granchi, C; Honeywell, R; Leon, LG; Maftouh, M; Minutolo, F; Peters, GJ; Rani, R; Sciarrillo, R; Smid, K | 1 |
| Chung, C; Kim, H; Kim, SK; Kim, T; Kim, TS; Koh, GY; Lee, DH; Lim, DS | 1 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
| Bassi, C; Bosco, G; Bosio, C; Camporesi, E; Cannato, M; Casarotto, A; Chen, C; Garetto, G; Guizzon, L; Mangar, D; Nasole, E; Toniolo, L; Yang, Z | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Isohashi, F; Kawamoto, K; Kobayashi, S; Kudo, T; Mori, M; Nagano, H; Sakai, D; Satoh, T; Tomimaru, Y; Wada, H | 1 |
| Chiba, S; Hori, Y; Shimizu, K | 1 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Butturini, G; Carter, R; Cox, T; Cunningham, D; Dervenis, C; Ghaneh, P; Goldstein, D; Izbicki, JR; Jackson, R; Karapetis, C; Lacaine, F; Lind, PA; Mayerle, J; Middleton, MR; Neoptolemos, JP; O'Reilly, D; Oláh, A; Palmer, D; Rawcliffe, CL; Robinson, BA; Sand, J; Scarfe, A; Stocken, DD; Sumpter, K; Valle, JW | 1 |
| Cai, X; Cui, JJ; Huang, WY; Song, WF; Wang, L; Wang, LW | 1 |
| Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Bahra, M; Bischoff, S; Bläker, H; Denkert, C; Dietel, M; Dörken, B; Lindner, JL; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Abbruzzese, JL; Bhosale, PR; Chatterjee, D; Chen, R; Chen, Y; Crane, CH; Cristini, V; Ferrari, M; Fleming, JB; Gottumukkala, VN; Javle, M; Kang, Y; Katz, MH; Koay, EJ; Lee, JE; Plunkett, W; Rozner, MA; Shen, H; Tamm, EP; Thomas, RM; Truty, MJ; Varadhachary, GR; Wang, H; Wolff, RA | 1 |
| Abdelmohsen, K; Acosta, Ade J; Brody, JR; Burkhart, RA; Gorospe, M; Iacobuzio-Donahue, CA; Jimbo, M; Laheru, D; Lal, S; Lankapalli, RH; McAllister, F; Moughan, J; Pineda, DM; Winter, JM; Winter, KA; Witkiewicz, AK; Yeo, CJ | 1 |
| Ii, N; Inoue, H; Isaji, S; Kishiwada, M; Kobayashi, M; Mizuno, S; Murata, Y; Sakurai, H; Shiraishi, T; Tabata, M; Usui, M; Yamada, T; Yamakado, K | 1 |
| Adsay, NV; Colbert, LE; Curran, WJ; El-Rayes, BF; Fisher, SB; Gandhi, K; Hall, WA; Hardy, CW; Kooby, DA; Kowalski, J; Landry, JC; Liu, EA; Madden, MZ; Maithel, SK; Nagaraju, GP; Pan, Y; Pantazides, BG; Pauly, R; Petrova, AV; Saka, B; Shelton, JW; Staley, CA; Warren, MD; Yu, DS | 1 |
| Blanco Codesido, M; García Alfonso, P; Martín Jiménez, M; Muñoz Martín, AJ; Pérez Ramírez, S; Rupérez Blanco, AB | 1 |
| Forster, T; Gebhard, MM; Gerhauser, C; Giese, N; Gladkich, J; Gross, W; Heilmann, K; Herr, I; Isayev, O; Labsch, S; Liu, L; Mattern, J; Nessling, M; Nwaeburu, CC; Rausch, V; Richter, K; Schaefer, M; Schemmer, P; Schoensiegel, F; Werner, J; Zhang, Y | 1 |
| Chang, DT; Chaudhry, M; Dholakia, AS; Griffith, ME; Hacker-Prietz, A; Herman, JM; Koong, AC; Laheru, DA; Leal, JP; Oteiza, KE; Pai, J; Pawlik, T; Raman, SP; Su, Z; Tryggestad, E; Wahl, RL; Wolfgang, CL | 1 |
| Ba'ssalamah, A; Brostjan, C; Eisenhut, A; Gnant, M; Kuehrer, I; Sahora, K; Schindl, M; Schoppmann, SF; Stift, J; Telek, B; Werba, G | 1 |
| Iida, T; Nakabayashi, Y; Okui, N; Otsuka, M; Shiba, H; Yanaga, K | 1 |
| Ambre, AH; Borowicz, PP; Guo, B; Haldar, MK; Katti, KS; Katti, P; Kulkarni, PS; Mallik, S; Muhonen, WW; Nahire, RR; Padi, SK; Reindl, K; Shabb, JB; Shrivastava, DK; Singh, RK | 1 |
| Al-Ejeh, F; Biankin, AV; Brown, MP; Chou, A; Grimmond, SM; Kalimutho, M; Khanna, KK; Miranda, M; Nagrial, AM; Pajic, M; Shi, W | 1 |
| Cui, J; Du, Y; Huang, S; Jia, Z; Jiang, W; Kong, X; Li, L; Li, Z; Wei, D; Xie, D; Xie, K | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Frese, KK; Griffiths, JR; Jodrell, DI; Madhu, B; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Bartsch, DK; Fendrich, V; Hudemann, C; Knoop, RF; Lauth, M; Plassmeier, L; Sparn, M; Waldmann, J | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Barth, RJ; Colacchio, TA; Gardner, TB; Gordon, SR; Hessami, N; Klibansky, DA; Mody, K; Pipas, JM; Putra, J; Ripple, GH; Smith, KD; Suriawinata, AA; Tsapakos, MJ; Tsongalis, GJ; Zaki, B | 1 |
| Batra, SK; Dey, P; Ganti, AK; Ponnusamy, MP; Rachagani, S; Vaz, AP | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Gladkich, J; Gross, W; Haberkorn, U; Herr, I; Isayev, O; Liu, L; Mattern, J; Mollenhauer, M; Nwaeburu, CC; Rausch, V; Rückert, F; Schönsiegel, F; Zach, S; Zhang, Y | 1 |
| Arakawa, H; Gong, J; Hayashi, K; Homma, S; Ikegami, M; Imazu, H; Ishidao, T; Ito, M; Kajihara, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Koyama, S; Misawa, T; Mori, M; Odahara, S; Ohkusa, T; Okamoto, M; Shimodaira, S; Sugiyama, H; Tajiri, H; Takakura, K; Toyama, Y; Tsukinaga, S; Uchiyama, K; Yanagisawa, S; Yoshizaki, S; Yusa, S | 1 |
| DeNardo, DG; Goedegebuure, SP; Knolhoff, BL; Linehan, DC; Luo, J; Meyer, MA; Nywening, TM; Wang-Gillam, A; West, BL; Zhu, Y | 1 |
| Hanazaki, K; Iiyama, T; Iwata, J; Kobayashi, M; Kosaki, T; Kozuki, A; Morita, S; Okabayashi, T; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
| Bera, A; Freeman, JW; Hill, P; Manoharan, MS; VenkataSubbaRao, K | 1 |
| Andriulli, A; Burbaci, FP; Cappello, F; Copetti, M; di Mola, FF; di Sebastiano, P; Fontana, A; Graziano, P; Lombardi, L; Maiello, E; Pazienza, V; Pellegrini, F; Rappa, F; Tavano, F; Vinciguerra, M | 1 |
| Abi-Jaoudeh, N; Avital, I; Beane, JD; Beresnev, T; Griffin, KF; Levy, EB; Pandalai, P; Rudloff, U; Shutack, Y; Webb, CC; Wood, B | 1 |
| Bouvet, M; Fujimura, K; Kaushal, S; Kelber, JA; Klemke, RL; Lowy, AM; Metildi, C; Strnadel, J; Wright, T | 1 |
| Bachet, JB; Cros, J; Demetter, P; Fléjou, JF; Maréchal, R; Svrcek, M | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Nguyen, AH; Toste, PA; Wu, N | 1 |
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Burkhart, C; Commane, M; Fleyshman, D; Garrigan, J; Gurova, KV; Kohrn, R; Kurbatov, V; Martello, L; Ramachandran, R; Toshkov, I | 1 |
| Béjot, JL; Berthommé, H; Biollay, C; Buscail, L; Cordelier, P; Epstein, AL; Gayral, M; Hanoun, N; Lulka, H; Sèlves, J; Trempat, P; Vignolle-Vidoni, A | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Kobayashi, S; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Chang, S; Chung, YH; Hwang, Y; Kim, NY; Kim, S; Kim, SJ; Koh, SS; Lee, Y; Min, HJ; Park, EH; Park, YW; Yoo, KS | 1 |
| Aulitzky, WE; Bergmann, L; Burkholder, I; Edler, L; Fuxius, S; Hartung, G; Heil, G; Köberle, D; Maute, L; Moritz, B; Richly, H; Rüssel, J; Scheulen, ME; Weidmann, E; Weigang-Köhler, K; Wörmann, B | 1 |
| Bold, RJ; Daylami, R; Muilenburg, DJ; Virudachalam, S | 1 |
| Duchêne, B; Jonckheere, N; Tréhoux, S; Van Seuningen, I | 1 |
| Han, D; Jin, J; Kim, Y; Min, H; Yi, EC | 1 |
| Aloia, T; Balachandran, A; Conrad, C; Cooper, AB; Evans, DB; Fleming, JB; Fogelman, D; Garg, N; Holmes, HM; Katz, MH; Lee, JE; Ngo-Huang, A; Parker, N; Petzel, M; Slack, R; Varadhachary, G; Vauthey, JN | 1 |
| Awasthi, N; Brekken, RA; Hinz, S; Schwarz, MA; Schwarz, RE | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Huang, P; Ju, HQ; Wu, M; Yanaga, K; Zhuang, ZN | 1 |
| Chen, J; Gao, S; Hao, J; Huang, C; Jia, L; Li, J; Qian, D; Ren, H; Wang, X; Xin, W; Yan, F; Zhao, T | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Marubashi, S; Mori, M; Nagano, H; Ogawa, K; Satoh, T; Takehara, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Sui, YN; Wang, F; Wang, LS; Wang, YH; Yan, K; Zhou, JH | 1 |
| Erkan, M; Esposito, I; Friess, H; Hong, X; Jäger, C; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Valkovska, N; Wu, W | 1 |
| Dredge, K; Hammond, E; Jung, DB; Jung, JH; Kim, B; Kim, EO; Kim, J; Kim, SH; Mukhopadhyay, D; Shridhar, V; Wang, E; Yun, M | 1 |
| Bajor, DL; Byrne, KT; Clendenin, C; Evans, RA; Furth, EE; Meyer, AR; Odorizzi, PM; Stanger, BZ; Vonderheide, RH; Wherry, EJ; Winograd, R | 1 |
| Ahluwalia, D; Bhupathi, D; Hart, CP; Li, W; Liu, Q; Meng, F; Ruprell, AS; Sun, JD; Wang, Y | 1 |
| Cioffi, M; Costello, E; Erkan, M; Greenhalf, W; Heeschen, C; Hidalgo, M; Kleeff, J; Sainz, B; Trabulo, S | 1 |
| Duconseil, P; Dusetti, N; Garcia, S; Gasmi, M; Gayet, O; Gilabert, M; Iovanna, J; Loncle, C; Lopez-Millan, MB; Molejon, MI; Moutardier, V; Ouaissi, M; Poizat, F; Tellechea, JI; Turrini, O | 1 |
| Ettrich, TJ; Perkhofer, L; Seufferlein, T | 1 |
| Bousquet, C; Bousquet-Dubouch, MP; Breibach, F; Chalabi-Dchar, M; Cordelier, P; Delisle, MB; Duluc, C; Gayral, M; Martineau, Y; Mathonnet, M; Moatassim-Billah, S; Perraud, A; Pyronnet, S; Samain, R; Schmid, H; Tomasini, R | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Madnick, DL; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Fortunato, F; Giese, NA; Gladkich, J; Gross, W; Hackert, T; Herr, I; Hinz, U; Liu, L; Ryschich, E; Strobel, O; Zhang, Y | 1 |
| Kamada, T; Kamijo, T; Sai, S; Shirai, T; Vares, G; Wakai, T; Yamada, S | 1 |
| Acin, Y; Atkins, J; Demarchi, M; Deplanque, G; Dubreuil, P; Flynn, P; Hammel, P; Hebbar, M; Hermine, O; Mansfield, CD; Melichar, B; Moussy, A; Moyé, L; Nowara, E; Piquemal, D; Ritter, D | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Petrelli, F | 1 |
| Amano, M; Asada, H; Ikeda, F; Kato, H; Kinugasa, H; Kuwaki, K; Miura, Y; Miyahara, K; Morimoto, Y; Nakahara, T; Nakamura, S; Nishimura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Aicher, A; Cioffi, M; Dorado, J; Hahn, S; Heeschen, C; Hidalgo, M; Lonardo, E; Miranda-Lorenzo, I; Ramirez, JC; Reis Vieira, C; Sainz, B; Sanchez-Ripoll, Y; Trabulo, SM | 1 |
| Beatty, GL; Clendenin, C; Evans, RA; Gladney, WL; Guirnalda, PD; Knoblock, DM; Lee, JW; Long, KB; Luque, SL; Vonderheide, RH; Winograd, R | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
| Abe, H; Baghdadi, M; Higuchi, K; Hirano, S; Inoko, K; Nakamura, T; Nakanishi, S; Sato, S; Seino, K; Shichinohe, T; Takahashi, M; Takano, H; Takeuchi, S; Tsuchikawa, T; Usui, Y; Wada, H | 1 |
| Guo, XZ; Li, HY; Li, YY; Liang, C; Mukaida, N; Ni, QX; Song, Y; Sun, MH; Wang, Z; Yu, XJ | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Alexandrow, MG; Bryant, VL; Elias, RM; McCarthy, SM; Yeatman, TJ | 1 |
| Anderson, K; Au, A; Bailey, P; Biankin, A; Carter, CR; Chang, D; Erler, JT; Evans, TR; Jamieson, NB; Karim, S; Leach, J; Marais, R; McGarry, L; McGhee, E; McKay, C; Miller, BW; Morton, JP; Oien, K; Pinese, M; Sansom, OJ; Saturno, G; Shanks, E; Springer, C; Steele, C; Timpson, P | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| Bianco, T; Borgida, A; Bristow, RG; Cao, P; Cheung, M; Gallinger, S; Hedley, DW; Holter, S; Ibrahimov, E; Kumareswaran, R; Lohse, I; Pintilie, M; Tsao, MS | 1 |
| Brekken, RA; Dellinger, MT; Dineen, SP; Haaland, G; Kirane, A; Lorens, JB; Ludwig, KF; Micklem, D; Ranaweera, R; Sandal, T; Sorrelle, N; Toombs, JE; Wang, M | 1 |
| Aguilar-Saavedra, JR; Beane, JD; Crean, CD; Dumas, RP; Matos, J; Schmidt, CM; Suvannasankha, A; Waters, JA; Yip-Schneider, M | 1 |
| Bai, X; Chen, BW; Chen, W; Hu, L; Liang, C; Liang, T; Shen, J; Wen, L; Xue, F; Zhi, X; Zhou, Y | 1 |
| Bielli, P; Calabretta, S; Capurso, G; Fave, GD; Fendrich, V; Passacantilli, I; Pilozzi, E; Sette, C | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Beesetty, Y; Caprioli, R; Castellanos, JA; Chen, X; Merchant, NB; Moses, HL; Nagathihalli, NS; Reyzer, ML; Shi, C; Skala, MC; Walsh, AJ | 1 |
| Arai, T; Ishiwata, T; Matsuda, Y; Ushijima, T; Yamashita, S; Yoshimura, H | 1 |
| Andersson, R; Ansari, D; Sasor, A; Vaz, J | 1 |
| Crowder, C; Hamner, JB; Singh, G; White, M | 1 |
| Artyukhin, AB; Brekken, RA; Christie, AL; Cruz, VH; Hale, MA; Heath, BR; Kollipara, RK; Lorens, JB; Ocal, O; Pashkov, V; Swift, GH; Tsoulfas, P; Wilkie, TM; Zolghadri, Y | 1 |
| Bai, L; Chen, LZ; Chiao, PJ; Deng, W; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zeng, JB | 1 |
| Craven, KE; Gore, J; Korc, M; Palam, LR; Wilson, JL | 1 |
| Arakawa, H; Ito, Z; Kajihara, M; Kanai, T; Kobayashi, H; Koido, S; Matsumoto, Y; Odahara, S; Ohkusa, T; Okamoto, M; Saito, K; Sugiyama, H; Sumiyama, K; Takakura, K; Takami, S; Tsukinaga, S; Uchiyama, K | 1 |
| Aguilar, M; Chiao, PJ; Fan, X; Fleming, JB; Fu, J; Gocho, T; Iida, T; Iwakura, Y; Ju, HQ; Lee, H; Li, H; Li, M; Li, Z; Ling, J; Melisi, D; Wu, M; Xu, K; Zhou, H; Zhuang, Z | 1 |
| Arrowsmith, C; BeGora, M; Cleary, S; Connor, AA; Crawford, HC; Gallinger, S; Holtzinger, A; Huang, L; Jagan, I; Kalloger, SE; Keller, G; Lohse, I; Muthuswamy, LB; Muthuswamy, SK; Ngai, N; Nostro, C; Renouf, DJ; Roehrl, M; Schaeffer, DF; Tsao, MS; Wang, R | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Dhayat, SA; Haier, J; Hummel, R; Mardin, WA; Matuszcak, C; Mees, ST; Seggewiß, J; Senninger, N; Ströse, AJ | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Kumar, V; Mahato, RI; Mondal, G; Shukla, SK; Singh, PK | 1 |
| Borzomati, D; Coppola, R; D'Angelillo, RM; Fiore, M; Floreno, B; Ippolito, E; Ramella, S; Trecca, P; Trodella, L; Trodella, LE; Valeri, S | 1 |
| Dambrauskas, Z; Gulbinas, A; Jakstaite, A; Kmieliute, K; Maziukiene, A; Silkuniene, G | 1 |
| Deng, M; Evans, D; Fang, Y; Gao, B; Kim, J; Lee, S; Liu, T; Lou, W; Lou, Z; Niu, N; Qin, B; Wang, L; Xie, F; Yu, J; Zhang, H | 1 |
| Binenbaum, Y; Gil, Z; Na'ara, S | 1 |
| Arumugam, T; Cao, J; Deng, D; Li, Z; Logsdon, CD; Ramachandran, V; Xu, L; Yang, J | 1 |
| Hwang, HK; Kang, CM; Kim, H; Kim, MJ; Lee, SH; Lee, WJ; Seong, J; Song, SY | 1 |
| Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Apte, MV; Biankin, AV; Goldstein, D; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Amano, K; Ebihara, T; Hiraki, Y; Hoshino, H; Ikeda, N; Inoue, T; Kamigaki, S; Kato, F; Kawada, M; Kimura, Y; Makari, Y; Mikami, J; Munakata, S; Nakata, K; Nakata, Y; Nishi, H; Ohzato, H; Sasamatsu, S; Shimizu, K; Tsujie, M; Yamamoto, T; Yamamura, J; Yoshimura, J | 1 |
| Fujiwara, H; Hatakeyama, T; Ichikawa, D; Ikoma, H; Imamura, T; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Matsumoto, T; Takebe, A; Tanaka, M; Terai, S; Toyama, H | 1 |
| Beck, JT; Berdov, BA; Devoe, CE; Dychter, S; Gladkov, OA; Harris, WP; Hingorani, SR; Holcombe, RF; Jiang, P; Korn, R; Pshevlotsky, EM; Raghunand, N; Shepard, HM; Tjulandin, SA; Wagner, SA | 1 |
| Abukiwan, A; Amponsah, PS; Bauer, N; Fan, P; Gao, C; Gladkich, J; Gross, W; Herr, I; Liu, L; Nwaeburu, CC; Schemmer, P; Xiao, X; Yin, Y; Zhang, Y; Zhao, Z | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Hirooka, S; Inoue, K; Kon, M; Kotsuka, M; Matsui, Y; Michiura, T; Ryota, H; Satoi, S; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Bockhorn, M; Brockmöller, J; Gaedcke, J; Ghadimi, BM; Güngör, C; Hackert, T; Hank, T; Haubrock, M; Izbicki, JR; Johnsen, SA; Lüske, CM; Pflüger, R; Rapp, J; Roppel, S; Schaudinn, A; Schirmer, MA; Strobel, O; Werner, J; Zimmer, C | 1 |
| Bhagwandin, VJ; Bishop, JM; Shay, JW; Wright, WE | 1 |
| Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Pratt, M; Roife, D | 1 |
| Honda, H; Kamada, T; Saisho, H; Shinoto, M; Shioyama, Y; Terashima, K; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Alborzinia, H; Cheng, X; Duvaci, T; Eisenbrand, G; Fredebohm, J; Ghafoory, S; Hafezi, M; Hoheisel, JD; Holenya, P; Kim, JY; Mehrabi, A; Merz, KH; Rafiee, R; Saffari, A; Theobald, J; Wölfl, S | 1 |
| Ahmad, N; Karki, A; Kong, Y; Konieczny, SF; Li, J; Liu, X; Schweickert, PG; Wang, R; Yang, Y | 1 |
| He, J; Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Dong, Z; Qin, L; Zhang, JT | 1 |
| Chang, T; Egawa, N; Honda, G; Kamisawa, T; Karasawa, K; Kobayashi, S; Kurata, M; Okuda, Y; Omuro, Y; Sakamoto, K; Tsuruta, K | 1 |
| Costello, E; Cox, T; Ghaneh, P; Greenhalf, W; Middleton, G; Neoptolemos, JP; Palmer, DH; Shaw, V | 1 |
| Donahue, TR; Gifford, JB; Hill, R; Hindoyan, A; Huang, W; Wu, H; Zeleniak, AE | 1 |
| Altaf, K; He, D; Ke, N; Li, A; Liu, X; Tan, C; Tang, J; Wang, Y; Xiong, J; Zhang, H | 1 |
| Aoyama, T; Atsumi, Y; Kobayashi, S; Miyagi, Y; Morimoto, M; Morinaga, S; Murakawa, M; Nakamura, Y; Ueno, M; Yamaoku, K; Yokose, T | 1 |
| Bikhchandani, M; Dawson, DW; Donahue, TR; Duong, M; Gawlas, I; Kadera, BE; Li, L; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N | 1 |
| Dutta, R; Karaca, M; Mahato, RI; Ozsoy, Y | 1 |
| Ai, J; Algül, H; Barenboim, M; Campbell, A; Demir, IE; Diakopoulos, KN; Doglioni, C; Görgülü, K; Hagemann, T; Jodrell, D; Karpathaki, AP; Kurkowski, MU; Lesina, M; Neesse, A; Protti, MP; Rose-John, S; Ruess, D; Sansom, O; Schmid, RM; Song, L; Wörmann, SM | 1 |
| Baldwin, GS; Beutler, JA; He, H; Huynh, N; Nikfarjam, M; Yeo, D | 1 |
| Ishiwata, T; Matsuda, Y; Matsushita, A; Naito, Z; Nakamura, Y; Sumiyoshi, H; Uchida, E | 1 |
| Alothman, S; Alqunaibit, D; Avanzi, A; Barilla, R; Daley, D; Engle, D; Giao Ly, NN; Greco, SH; Hajdu, C; Hundeyin, M; Mani, VR; Miller, G; Ochi, A; Pansari, M; Pergamo, M; Rendon, M; Seifert, L; Tippens, D; Tiwari, S; Torres-Hernandez, A; Werba, G; Zambirinis, CP | 1 |
| Azzi, L; Bachet, JB; Bartholin, L; Bernard, D; Cros, J; de la Fouchardière, C; Dubus, P; Gout, J; Griveau, A; Guitton, J; Le Calvé, B; Maréchal, R; Payen, L; Svrcek, M; Vindrieux, D; Wiel, C | 1 |
| Arumugam, P; Bapiro, TE; Carapuça, EF; Delvecchio, FR; Feig, C; Gemenetzidis, E; Grose, RP; Kocher, HM; Lemoine, NR; Richards, FM; Williams, MD; Wilson, AS | 1 |
| Beesetti, S; Bhoopalan, H; Biswal, J; Chidambaram, S; Jagadeeshan, S; Jeyaraman, J; Malathi, R; Mavuluri, J; Nair, AS; Pitani, RS; Raghavan, S; Rayala, SK; Singhal, M; Subramanian, A; Sundaram, S; Surabhi, RP; Tentu, S; Venkatraman, G | 1 |
| Giese, T; Klein, K; Schenk, M; Teske, C; Weitz, J; Welsch, T; Werner, K | 1 |
| Alexander, HR; Bergmann, F; Bernhardt, M; Funamizu, N; Gaedcke, J; Gaida, MM; Ghadimi, BM; Hanna, N; He, P; Hussain, SP; Ried, T; Satoskar, AR; Schetter, A; Tang, W; Uwagawa, T; Wang, J; Werner, J; Yanaga, K; Yang, S | 1 |
| Chiao, PJ; Fan, XQ; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zhou, HJ; Zhuang, ZN | 1 |
| Akahoshi, K; Ban, D; Kirimura, S; Kudo, A; Matsumura, S; Minoru, T; Mitsunori, Y; Oba, A; Ochiai, T; Tanaka, S | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Perez, MVR; Pratt, M; Roife, D | 1 |
| Hirooka, S; Inoue, K; Kon, M; Matsui, Y; Michiura, T; Miyasaka, C; Ohe, C; Ryota, H; Satoi, S; Tanigawa, N; Uemura, Y; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Bailey, P; Balkwill, F; Barry, ST; Biankin, AV; Bryson, S; Candido, JB; Carter, CR; Chang, DK; Clarke, M; Connelly, J; Eberlein, C; Evans, TRJ; Foth, M; Jamieson, N; Karim, SA; Leach, JDG; McDaid, K; Morton, JP; Nibbs, RJB; Nixon, C; Rishi, L; Sansom, OJ; Steele, CW; Strathdee, D; Upstill-Goddard, R; Wilson, Z | 1 |
| Chang, K; Chen, C; Freeman, JW; Jagirdar, J; Karnad, A; Kumar, AP; Zhao, S | 1 |
| Cai, Q; Fu, H; Hu, Z; Shi, J; Wei, Z; Xu, J; Yan, R; Yang, D; Zhang, Y | 1 |
| Byrne, KT; Vonderheide, RH | 1 |
| Bajor, J; Balázs, A; Czakó, L; Czimmer, J; Farkas, G; Gódi, S; Halász, A; Hegyi, P; Izbéki, F; Kahán, Z; Kelemen, D; Kui, B; Lakatos, G; Leindler, L; Papp, R; Pár, G; Szabó, I; Szentesi, A; Szentkereszty, Z; Szepes, Z; Szmola, R; Szücs, Á; Takács, T; Vincze, Á | 1 |
| DeNardo, DG; Hawkins, WG; Hegde, S; Herndon, JM; Jiang, H; Knolhoff, BL; Meyer, MA; Nywening, TM; Pachter, JA; Shapiro, IM; Wang-Gillam, A; Weaver, DT; Zhu, Y | 1 |
| Chen, H; Deng, X; Gu, J; Li, Y; Peng, C; Shen, B; Shi, M; Wang, D; Wang, X; Wei, G; Zhan, Q; Zhang, J; Zhu, Y | 1 |
| Alexander, HR; Gaedcke, J; Gaida, MM; Ghadimi, BM; Hanna, N; He, P; Hussain, SP; Lee, DH; Ried, T; Schetter, AJ; Wang, J; Yang, S; Yfantis, HG | 1 |
| Biederman, L; Blanco, F; Brody, JR; Jimbo, M; Jing, Y; Londin, E; Rigoutsos, I; Telonis, AG; Xia, NL; Zhou, H | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Bahra, M; Bläker, H; Denkert, C; Dörken, B; Jühling, A; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Striefler, JK; Wislocka, L | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Adiseshaiah, PP; Crist, RM; Hook, SS; McNeil, SE | 1 |
| Chen, ZN; Fu, ZG; Jiang, JL; Li, L; Meng, Y; Wu, B; Wu, XQ; Xu, BQ; Xu, L | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomihara, H; Wada, H; Yamada, D | 1 |
| Ciardiello, F; Conzo, G; De Vita, F; Diana, A; Fabozzi, A; Febbraro, A; Galizia, G; Giordano, G; Laterza, MM; Orditura, M; Petrillo, A; Savastano, B; Troiani, T; Ventriglia, J | 1 |
| Adamson, DJ; Arif, SS; Bidoli, P; Carroll, KJ; Chang, D; Cheeseman, S; Dalgleish, AG; Diaz-Beveridge, R; Fernandez-Martos, C; Gaya, A; Glynne-Jones, R; Granetto, C; Martín, AJ; Massuti, B; McAdam, K; McDermott, R; Mudan, SS; Papamichael, D; Pazo-Cid, R; Stebbing, J; Vieitez, JM; Wagle, S; Zaniboni, A | 1 |
| Bernanke, AG; Blobe, GC; Hesler, RA; Huang, JJ; McCall, SJ; Nixon, AB; Starr, MD; Treboschi, VM; White, RR | 1 |
| Akladios, C; Aprahamian, M; Ignat, M; Mutter, D | 1 |
| Korc, M; Kota, J; Kwon, JJ; Quirin, KA; Wek, RC; Willy, JA; Yin, XM | 1 |
| Hwnag, YI; Jeon, J; Kang, JS; Kim, H; Kim, TW; Kim, Y; Lee, WJ; Park, JH; Park, JK | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Du, L; Gao, F; Li, F; Liang, X; Lin, L; Liu, Y; Qiao, X; Qin, P; Xing, L; Zhang, J; Zhao, Q | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY | 1 |
| Biermann, M; Bjånes, T; Dimcevski, G; Gilja, OH; Gjertsen, BT; Hoem, D; Kotopoulis, S; McCormack, E; Molven, A; Postema, M; Schjøtt, J; Sorbye, H | 1 |
| Bachet, JB; Calomme, A; Demetter, P; Drouillard, A; Maréchal, R; Ouazzani, S; Puleo, F; Van Laethem, JL; Verset, G | 1 |
| Chen, K; Chen, X; Duan, W; Han, L; Jiang, Z; Lei, J; Li, J; Li, X; Ma, J; Ma, Q; Ma, Z; Sun, L; Wang, F; Wang, Z; Wu, E; Wu, Z; Xu, Q | 1 |
| Chen, H; Fan, W; He, Y; Hu, H; Tang, S; Wang, P; Xu, P; Xu, Z; Yang, G; Yu, M; Zhang, Z; Zhao, X | 1 |
| Lin, Y; Qin, C; Su, Z; Xian, G; Zhang, Z; Zhao, J | 1 |
| Hirono, S; Imaoka, H; Ishii, H; Katanuma, A; Katsuda, M; Kawai, M; Maguchi, H; Miyazawa, M; Okada, KI; Ozaka, M; Yamao, K; Yamaue, H | 1 |
| Brody, JR; Buchler, M; Costello, E; Dabbish, N; Ghaneh, P; Greenhalf, W; Grigoli, A; Halloran, C; Jiang, W; Jimbo, M; Leiby, BE; Neoptolemos, JP; Palmer, D; Tatarian, T; Winter, JM; Yeo, CJ | 1 |
| Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K | 1 |
| Azad, A; D'Costa, Z; Diana, A; Dushek, O; Fokas, E; Jones, K; Kruger, P; Liu, S; McKenna, WG; Muschel, RJ; Sansom, OJ; Yin Lim, S | 1 |
| Amponsah, PS; Bauer, N; Fan, P; Fellenberg, J; Gladkich, J; Herr, I; Zhao, Z | 1 |
| Bazin, IS; Bodoky, G; Deplanque, G; Elekes, A; Evans, TRJ; Harrison, M; Lin, C; Melichar, B; Moore, MJ; O'Dwyer, PJ; Pezet, D; Rock, E; Rosemurgy, A; Strauss, L; Van Cutsem, E | 1 |
| Biankin, A; Goldstein, D; Johns, A; Mawson, A; McCarroll, J; Nunez, A; Phillips, P; Sharbeen, G; Youkhana, J | 1 |
| Park, K | 1 |
| Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A | 1 |
| Shen, B; Shi, M; Tang, X; Wen, C; Zhang, Y | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Hori, Y; Nishiyama, T; Shimizu, K | 1 |
| Aicher, B; Avan, A; Boggi, U; Funel, N; Giovannetti, E; Granchi, C; Leon, LG; Maftouh, M; Massihnia, D; Minutolo, F; Peters, GJ; Raktoe, R; Russo, A; van Krieken, A | 1 |
| Aboukameel, A; Azmi, AS; Baloglu, E; Kauffman, M; Landesman, Y; Mohammad, RM; Muqbil, I; Philip, PA; Senapedis, W; Shacham, S | 1 |
| Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C | 1 |
| Kang, R; Lotze, MT; Sun, X; Tang, D; Zeh, HJ; Zhang, Q; Zhu, S | 1 |
| Ito, F; Kaneta, A; Miura, J; Otani, S; Saito, T; Tsuchiya, T | 1 |
| Aicher, A; Aires, A; Cortajarena, AL; Heeschen, C; Trabulo, S | 1 |
| Fields, RC; Hawkins, WG; Linehan, DC; Liu, J; Ohman, KA; Strasberg, SM; Tan, BR; Tan, MC | 1 |
| Agaimy, A; Akdemir, KC; Amin, S; Carugo, A; Chin, L; Colla, S; Corti, D; DePinho, RA; Dey, P; Draetta, GF; Fleming, JB; Garvey, J; Genovese, G; Ghosh, P; Giuliani, V; Goggins, MG; Gutschner, T; Heffernan, TP; Jiang, S; Kwong, LN; Leo, E; Li, L; Liu, CG; Maitra, A; Minelli, R; Molin, MD; Muller, F; Nezi, L; Pettazzoni, P; Roberts, CW; Robinson, FS; Seth, S; Sgambato, A; Svelto, M; Takahashi, K; Tepper, J; Toniatti, C; Viale, A; Wang, H; Wood, LD; Wu, CC; Ying, H; Zhang, J | 1 |
| Aoki, T; Hasegawa, K; Hoshikawa, M; Kakimi, K; Kokudo, N; Matsushita, H | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Hasegawa, S; Kawamoto, K; Kishimoto, T; Mikamori, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Wada, H; Yamada, D | 1 |
| Bird, NT; Dodd, J; Elmasry, M; Ghaneh, P; Greenhalf, W; Jones, R; Kitteringham, N; Malik, H; Neoptolemos, JP; Palmer, D; Psarelli, E | 1 |
| Altendorf-Hofmann, A; Betzler, C; Bruns, C; Camaj, P; Däberitz, T; Jauch, KW; Knösel, T; Niess, H; Popp, F; Pozios, I; Seeliger, H; Settmacher, U; Wang, X; Zhao, Y | 1 |
| Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H | 1 |
| Andersson, B; Andersson, R; Ansari, D; Nilsson, J; Said-Hilmersson, K; Sasor, A; Urey, C | 1 |
| Avan, A; Funel, N; Giovannetti, E; Gomez, VE; Griffioen, AW; Leon, LG; Rovithi, M; Verheul, HM; Wurdinger, T | 1 |
| Saif, MW | 1 |
| Ammerpohl, O; Fölsch, UR; Kalthoff, H; Koch, D; Müerköster, SS; Schäfer, H; Sipos, B; Tsao, MS; Werbing, V | 1 |
| Kato, A; Kimura, F; Miyazaki, M; Nomura, F; Ohtsuka, M; Shida, T; Shimizu, H; Takano, S; Togawa, A; Tomonaga, T; Yoshidome, H; Yoshitomi, H | 1 |
| Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
| Abbruzzese, JL; Amos, CI; Chen, J; Evans, DB; Frazier, ML; Killary, AM; Li, D; Sen, S | 1 |
| Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL | 1 |
| Imada, H; Korogi, Y; Morioka, T; Nakano, K; Narisada, H; Ohguri, T; Yahara, K | 1 |
| Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Adams, J; Allard, D; Caldwell, ME; Chang, A; Combs, C; Davidson, CJ; Davies, SE; Denicola, G; Dhara, M; Egorin, M; Feig, C; Frese, KK; Goldgraben, MA; Gopinathan, A; Griffiths, J; Grützmann, R; Hingorani, SR; Honess, D; Howat, WJ; Hruban, RH; Huang, P; Iacobuzio-Donahue, C; Ireland-Zecchini, H; Izeradjene, K; Jacobetz, MA; Madhu, B; McGovern, K; McIntyre, D; Olive, KP; Pilarsky, C; Plunkett, W; Reichelt, S; Rückert, F; Tuveson, DA; Wang, L; Whitebread, N; Winter, SP | 1 |
| Brody, JR; Costantino, CL; Cozzitorto, JA; Dasgupta, A; Gorospe, M; Keen, JC; Kennedy, EP; Kuwano, Y; Witkiewicz, AK; Yeo, CJ | 1 |
| Hanahan, D; Olson, P | 1 |
| Larsen, CJ | 1 |
| Qian, C; Yao, J | 1 |
| Aggarwal, BB; Anand, P; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Pandey, MK; Sethi, G | 1 |
| Abbruzzese, JL; Javle, M; Li, D; Okazaki, T; Tanaka, M | 1 |
| Awasthi, N; Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Shoji, A; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Eguchi, H; Gotoh, K; Ishikawa, O; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H; Yamada, T; Yano, M | 1 |
| Bossone, G; Cognetti, F; Gelibter, AJ; Marolla, P; Milella, M; Pino, MS; Sperduti, I | 1 |
| Hiraya, D; Kagohashi, K; Kondo, T; Sakamoto, N; Satoh, H | 1 |
| Bardeesy, N; Brekken, RA; Carbon, JG; Dineen, SP; Greer, R; Gupta, P; Minna, JD; Roland, CL; Sun, H; Toombs, JE; Williams, N | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Di Marco, M; Macchini, M; Nobili, E; Vecchiarelli, S | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Erozenci, LA; Falcone, A; Funel, N; Giovannetti, E; Groen, A; Leon, LG; Peters, GJ; Pollina, LE; Vasile, E; Verheul, HM | 1 |
| Fujisawa, T; Joshi, BH; Nakajima, A; Nakashima, H; Puri, RK | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Baker, JH; Buczkowski, AK; Cham, KK; Chang, CW; Chu, EM; Chung, SW; Flexman, JA; Kozlowski, P; Minchinton, AI; Ng, SS; Owen, DA; Reinsberg, SA; Scudamore, CH; Takhar, KS; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Brody, JR; Dasgupta, A; Kleer, CG; Potoczek, M; Toll, AD; Witkiewicz, AK; Yeo, CJ | 1 |
| Fujiwara, K; García-García, E; Hidalgo, M; López-Ríos, F; Matsui, WH; Rajeshkumar, NV; Rasheed, ZA | 1 |
| Brown, DB; Carr, BI; Gonsalves, CF; Witkiewicz, AK; Yeo, CJ | 1 |
| Guerra, B; Kreutzer, JN; Ruzzene, M | 1 |
| Van Dyke, T | 1 |
| Erkan, M; Friess, H; Kleeff, J; Michalski, CW; Quan, L; Raggi, MC; Reiser-Erkan, C; Wang, W; Yupei, Z | 1 |
| Abolhassani, M; Baronzio, G; Behzadi, M; Campion, F; Fiorentini, G; Guais, A; Mainini, C; Montagnani, F; Sanders, E; Schwartz, L | 1 |
| Arlt, A; Müerköster, SS; Schäfer, H | 1 |
| Barron, MR; Bentrem, DJ; Dangi-Garimella, S; Grippo, PJ; Heiferman, MJ; Krantz, SB; Munshi, HG; Shields, MA | 1 |
| Fujita, H; Hayashi, A; Itaba, S; Ito, T; Kayashima, T; Manabe, T; Mizumoto, K; Nakata, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Souzaki, R; Tajiri, T; Tanaka, M; Yu, J | 1 |
| Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| Goto, H; Ko, SB | 1 |
| Aparicio, T; Azzedine, A; Barhoumi, M; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Arriví, A; Company, M; Cuadrado, A; Dolz, C; Falcó, E; García Bonafe, M; González de Cabo, M; Morales, R; Noguera, JF; Riera, J; Socías, A; Vicens, JC; Vilella, A | 1 |
| Fujita, H; Hashizume, M; Kayashima, T; Mizumoto, K; Moriyama, T; Nagai, E; Ohtsuka, T; Ohuchida, K; Tanaka, M; Ueda, J | 1 |
| Hasegawa, S; Hayashi, T; Hirayama, K; Ikematsu, Y; Kageyama, S; Kanai, T; Mori, H; Nakata, Y; Nishiwaki, Y; Okawada, T; Ozawa, T; Sugimura, H; Tamura, H | 1 |
| Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J | 1 |
| Beatty, GL; Chiorean, EG; Fishman, MP; Huhn, RD; Li, D; O'Dwyer, PJ; Saboury, B; Sharp, LL; Song, W; Sun, W; Teitelbaum, UR; Torigian, DA; Vonderheide, RH | 1 |
| Collisson, EA; Cooc, J; Danenberg, KL; Feiler, HS; Gibb, WJ; Gray, JW; Gu, S; Hanahan, D; Jakkula, L; Kim, GE; Ko, AH; Olshen, AB; Olson, P; Sadanandam, A; Spellman, PT; Tempero, MA; Truitt, M; Weinkle, J | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Ciombor, KK; Ferrell, A; Flores, A; Levi, J; Lopes, G; Macintyre, J; Merchan, JR; Ribeiro, A; Rocha-Lima, CM; Sleeman, D | 1 |
| Galizia, MS; Miller, FH; Mulcahy, MF; Rezai, P; Small, W; Tochetto, SM; Yaghmai, V | 1 |
| Gattuso, P; Groh, V; Kaufman, HL; Plate, J; Prinz, RA; Rao, GS; Spies, T; Xu, X | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
| Gunn, JR; Korc, M; Sempere, LF | 1 |
| An, Y; Chen, P; Ji, ZL; Jiang, KR; Lu, ZP; Miao, Y; Wie, JS; Wu, JL; Xu, ZK; Yao, J | 1 |
| Bockhorn, M; Effenberger, KE; Güngör, C; Izbicki, JR; Kalinina, T; Vashist, YK; Yekebas, E; Zander, H | 1 |
| Favaudon, V; Fernet, M; Huguet, F; Monnier, L; Touboul, E | 1 |
| de Oliveira, E; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jimeno, A; Karikari, C; Laheru, D; Maitra, A; Rajeshkumar, NV; Rubio-Viqueira, B; Salomon, A; Sharma, R; Tan, AC; Taylor, G; Uson, M; Villaroel, MC | 1 |
| Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Harder, J; Hartmann, A; Hollerbach, S; Kullmann, F; Kutscheidt, A; Messmann, H; Stöhr, R; Trojan, J; Troppmann, M | 1 |
| Assmann, G; Bader, DC; Bruns, C; Buchner, D; De Toni, EN; Gallmeier, E; Göke, B; Guo, Y; Jung, A; Kirchner, T; Laubender, RP; Ochs, S; Palagyi, A; Schäfer, C; Seeliger, H; Ziesch, A | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE; Yen, PL | 1 |
| Dovzhanskiy, DI; Felix, K; Giese, NA; Krysko, DV; Welsch, L; Welsch, T; Werner, J | 1 |
| Han, S; Hu, G; Jiang, Z; Li, F; Ouyang, K; Qin, X; Tang, X; Wang, K; Wen, D; Xie, F; Zhang, L; Zhu, M | 1 |
| Conroy, T; Mitry, E | 1 |
| Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S | 1 |
| Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Kitasato, Y; Mikagi, K; Nakayama, M; Okabe, Y; Yasunaga, M; Yoshitomi, M | 1 |
| Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S | 1 |
| Ausseil, F; Cordelier, P; Dedieu, L; Ducommun, B; Dufau, I; Frongia, C; Sicard, F; Valette, A | 1 |
| Abdalla, EK; Balachandran, A; Crane, CH; Fleming, JB; Fogelman, DR; Katz, MH; Lee, JE; Pisters, PW; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wolff, RA; Xiao, L | 1 |
| Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
| Bapiro, TE; Cook, N; Demuth, T; Frese, KK; Gopinathan, A; Howat, WJ; Jacobetz, MA; Jodrell, DI; Miller, JL; Rao, SS; Tuveson, DA | 1 |
| Alexander, HR; Funamizu, N; Gaedcke, J; Ghadimi, BM; Hanna, N; Hassan, R; He, P; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Yfantis, HG; Zhang, G | 1 |
| Abdollahi, A; Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Hof, H; Kessel, K; Rieken, S; Schirmacher, P; Weitz, J; Welzel, T; Werner, J | 1 |
| Bae, I; Hong, YB; Kim, JS; Seong, YS; Yi, YW | 1 |
| Brody, JR; Holdbrook, T; Leiby, BE; Littman, SJ; Pequignot, E; Valsecchi, ME; Witkiewicz, AK; Yeo, CJ | 1 |
| Chang, AE; Cuevas, C; Goel, VK; Hingorani, SR; Provenzano, PP; Von Hoff, DD | 1 |
| Chalasani, P; Jolivet, J; Kurtin, S; Mahadevan, D; Pretzinger, C; Ramanathan, RK; Rensvold, D; Von Hoff, DD; Weiss, GJ | 1 |
| Bapiro, TE; Caldwell, ME; Chan, DS; Cook, N; Feig, C; Frese, KK; Frost, GI; Jacobetz, MA; Jiang, P; Jodrell, DI; Kultti, A; Lolkema, MP; Maneval, DC; Nakagawa, T; Neesse, A; Shepard, HM; Skepper, JN; Thompson, CB; Tuveson, DA; Zecchini, HI | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Clark, JW | 1 |
| Bapiro, TE; Cook, N; Frese, KK; Jodrell, DI; Lolkema, MP; Neesse, A; Tuveson, DA | 1 |
| Chen, Y; Liang, X; Lin, C; Luan, Q; Ma, F; Meng, X; Pei, W; Qian, H; Wang, H; Zhan, Q; Zhang, X; Zhao, P; Zhao, Z; Zhou, S | 1 |
| Avan, A; Crea, F; Danesi, R; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Marquez, VE; Paolicchi, E; Peters, GJ | 1 |
| Chen, H; Chen, J; Jin, G; Ma, H; Shao, Z; Wang, Y; Xu, X | 1 |
| Jiang, W; Lin, J; Liu, X; Thomas, DG; Xie, H | 1 |
| Arnold, SM; Dovzhanskiy, DI; Felix, K; Giese, N; Hackert, T; Oehme, I; Werner, J; Witt, O | 1 |
| André, T; Bachet, JB; Bardier-Dupas, A; Cass, CE; Closset, J; Couvelard, A; Dalban, C; Demetter, P; Devière, J; Dumontet, C; Emile, JF; Graham, K; Hammel, P; Jordheim, LP; Louvet, C; Mackey, JR; Maréchal, R; Matera, EL; Paye, F; Penna, C; Rougier, P; Salmon, I; Sauvanet, A; Svrcek, M; Van Laethem, JL | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 2 |
| Costello, E; Greenhalf, W; Neoptolemos, JP | 1 |
| Adesso, L; Barbagallo, F; Calabretta, S; Capurso, G; Delle Fave, G; Geremia, R; Pilozzi, E; Sette, C | 1 |
| Alexander, HR; Back, TC; Chan, T; Funamizu, N; Gaedcke, J; Ghadimi, MB; Hanna, N; He, P; Hu, C; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Subleski, J; Weiss, JM; Yanaga, K; Yfantis, HG; Zhang, G | 1 |
| Frampton, AE; Jiao, LR; Krell, J; Stebbing, J | 1 |
| Duan, W; Li, X; Liu, H; Ma, Q; Wu, E; Xu, H | 1 |
| Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM | 1 |
| Kagohashi, K; Kurishima, K; Nakazawa, K; Satoh, H; Tamura, T | 1 |
| Gremeaux, L; Topal, B; Van den Broeck, A; Vankelecom, H | 1 |
| Hayashi, A; Ishigaki, Y; Motoo, Y; Shimasaki, T; Takata, T; Tomosugi, N; Tsuchida, H | 1 |
| Avan, A; Frampton, AE; Funel, N; Giovannetti, E; Maftouh, M; Nicolini, F; Pelliccioni, S; Peters, GJ; Quint, K; Schuurhuis, GJ | 1 |
| Bachet, JB; Rougier, P; Seufferlein, T; Van Cutsem, E | 1 |
| Basu, B; Jodrell, D | 1 |
| Bandarchi, B; Leung, L; Organ, S; Panchal, D; Pintilie, M; Radulovich, N; To, C; Tsao, MS; Zhu, CQ | 1 |
| Al-Wadei, HA; Banerjee, J; Schuller, HM | 1 |
| Boettcher, M; Eisen, C; Fredebohm, J; Gaida, MM; Giese, NA; Greulich-Bode, KM; Heller, A; Hoheisel, JD; Hotz-Wagenblatt, A; Keleg, S; Lathrop, M; Tost, J | 1 |
| An, Y; Cai, B; Chen, J; Gao, W; Jiang, K; Li, Q; Lv, N; Miao, Y; Tang, D; Tu, M; Wei, J; Wu, J; Xue, X; Yao, J | 1 |
| Chiorean, EG; Elzey, BD; Hazbun, T; Konieczny, SF; Kuang, S; Liu, X; Liu, XS; Ratliff, TL; Rice, SJ; Song, B | 1 |
| Krug, S; Michl, P | 1 |
| Bayry, J; Bazhin, AV; Karakhanova, S; Link, J; Shevchenko, I; Soltek, S; Umansky, V; Werner, J | 1 |
| Abdel-Rahman, S; Berger, F; Dieterle, N; Issels, RD; Milani, V; Salat, C; Tschoep-Lechner, KE | 1 |
| Boggi, U; Campani, D; Caparello, C; Caponi, S; Cappelli, C; Costa, F; De Lio, N; Falcone, A; Funel, N; Ginocchi, L; Lencioni, M; Lucchesi, M; Mosca, F; Pollina, L; Ricci, S; Vasile, E | 1 |
| Brullé, L; Le Pape, A; Lerondel, S; Martel, E; Pouvesle, JM; Richard, S; Riès, D; Robert, E; Trichet, V; Vandamme, M | 1 |
| Duan, X; Mao, X; Sun, W | 1 |
| Asaoka, Y; Ijichi, H; Ikenoue, T; Isayama, H; Koike, K; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Omata, M; Tada, M; Tateishi, K; Yamamoto, K | 1 |
| Buscail, L; Cordelier, P; Delpu, Y; Hanoun, N; Lopez, F; Lulka, H; Saint-Laurent, N; Sicard, F; Torrisani, J | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakamori, S; Nakazuru, S; Okami, J; Sakon, M; Tsujie, M; Umeshita, K | 1 |
| Schramm, H | 1 |
| Cooper, AJ; Johnson, CD; Whitehouse, PA | 1 |
| Boige, V; Ducreux, M; Malka, D | 1 |
| Elomaa, I; Joensuu, TK; Kärkkäinen, P; Kiviluoto, T; Kivisaari, L; Tenhunen, M; Vento, P; Westberg, R | 1 |
| Cronk, M; Thomson, D; Walpole, E | 1 |
| Dühmke, E; Heinemann, V; Thoma, M; Weingandt, H; Wilkowski, R | 1 |
| Akazawa, Y; Isomoto, H; Kohno, S; Mizuta, Y; Nakagoe, T; Ohara, H; Ohba, K; Ohnita, K; Omagari, K; Shiozawa, K; Shirono, K; Takeshima, F; Tanaka, K; Yasutake, T | 1 |
| Doi, R; Fujimoto, K; Ito, D; Kami, K; Kawaguchi, Y; Koizumi, M; Mori, T; Toyoda, E | 1 |
| Beck, AM; Carrigan, PE; Hayes, GM; Miller, LJ | 1 |
| Hirono, S; Ina, S; Kawai, M; Tani, M; Terasawa, H; Uchiyama, K; Yamaue, H | 1 |
| Brueckl, WM; Brunner, TB; Grabenbauer, GG; Meyer, T; Sauer, R; Tinkl, D | 1 |
| Kopchak, KV; Kopchak, VM; Romaniv, IaV | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Michalski, C | 1 |
| Cai, LZ; Fu, YW; Liang, QL; Liu, GX; Pan, DC; Xie, JR; Yang, Q; Yin, ZM | 1 |
| Chen, G; Chen, H; Friess, H; Greenblatt, DY; Guo, J; Kleeff, J; Leung, PS; Liao, Q; Shen, S; Zhao, Y | 1 |
| Fok, JY; Kumar, R; Manavathi, B; Mann, AP; Mehta, K; Verma, A; Wang, H | 1 |
| Schmid, RM | 1 |
| Ashley, SW; Liau, SS; Whang, EE | 1 |
| Buchsbaum, DJ; DeRosier, LC; Huang, ZQ; Sellers, JC; Vickers, SM | 1 |
| Ammerpohl, O; Griep, U; Grutzmann, R; Janssen, O; Kalthoff, H; Kloppel, G; Pilarsky, C; Saeger, HD; Schniewind, B; Sipos, B; Trauzold, A | 1 |
| Adler, G; Seufferlein, T; von Wichert, G | 1 |
| Fok, JY; Mehta, K | 1 |
| Brunetti, E; Bucci, B; Michienzi, S; Misiti, S; Panacchia, L; Patriarca, V; Stigliano, A; Toscano, V; Verga Falzacappa, C | 1 |
| Fukushima, M; Maruyama, R; Nio, Y; Toga, T | 1 |
| Nimura, Y | 1 |
| Cao, P; Hedley, DW; Pham, NA; Tsao, MS | 1 |
| Husain, SR; Kioi, M; Nakajima, A; Puri, RK; Royal, RE; Shimamura, T | 1 |
| Ammerpohl, O; Bohm, B; Brockschmidt, C; Eismann, T; Giamas, G; Henne-Bruns, D; Hillenbrand, A; Hirner, H; Huber, N; Kalthoff, H; Knippschild, U; Leithäuser, F; Radunsky, B; Trauzold, A | 1 |
| Gallick, GE; Kim, MP | 1 |
| Liau, SS; Whang, E | 1 |
| Clarenbach, R; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt, T; Schmidt-Wolf, IG; Schmitz, V; Tiemann, K; Ziske, C | 1 |
| Abbruzzese, JL; Chang, P; Evans, DB; Jiao, L; Li, D; Okazaki, T | 1 |
| Bevilacqua, G; Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Del Tacca, M; Funel, N; Giovannetti, E; Mey, V; Mosca, F; Nannizzi, S; Pollina, LE; Ricciardi, S | 1 |
50 review(s) available for gemcitabine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Cytotoxic Nitrobenzoyl Sesquiterpenoids from an Antarctica Sponge-Derived
Topics: Antarctic Regions; Antineoplastic Agents; Apoptosis; Aspergillus; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Sesquiterpenes | 2022 |
Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Ferroptosis; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Reactive Oxygen Species; Signal Transduction | 2021 |
Pancreatic Adenocarcinoma Management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Metastatic pancreatic ductal adenocarcinoma followed by a fatal diffuse large B-cell lymphoma: A rare case report and literature review.
Topics: Adenocarcinoma; Aged; Carcinoma, Pancreatic Ductal; Female; Gemcitabine; Humans; Lymphadenopathy; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms | 2023 |
Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies.
Topics: Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Deacetylases; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA, Untranslated; Signal Transduction; Tumor Microenvironment | 2019 |
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Topics: Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Tumor Microenvironment | 2020 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease Management; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Precision Medicine | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Ducts; Pancreatic Neoplasms; Signal Transduction | 2017 |
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neoplasm Staging; Osteonectin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Permeability; Treatment Outcome | 2017 |
Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Topics: Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Osteonectin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pyridines; Stromal Cells; Survival Analysis; Treatment Outcome | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
Advances in oncolytic adenovirus therapy for pancreatic cancer.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2018 |
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Frail Elderly; Frailty; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review.
Topics: Activating Transcription Factor 6; Animals; Antibodies; Carcinoma, Pancreatic Ductal; Communicable Diseases; Deoxycytidine; Diabetes Complications; Disease Models, Animal; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression Regulation; Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Pancreatitis, Chronic; Protein Serine-Threonine Kinases; Risk Factors; RNA, Small Interfering; Sulfones | 2018 |
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Tumor Burden | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2019 |
Pancreatic Ductal Adenocarcinoma Derived From an Intraductal Papillary Neoplasm With Synchronous Incidental Glucagonoma: A Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Glucagonoma; Humans; Incidental Findings; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Treatment Outcome | 2019 |
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome; Tumor Microenvironment | 2014 |
Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival | 2015 |
SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms; Prognosis; Signal Transduction; Treatment Outcome | 2015 |
Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleotide Reductases; Signal Transduction; Survival Analysis; Tumor Microenvironment | 2015 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Delivery Systems; Extracellular Matrix; Gemcitabine; Hedgehog Proteins; Humans; Nanomedicine; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2017 |
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radiotherapy, Adjuvant; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Differentiation; Chemoembolization, Therapeutic; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Targeting apoptosis pathways in pancreatic cancer.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Histone Deacetylases; Humans; MAP Kinase Signaling System; MicroRNAs; NF-kappa B; Pancreatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; ras Proteins; TOR Serine-Threonine Kinases | 2013 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cystadenoma, Mucinous; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, Tumor Suppressor; Humans; Intercellular Signaling Peptides and Proteins; Mutation; Neoplasm Proteins; Oncogenes; Pancreatic Neoplasms; Precancerous Conditions; Radiation Tolerance; Signal Transduction | 2011 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; CD40 Antigens; Computational Biology; Deoxycytidine; Drug Therapy, Combination; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Gene Rearrangement; Hedgehog Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2012 |
Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment.
Topics: Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Neuronal Plasticity; Paracrine Communication; Tumor Microenvironment | 2012 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Emerging drugs in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Growth Inhibitors; Humans; Immunotherapy; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Receptors, Growth Factor; Risk Factors; Survival Rate; Treatment Outcome | 2004 |
Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal | 2005 |
Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Pancreatic Ductal; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2005 |
Pancreatic cancer: from bench to 5-year survival.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticojejunostomy; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
[Palliative treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Incidence; Nutrition Therapy; Pain Management; Palliative Care; Pancreatic Neoplasms; Quality of Life | 2007 |
[Treatment of pancreatic cancer--surgical point of view].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2007 |
99 trial(s) available for gemcitabine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.
Topics: Aged; Aged, 80 and over; Albumins; Arteries; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Vascular Neoplasms | 2021 |
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2022 |
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Stromal Cells | 2021 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Tumor Microenvironment; Tyrosine Kinase Inhibitors | 2023 |
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Gemcitabine; Humans; Male; Middle Aged; Mucin 5AC; Paclitaxel; Pancreatic Neoplasms | 2023 |
Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Gemcitabine; Humans; Hyperthermia, Induced; Paclitaxel; Pancreatic Neoplasms; Protons | 2023 |
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2019 |
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2019 |
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Non-Randomized Controlled Trials as Topic; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2020 |
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Topics: Aged; Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Pyridines; Treatment Outcome | 2020 |
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors | 2020 |
Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2020 |
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Heparitin Sulfate; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Rate | 2020 |
Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Perioperative Care; Prospective Studies; Treatment Outcome | 2020 |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Analysis | 2021 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Topics: Adenocarcinoma; Aged; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Mucin-1; WT1 Proteins | 2020 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2021 |
Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients.
Topics: Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Interleukin-10; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Thrombocytopenia | 2021 |
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Prospective Studies; Survival Rate; Treatment Outcome | 2021 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; China; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2021 |
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2021 |
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Treatment Outcome; Young Adult | 2017 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Margins of Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Analysis | 2019 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cisplatin; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Vaccines, Subunit; WT1 Proteins | 2018 |
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzene Derivatives; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Propionates; Receptors, Notch; Signal Transduction; Sulfones | 2018 |
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Arctium; Area Under Curve; Biomarkers; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Furans; Gemcitabine; Gluconeogenesis; Humans; Kaplan-Meier Estimate; Kidney; Lactic Acid; Lignans; Liver; Mitochondria; Oxidative Phosphorylation; Pancreatic Neoplasms; Plant Extracts | 2018 |
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Janus Kinase 1; Janus Kinase 2; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Pyrimidines; Tissue Distribution | 2019 |
Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemora
Topics: Aged; Antimetabolites, Antineoplastic; Ascitic Fluid; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment | 2018 |
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult | 2018 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms; Polyethylene Glycols; Progression-Free Survival; Proportional Hazards Models | 2018 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Topics: Administration, Oral; Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Multicenter Studies as Topic; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Young Adult | 2019 |
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Benzimidazoles; Blood Coagulation; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Factor VIIa; Female; Gemcitabine; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Time Factors | 2019 |
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Repositioning; Gemcitabine; Humans; Maximum Tolerated Dose; Paclitaxel; Pancreas; Pancreatic Neoplasms; Patient Selection; Research Design; Response Evaluation Criteria in Solid Tumors; Tretinoin | 2019 |
Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.
Topics: Acute Disease; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2019 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tegafur | 2013 |
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2013 |
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate | 2013 |
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Macrophages; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Survival; Treatment Outcome | 2013 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Survival Rate | 2014 |
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Osteonectin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2014 |
Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Topics: Aged; Antimetabolites, Antineoplastic; Biological Transport, Active; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Adducts; DNA, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Biological; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tomography, X-Ray Computed | 2014 |
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Blood Glucose; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Induction Chemotherapy; Liver; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiosurgery; Regression Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Epitopes; Female; Follow-Up Studies; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Survival Rate; T-Lymphocytes, Cytotoxic; Vaccination; WT1 Proteins | 2014 |
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advance
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Catheterization; Deoxycytidine; Duodenal Diseases; Duodenum; Female; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Ischemia; Male; Maximum Tolerated Dose; Middle Aged; Pancreas; Pancreatic Neoplasms; Perfusion; Splenic Artery; Treatment Outcome | 2015 |
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2015 |
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Pharmacogenetics; Piperidines; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunologic Tests; Immunotherapy; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; WT1 Proteins | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal | 2015 |
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Russia; Treatment Outcome; United States | 2016 |
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polysaccharides; Survival Analysis; Treatment Outcome | 2016 |
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2015 |
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C-Reactive Protein; CA-19-9 Antigen; Cancer Vaccines; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2016 |
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Europe; Female; Gemcitabine; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2016 |
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Microbubbles; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; Ultrasonic Therapy | 2016 |
Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epitopes; Female; Gemcitabine; HLA-A24 Antigen; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Kinesins; Male; Middle Aged; Neoplasm Proteins; Pancreatectomy; Pancreatic Neoplasms; Peptide Fragments; T-Cell Antigen Receptor Specificity; T-Lymphocytes, Cytotoxic; Vaccines, Subunit; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cytoplasm; Deoxycytidine; Disease-Free Survival; ELAV-Like Protein 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Tissue Array Analysis; Treatment Outcome | 2018 |
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dasatinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Treatment Outcome | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Interferon-alpha; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Missouri; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Transplantation, Autologous | 2017 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate | 2017 |
A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Radiotherapy, Adjuvant; Survival Rate; Time Factors; Tumor Protein p73; Tumor Suppressor Proteins | 2009 |
Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2010 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Remission Induction | 2011 |
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Humans; Immunologic Surveillance; Macrophage Activation; Macrophages; Male; Mice; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes; Tumor Microenvironment; Young Adult | 2011 |
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Burden | 2011 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, ras; Humans; Middle Aged; Mutation; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2011 |
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2004 |
[Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA Damage; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Radiotherapy | 2008 |
642 other study(ies) available for gemcitabine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Drug Design; Endoplasmic Reticulum Chaperone BiP; Humans; Mice; Mitochondria; Oxidative Stress; Pancreatic Neoplasms; Quinazolinones; Reactive Oxygen Species; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2018 |
Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Computational Biology; Computer Simulation; Deoxycytidine; DNA Damage; Down-Regulation; Drug Design; Drug Resistance, Neoplasm; G-Quadruplexes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Syntheses and anti-pancreatic cancer activities of rakicidin A analogues.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combinatorial Chemistry Techniques; Humans; Lipopeptides; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides, Cyclic; Structure-Activity Relationship; Tumor Hypoxia | 2018 |
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Thiadiazoles; Thiophenes; Tumor Cells, Cultured | 2020 |
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Silencing; Genes, Homeobox; Hedgehog Proteins; Homeodomain Proteins; Humans; Mice; Pancreatic Neoplasms; Signal Transduction; Zinc Finger Protein GLI1 | 2022 |
Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome.
Topics: Aged; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enterobacteriaceae; Female; Gemcitabine; Humans; Male; Microbiota; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Stents; Tumor Microenvironment | 2021 |
Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptors, CXCR4; RNA, Small Interfering; Tissue Distribution | 2021 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Self Renewal; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Multimodal Imaging; Pancreatic Neoplasms; Tumor Microenvironment | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Tumor Microenvironment | 2022 |
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Endothelial Cells; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2022 |
Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Probability; Prognosis; Retrospective Studies | 2022 |
Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Methylenetetrahydrofolate Dehydrogenase (NADP); MicroRNAs; Minor Histocompatibility Antigens; Pancreatic Neoplasms; RNA, Circular | 2022 |
Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Autophagy; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nuclear Receptor Subfamily 4, Group A, Member 2; Pancreatic Neoplasms; Receptors, Cytoplasmic and Nuclear | 2021 |
Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer.
Topics: Bacteria; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lipopolysaccharides; Pancreatic Neoplasms | 2022 |
Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models.
Topics: Animals; Bacteria; Butyrates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Pancreatic Neoplasms | 2022 |
Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glycolysis; Humans; Pancreatic Neoplasms; Pentose Phosphate Pathway | 2022 |
HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases | 2022 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment.
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Energy Metabolism; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Colchicine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; LIM Domain Proteins; Mice; Neoplasm Proteins; NF-kappa B; Nucleosomes; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamate-Ammonia Ligase; Glutaminase; Glutamine; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonuclease III; RNA, Small Interfering | 2022 |
Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Pancreatic Neoplasms; RNA, Long Noncoding; Tandem Mass Spectrometry | 2022 |
Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.
Topics: Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Gemcitabine; Humans; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Tomography; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2022 |
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hypoxia; Mice; Oxidoreductases Acting on CH-CH Group Donors; Pancreatic Neoplasms; Tumor Microenvironment | 2022 |
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.
Topics: Aminoglycosides; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Enediynes; ErbB Receptors; Gemcitabine; Humans; Ligands; NF-kappa B; Pancreatic Neoplasms; Smad4 Protein; TOR Serine-Threonine Kinases | 2022 |
Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15.
Topics: Anti-Inflammatory Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Receptors, Peptide; RNA, Small Interfering; Thrombomodulin | 2022 |
High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway.
Topics: Animals; Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Matrix Metalloproteinase 3; Mice; Pancreatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Streptozocin | 2022 |
Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2022 |
A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diet, Ketogenic; Female; Gemcitabine; Male; Mice; Pancreatic Neoplasms | 2022 |
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Signal Transduction | 2023 |
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Topics: Apoptosis; Arsenic Trioxide; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Clusterin; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 1-beta; Humans; Mice; Pancreatic Neoplasms | 2022 |
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Topics: Animals; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Mice; Myeloid-Derived Suppressor Cells; Oncolytic Viruses; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Pharmacoinformatic screening of phytoconstituent and evaluation of its anti-PDAC effect using
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Ligands; Pancreatic Neoplasms | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Immunity; Insulins; Male; Metformin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism.
Topics: Carcinoma, Pancreatic Ductal; Diclofenac; Gemcitabine; Humans; Nucleotidases; Pancreatic Neoplasms | 2023 |
A small Rho GTPase RAB25 with a potential role in chemotherapy resistance in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; rab GTP-Binding Proteins | 2023 |
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Hypoxia; Pancreatic Neoplasms | 2023 |
A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.
Topics: Animals; Biomimetics; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2023 |
Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.
Topics: Alginates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2023 |
hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Pancreatic Neoplasms | 2023 |
Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2023 |
Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy.
Topics: Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering | 2023 |
Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Transforming Growth Factor beta1 | 2023 |
Quantifying heterogeneity to drug response in cancer-stroma kinetics.
Topics: Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing.
Topics: Acetyltransferases; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Immunity; Pancreatic Neoplasms | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Medicare; Pancreatic Neoplasms; Retrospective Studies; United States | 2023 |
In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrogels; Immunotherapy; Membrane Proteins; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.
Topics: Adenosine; Animals; Carcinoma, Pancreatic Ductal; DEAD-box RNA Helicases; Gemcitabine; Humans; Lung Neoplasms; Methylation; Methyltransferases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger | 2023 |
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Coenzyme A Ligases; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Ferroptosis; Gemcitabine; Humans; Mice; MicroRNAs; Pancreatic Neoplasms | 2023 |
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.
Topics: Artificial Intelligence; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Hypoxia; Mice; Pancreatic Neoplasms; Prodrugs; Recombinational DNA Repair | 2023 |
Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Mice; Mucin-1; Pancreatic Neoplasms; Receptors, Calcitriol | 2023 |
Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Interleukin-13 Receptor alpha2 Subunit; Mice; Pancreatic Neoplasms | 2022 |
Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transforming Growth Factor beta | 2023 |
Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA, Mitochondrial; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species | 2023 |
Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Treatment Outcome | 2023 |
TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Gemcitabine; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Prognosis | 2023 |
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Gemcitabine; Humans; Irbesartan; Mice; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Topics: Angiopoietin-Like Protein 4; Apolipoprotein L1; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Transcriptome | 2023 |
Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Mitochondria; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Immune Tolerance; Immunosuppression Therapy; Mice; Pancreatic Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages | 2023 |
Species-Deconvolved Proteomics for
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Heterografts; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Proteomics; Reproducibility of Results | 2023 |
Reversible promoter demethylation of PDGFD confers gemcitabine resistance through STAT3 activation and RRM1 upregulation.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Demethylation; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Humans; Lymphokines; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Ribonucleoside Diphosphate Reductase; Up-Regulation | 2023 |
N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cdh1 Proteins; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Messenger | 2023 |
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin-7; RNA, Guide, CRISPR-Cas Systems; STAT5 Transcription Factor | 2023 |
Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Heat-Shock Response; Humans; Pancreatic Neoplasms; Pyruvaldehyde | 2023 |
A Ketogenic Diet in Combination with Gemcitabine Mitigates Pancreatic Cancer-Associated Cachexia in Male and Female KPC Mice.
Topics: Animals; Cachexia; Carcinoma, Pancreatic Ductal; Diet, Ketogenic; Female; Gemcitabine; Male; Mice; Pancreatic Neoplasms | 2023 |
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Fibroblasts; Gemcitabine; Interleukin-2; Lymphocytes; Mice; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Thalidomide; Xenograft Model Antitumor Assays | 2023 |
Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α expression.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hypoxia; Pancreatic Neoplasms; Up-Regulation | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as an Image-Guided Tumor-Selective Drug-Delivery System to Treat Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms | 2023 |
Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine Kinase; ELAV-Like Protein 1; Gemcitabine; Humans; Pancreas; Pancreatic Hormones; Pancreatic Neoplasms; Receptors, Aryl Hydrocarbon; RNA, Messenger | 2023 |
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
Topics: Animals; Carcinoma, Pancreatic Ductal; Core Binding Factor Alpha 2 Subunit; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Peptide Initiation Factors | 2023 |
Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
Topics: Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; T-Lymphocyte Subsets | 2023 |
Matrix stiffness triggers chemoresistance through elevated autophagy in pancreatic ductal adenocarcinoma.
Topics: Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunization; Pancreatic Neoplasms; Stromal Cells; Tumor Microenvironment; Vaccines, DNA | 2023 |
Tumor Microenvironment Responsive CD8
Topics: Animals; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Gemcitabine; Mice; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Wnt Signaling Pathway; Wnt-5a Protein | 2023 |
Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Topics: Apoptosis; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; Niclosamide; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Ubiquitination; Wnt Signaling Pathway | 2023 |
Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome.
Topics: Animals; B7-H1 Antigen; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2023 |
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Growth Inhibitors; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases | 2023 |
LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Fructose-Bisphosphate Aldolase; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Pancreatic Neoplasms; Phenotype; Phosphatidylinositol 3-Kinases; Tumor Microenvironment | 2023 |
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Mice; Mucins; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms | 2023 |
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; DNA Damage; Gemcitabine; Hepatocyte Nuclear Factor 3-alpha; Humans; MicroRNAs; Mixed Function Oxygenases; Pancreatic Neoplasms; Proto-Oncogene Proteins; RNA Precursors; RNA, Circular | 2023 |
Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Xenograft Model Antitumor Assays | 2019 |
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Integrins; Male; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptidomimetics; Xenograft Model Antitumor Assays | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors | 2020 |
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Topics: Adenocarcinoma; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Mice; Nuclear Proteins; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2019 |
Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intestine, Small; Lab-On-A-Chip Devices; Microfluidic Analytical Techniques; Models, Biological; Neoplasm Proteins; Pancreatic Neoplasms | 2019 |
Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Exercise; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Physical Conditioning, Animal; Vascular Remodeling; Xenograft Model Antitumor Assays | 2019 |
Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Models, Biological; Mucin-1; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Computational Biology; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Deletion; Humans; Pancreatic Neoplasms; Smad4 Protein; Tumor Cells, Cultured | 2019 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Receptors, Interleukin-17; Tissue Array Analysis; Vascular Endothelial Growth Factor A | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoglobulin G; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; THP-1 Cells; Xenograft Model Antitumor Assays | 2019 |
Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Topics: ADAM Proteins; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Datasets as Topic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Sequence Analysis, RNA; Up-Regulation | 2019 |
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2020 |
ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2020 |
Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2020 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2019 |
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2019 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Damage; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Naphthyridines; Pancreatic Neoplasms; RNA, Messenger; Spheroids, Cellular | 2019 |
Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Microenvironment; Ultrasonic Therapy | 2019 |
Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prognosis; Prospective Studies; Renal Insufficiency; Survival Rate | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Typing; Oxaliplatin; Pancreatic Neoplasms; Proteome; Proteomics; Survival Rate; Treatment Outcome | 2020 |
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Topics: Albumins; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interferon-gamma; Killer Cells, Natural; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin Thiolesterase | 2020 |
Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2020 |
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutaminase; Glutamine; Heterografts; Humans; Mice; Mice, Nude; Mutation; Neoplasm Proteins; NF-E2-Related Factor 2; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Random Allocation; Tissue Array Analysis; Up-Regulation | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dasatinib; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Stromal Cells; Survival Analysis; Xenograft Model Antitumor Assays | 2020 |
PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Topics: 3' Untranslated Regions; Adenocarcinoma; Animals; Autophagy; Autophagy-Related Protein 12; Base Sequence; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Stress, Physiological; Tumor Hypoxia; Up-Regulation | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Staff, Hospital; Middle Aged; Netherlands; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Regression Analysis; Young Adult | 2020 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Magnetite Nanoparticles; Male; Metformin; Mice, Inbred BALB C; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides | 2020 |
Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Fluorescent Dyes; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Organoids; Pancreatic Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Heat-Shock Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Chaperones; Pancreatic Neoplasms; Phosphorylation; Prognosis; Survival Rate | 2020 |
Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression.
Topics: Bias; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Regression Analysis | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Duration of Therapy; Emergency Service, Hospital; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Insurance, Health; Irinotecan; Leucovorin; Male; Medicare Part C; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2020 |
IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-1; Male; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; STAT3 Transcription Factor | 2020 |
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Proteomics; Tumor Microenvironment | 2020 |
Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Deoxycytidine; Endosonography; Female; Ferric Compounds; Gemcitabine; Iron; Mice, Inbred C57BL; Microbubbles; Oxides; Pancreatic Neoplasms; Tumor Burden; Ultrasonic Therapy; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Substitution; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Salvage Therapy | 2020 |
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphangiogenesis; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Survival Rate; Transforming Growth Factor beta1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms | 2020 |
CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoplasm; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Humans; Mice; Pancreatic Neoplasms; Prognosis; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53 | 2020 |
Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Nanogels; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; High-Throughput Screening Assays; Humans; Keratin-17; Mice, Inbred C57BL; Microtubules; Paclitaxel; Pancreatic Neoplasms; Podophyllotoxin; Tumor Burden | 2020 |
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Agents; Azepines; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Protein Domains; Proto-Oncogene Proteins c-fos; Transcription Factors; Triazoles | 2020 |
LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Male; Middle Aged; Oncostatin M Receptor beta Subunit; Pancreatic Neoplasms; Sp1 Transcription Factor; Transcriptome; Young Adult | 2020 |
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Infusions, Intralesional; Infusions, Intravenous; Male; Mice; Pancreas; Pancreatic Neoplasms; Pressure; Tissue Distribution | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Survival Rate; United Kingdom | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiography; Survival Rate; Treatment Outcome | 2020 |
Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Ultrasonic Therapy; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2020 |
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Knockout Techniques; Humans; Indoles; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Pancreatic Neoplasms; Pyridines; Pyrimidines; Quinolines; RNA, Small Interfering; Sulfonamides; Sulfoxides; Xenograft Model Antitumor Assays | 2020 |
Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Irinotecan; Liposomes; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols | 2020 |
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Momordica charantia; Neoplasm Invasiveness; Pancreatic Neoplasms; Plant Extracts; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Gemcitabine; Gene Expression; Gene Knockout Techniques; Humans; Letrozole; Leuprolide; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
[A Case of a Huge, Mixed-Type IPMC with Suspected Rupture of the Omental Bursa That Was Effectively Treated with Gemcitabine plus Nab-Paclitaxel].
Topics: Adenocarcinoma, Mucinous; Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Cavity; Positron Emission Tomography Computed Tomography | 2020 |
Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Pancreatic Neoplasms; Receptors, Cell Surface; Receptors, Death Domain; RNA, Small Interfering | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
Topics: Animals; Apolipoprotein A-II; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lipoproteins, HDL; Male; Mice; Nanoparticles; Pancreatic Neoplasms; Particle Size; Prodrugs; Scavenger Receptors, Class B; Xenograft Model Antitumor Assays | 2020 |
Mechanical Control of Cell Proliferation Increases Resistance to Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Stress, Mechanical | 2020 |
Precise and efficient silencing of mutant Kras
Topics: Amino Acid Substitution; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; CRISPR-Cas Systems; Deoxycytidine; Dependovirus; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Genetic Therapy; Genetic Vectors; Humans; Mice; Mutation; Pancreatic Neoplasms; Proof of Concept Study; Proto-Oncogene Proteins p21(ras); RNA, Guide, Kinetoplastida; Xenograft Model Antitumor Assays | 2020 |
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Reproducibility of Results; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Metabolomics; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Retinal Dehydrogenase | 2021 |
Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunomodulation; Mice; Niacinamide; Vitamin B Complex | 2020 |
The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphoproteins; Prognosis; RNA-Binding Proteins | 2021 |
ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Ribonuclease III; Signal Transduction; Sp1 Transcription Factor; Transcriptional Activation; Xenograft Model Antitumor Assays | 2021 |
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies; Transcriptome | 2021 |
Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Correlation of Data; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Frizzled Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Up-Regulation; Wnt Signaling Pathway; Wnt-5a Protein | 2021 |
Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitinase-3-Like Protein 1; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Fibronectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Macrophages; Pancreatic Neoplasms; Pentoxifylline; Proteomics; Pyridones; Survival Analysis; Up-Regulation | 2021 |
pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Topics: Acinar Cells; Adenocarcinoma; Animals; Antineoplastic Agents; Calcium; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Dedifferentiation; Cell Transformation, Neoplastic; Cells, Cultured; Ceruletide; Deoxycytidine; Disease Progression; Gemcitabine; GTP-Binding Proteins; Histone Deacetylase Inhibitors; Mice; Pancreatic Ducts; Pancreatic Neoplasms; Pancreatitis; Proto-Oncogene Proteins p21(ras); RGS Proteins; Signal Transduction | 2020 |
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Deoxycytidine; Drug Resistance, Neoplasm; Electron Transport Complex I; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mitochondria; Oxidative Phosphorylation; Pancreatic Neoplasms; PC-3 Cells; Phenformin; Xenograft Model Antitumor Assays | 2020 |
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Galactosyltransferases; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Neoplasm Recurrence, Local; Organoids; Transcription Factor RelA | 2021 |
Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microwaves; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2021 |
S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Coculture Techniques; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Targeting; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; S100 Proteins; Xenograft Model Antitumor Assays | 2021 |
STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Calcium Signaling; Carcinoma, Pancreatic Ductal; Cell Nucleus; Cell Proliferation; Cytosol; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Stromal Interaction Molecule 1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoconjugates; Male; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2021 |
MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Membrane Transport Proteins; Mice; Mucin-4; Neoplasm Transplantation; Pancreatic Neoplasms; Polysaccharides | 2021 |
Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Silencing; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; RNA-Binding Proteins; RNA, Small Interfering; Stromal Cells; Tumor Cells, Cultured | 2021 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD27 Ligand; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2021 |
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; S100 Proteins; Tissue Array Analysis; Up-Regulation | 2021 |
Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tegafur; Treatment Outcome | 2021 |
Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Expression Profiling; Humans; Laminin; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Laminin; Male; Middle Aged; Prognosis | 2021 |
H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aging; Animals; beta-Galactosidase; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Heterografts; Histones; Humans; Mice | 2021 |
TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Ferroptosis; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Signal Transduction; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2021 |
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Aggregation; Cell Division; Cell Movement; Cell Self Renewal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; GPI-Linked Proteins; Humans; Mesothelin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Organ Size; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Peritonitis | 2021 |
Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Karyotyping; Mutation; Octamer Transcription Factor-3; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Suppressor Protein p53 | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Staining and Labeling | 2021 |
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment | 2021 |
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report.
Topics: Abdominal Wall; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Proteins; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Programmed Cell Death 1 Receptor; Progression-Free Survival; Prospective Studies; T-Lymphocytes, Regulatory | 2021 |
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Assessment; Sialoglycoproteins | 2021 |
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Up-Regulation | 2021 |
In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms | 2021 |
Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Topics: Acetylcysteine; Adenocarcinoma; Apoptosis; Aspirin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Transcriptome | 2021 |
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nutrition Assessment; Nutrition Therapy; Nutritional Status; Oxonic Acid; Pancreatic Neoplasms; Phytotherapy; Polysaccharides; Shiitake Mushrooms; Tegafur; Treatment Outcome | 2021 |
Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.
Topics: Animals; Antimetabolites, Antineoplastic; Calcium; Calreticulin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoribonucleases; Gemcitabine; Gene Knockout Techniques; Gene Silencing; Heterografts; HSP47 Heat-Shock Proteins; Humans; Inositol 1,4,5-Trisphosphate Receptors; Mice; NADPH Oxidases; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Unfolded Protein Response | 2021 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peripheral Nerves; Retrospective Studies; Survival Rate; Tegafur | 2021 |
Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; Male; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Polyethylene Glycols; Rats | 2021 |
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferase, Cytoplasmic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Energy Metabolism; Enzyme Activation; Enzyme Activators; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sirtuins; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carcinoma, Pancreatic Ductal; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Gastrointestinal Microbiome; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
Topics: 5'-Nucleotidase; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Troglitazone; Xenograft Model Antitumor Assays | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Phenotype | 2021 |
T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Receptor, Transforming Growth Factor-beta Type I; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Allografts; Amino Acid Motifs; Animals; Apoptosis; B7-H1 Antigen; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Drug Synergism; Endocytosis; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunosuppression Therapy; Immunotherapy; Lysosomes; Mice; Microfilament Proteins; Molecular Targeted Therapy; NIMA-Interacting Peptidylprolyl Isomerase; Oncogenes; Organoids; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Survival Analysis; Toll-Like Receptor 2; Xenograft Model Antitumor Assays | 2021 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cholesterol; Clusterin; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Melitten; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; MicroRNAs; Pancreatic Neoplasms; Prognosis; RNA-Binding Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; NEDD8 Protein; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proto-Oncogene Proteins p21(ras); Translational Research, Biomedical | 2017 |
Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Retrospective Studies; Serum Albumin; Survival Rate; Time Factors | 2017 |
Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Calcium Compounds; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphorylation; Silicates; Xenograft Model Antitumor Assays | 2017 |
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Albumin-Bound Paclitaxel; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Time Factors; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Age Factors; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Preoperative Period; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2017 |
Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Interleukin-17; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Treatment Outcome | 2017 |
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fructose-Bisphosphatase; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; ras GTPase-Activating Proteins; Signal Transduction; Transfection | 2017 |
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD3 Complex; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Integrin beta4; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; T-Lymphocytes, Cytotoxic | 2017 |
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Damage; Fluorouracil; Gemcitabine; Gene Expression; Genomic Instability; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phthalazines; Piperazines | 2017 |
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gemcitabine; Humans; Lipids; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Heterografts; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.
Topics: Adenocarcinoma; Animals; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Hepatocyte Growth Factor; Humans; Imidazoles; Mice; Mice, Transgenic; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; Pyridines; Triazines; Tumor Microenvironment | 2017 |
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Gammaproteobacteria; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mycoplasma hyorhinis; Neoplasms, Experimental; Pancreatic Neoplasms | 2017 |
NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; I-kappa B Kinase; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Peptide Fragments; Peptides; Protein Domains; Random Allocation; Xenograft Model Antitumor Assays | 2017 |
Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression.
Topics: AC133 Antigen; Aged; Animals; Anoikis; Antimetabolites, Antineoplastic; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression; Gene Silencing; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Pancreatic Neoplasms; Phenotype; RNA, Messenger; Spheroids, Cellular; Transcription Factors; Vimentin | 2017 |
Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CCL5; Chemokine CXCL1; Chemotaxis, Leukocyte; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-12 Subunit p35; Interleukin-8; Interleukins; Macrophages; Mice, SCID; Microvessels; Minor Histocompatibility Antigens; Monocytes; Neovascularization, Pathologic; Pancreatic Neoplasms; Paracrine Communication; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anoctamins; Anti-Bacterial Agents; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Knockdown Techniques; HEK293 Cells; Humans; Male; Membrane Proteins; Mice; Middle Aged; Neoplasm Transplantation; Pancreatic Neoplasms; Phospholipid Transfer Proteins; Prognosis; RNA, Messenger; Survival Rate; Tumor Stem Cell Assay | 2017 |
Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2017 |
Development and
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; In Vitro Techniques; Liposomes; Mucin-4; Pancreatic Neoplasms; Tumor Cells, Cultured | 2017 |
Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase Inhibitors; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyaluronan Receptors; Limonins; Mitochondria; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; Time Factors; Tumor Suppressor Protein p53 | 2018 |
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation | 2018 |
Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells.
Topics: 3' Untranslated Regions; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Polyadenylation; Polyribosomes; Ribonucleoproteins; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; Tomography, X-Ray Computed | 2018 |
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Heterografts; Humans; Keratins; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Neuroendocrine Cells; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-myc; Synaptophysin | 2017 |
Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Perioperative Care; Prognosis; Survival Rate; Tumor Cells, Cultured | 2018 |
3D collagen fibrillar microstructure guides pancreatic cancer cell phenotype and serves as a critical design parameter for phenotypic models of EMT.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Collagen; Deoxycytidine; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Conformation; S Phase | 2017 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gas Chromatography-Mass Spectrometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lactic Acid; Male; Metabolomics; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2018 |
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Mice; Precision Medicine; Ribonucleotide Reductases; RNA, Small Interfering | 2018 |
The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Osteonectin; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2018 |
Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Biosynthetic Pathways; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Eflornithine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Pancreas; Pancreatic Neoplasms; Polyamines; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Thymidine Monophosphate; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2018 |
The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome; Tubulin | 2018 |
Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Fibrosis; Gemcitabine; Humans; Interleukin-1 Receptor-Associated Kinases; Interleukin-1beta; Mice; Mice, Knockout; NF-kappa B; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2018 |
[A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Peritoneal Neoplasms; Treatment Outcome | 2017 |
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Indoles; Lysine; Methylation; Pancreatic Neoplasms | 2018 |
Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Metabolomics; Mice; Mice, Nude; Microbiota; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Deoxycytidine; Enzyme Inhibitors; Esterification; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Sterol O-Acyltransferase | 2018 |
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2018 |
LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Up-Regulation | 2018 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyridones; Pyrimidinones | 2018 |
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Glycoproteins; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptors, Immunologic; RNA Interference; Transcription Factor AP-2; Xenograft Model Antitumor Assays | 2018 |
Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chick Embryo; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Simvastatin | 2018 |
[Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Weight Loss | 2018 |
Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.
Topics: Acinar Cells; Adenocarcinoma; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Silencing; Genetic Loci; Mice; Neoplastic Stem Cells; Rats; Transcription Factors | 2018 |
Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cell Line, Tumor; Datasets as Topic; Deoxycytidine; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins pp60(c-src); Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Transcriptome | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Risk Factors; Survival Rate; Tegafur | 2018 |
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Mice, Nude; Oxygen; Pancreatic Neoplasms; Prodrugs; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Topics: Animals; Bcl-2-Like Protein 11; Benzodiazepines; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |
Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2018 |
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Indoles; Mice; Morpholines; Pyrimidines; Sulfonamides; Sulfoxides | 2018 |
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Survival; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Indazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Piperazines; RNA, Long Noncoding | 2018 |
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Snail Family Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2018 |
miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-fyn; Signal Transduction; Time Factors | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Laparotomy; Leucovorin; Lymph Nodes; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2019 |
Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Transfer Techniques; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Pancreatic Neoplasms; rab27 GTP-Binding Proteins; Tumor Microenvironment; Up-Regulation | 2018 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Homeodomain Proteins; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Knockout; Mutation; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Trans-Activators; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2018 |
A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; MAP Kinase Signaling System; Methyltransferases; Pancreatic Neoplasms; Proto-Oncogene Proteins B-raf; Signal Transduction; Thioguanine; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Humans; Mice; Pancreas; Pancreatic Neoplasms | 2018 |
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA2 Protein; Humans; Mice; Mice, Knockout; Pancreatic Neoplasms; Prognosis; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured | 2018 |
Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Survival; Coculture Techniques; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Risk Factors; Sensitivity and Specificity; Stromal Cells; Tumor Cells, Cultured | 2018 |
Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.
Topics: AMP-Activated Protein Kinase Kinases; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Cytosol; Deoxycytidine; Deoxyglucose; Gemcitabine; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Mutation; Pancreatic Neoplasms; Protein Kinases; Protein Transport; Signal Transduction; Sirtuin 1; Tumor Suppressor Protein p53 | 2018 |
The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-E2-Related Factor 2; Pancreatic Ducts; Precancerous Conditions; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2019 |
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Nanoparticles; Pancreatic Neoplasms; Quercetin | 2019 |
Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Matrix Attachment Region Binding Proteins; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Neutralizing; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemokines; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Nude; Neutralization Tests; NF-kappa B; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Survival Analysis | 2018 |
The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.
Topics: Animals; Binding Sites; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Nuclear Proteins; Pancreatic Neoplasms; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Up-Regulation; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2019 |
Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Survival; Clonal Evolution; Deoxycytidine; Elafin; Gemcitabine; Glycolysis; Heterografts; Humans; Mice; Oncogene Protein v-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y2; RNA, Small Interfering; Sequence Analysis, RNA; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2019 |
Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Cell Survival; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Heat-Shock Proteins; Humans; Membrane Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Phosphorylation; Primary Cell Culture; Protein Domains; Signal Transduction; Unfolded Protein Response | 2019 |
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiotherapy; Reoperation; Retrospective Studies; Survival Rate | 2019 |
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreas; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; STAT3 Transcription Factor | 2019 |
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Topics: ADAM Proteins; Adenocarcinoma; Animals; Basement Membrane; Biocatalysis; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Lymphangiogenesis; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Signal Transduction | 2019 |
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Mice; Mice, Nude; Monensin; Pancreas; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Mice; Mice, Transgenic; Microscopy, Fluorescence; Models, Biological; Necrosis; Oxidative Stress; Pancreatic Neoplasms; Sonication; Spheroids, Cellular | 2018 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2019 |
Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Leptin; Male; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Up-Regulation | 2019 |
Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Interferon Type I; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Gels; Gemcitabine; Humans; Mice; Mice, Nude; Nanostructures; Pancreatic Neoplasms; Platinum; Polymers | 2019 |
PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA Repair; Epithelial-Mesenchymal Transition; Etoposide; Forkhead Box Protein M1; Gemcitabine; HEK293 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Mice; Mice, Knockout; Pancreas; Pancreatic Neoplasms; Protein Isoforms; Transcription, Genetic | 2019 |
Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
Topics: 5'-Nucleotidase; Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; Mice, Transgenic; Models, Biological; Pancreatic Neoplasms; Prognosis; Xenograft Model Antitumor Assays | 2019 |
SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding | 2019 |
STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gemcitabine; Humans; Interferon-gamma; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT1 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrimidines; RAW 264.7 Cells; Xenograft Model Antitumor Assays | 2019 |
Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Mice; p21-Activated Kinases; Pancreatic Neoplasms; Treatment Outcome; Tretinoin; Xenograft Model Antitumor Assays | 2019 |
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Monitoring; Female; Gemcitabine; Humans; Immunotherapy; Magnetic Resonance Imaging; Magnetite Nanoparticles; Maximum Tolerated Dose; Mice; Pancreas; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Tumor Microenvironment | 2019 |
Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
Topics: 14-3-3 Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Polarity; Cell Proliferation; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Macrophages; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2019 |
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Paclitaxel; Pancreatic Neoplasms; Peritoneal Dialysis; Tomography, X-Ray Computed | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2019 |
Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Fendiline; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Verteporfin; YAP-Signaling Proteins | 2019 |
Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor.
Topics: Antimetabolites, Antineoplastic; Cadherins; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Spheroids, Cellular; Tumor Microenvironment; Vimentin | 2019 |
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2019 |
Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Mice; Microtubules; Paclitaxel; Pancreatic Neoplasms; Protein Multimerization; Tubulin Modulators; Xenograft Model Antitumor Assays | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Hydrogen Peroxide; Mice; Mice, Nude; Pancreatic Neoplasms; Prodrugs; Reactive Oxygen Species; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Matrix; Fibronectins; Flavonoids; Gemcitabine; Humans; MAP Kinase Signaling System; Oligopeptides; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Proteome; Proto-Oncogene Proteins c-akt | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Carcinoma, Pancreatic Ductal; Class Ia Phosphatidylinositol 3-Kinase; Class Ib Phosphatidylinositol 3-Kinase; Deoxycytidine; Diet, High-Fat; Disease Models, Animal; Drug Resistance, Neoplasm; Fatty Acids, Omega-6; Female; Gemcitabine; Glucose; Humans; Lipid Metabolism; Liver; Male; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Pancreas; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Up-Regulation | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
DNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biosensing Techniques; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Hydrogen Peroxide; Irinotecan; Luminescence; Mice, SCID; Nanotubes, Carbon; Pancreatic Neoplasms; Spectrum Analysis, Raman; Xenograft Model Antitumor Assays | 2019 |
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interleukin-6; Leukemia Inhibitory Factor; Mice; Mutation; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2019 |
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2020 |
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptome | 2019 |
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Tumor Cells, Cultured; Valine; Xenograft Model Antitumor Assays | 2013 |
miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Transfection; Xenograft Model Antitumor Assays | 2013 |
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Receptor, Notch3; Receptors, Notch; Retrospective Studies; RNA, Messenger | 2013 |
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytokines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Random Allocation; RNA-Binding Proteins; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Survival Analysis; Treatment Outcome | 2013 |
Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Transfection; Xenograft Model Antitumor Assays | 2014 |
Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium Chloride; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Signal Transduction; Transcription Factors; Zinc Finger Protein GLI1 | 2013 |
Towards a tailored therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Precision Medicine; Receptors, CXCR4 | 2013 |
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Topics: Anilides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines; Signal Transduction; SOXB1 Transcription Factors; Stem Cells | 2013 |
Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Mitoxantrone; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Thiolester Hydrolases | 2013 |
Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Imidazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridazines; RNA, Small Interfering | 2013 |
miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Transcription Factors; Transfection | 2013 |
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Survival Rate; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Connective Tissue Growth Factor; Deoxycytidine; Gemcitabine; Liver Neoplasms; Mice; Pancreatic Neoplasms; Survival Analysis; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution | 2013 |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Nucleus; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Transcription Factor RelA; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1 | 2013 |
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; LIM-Homeodomain Proteins; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Side-Population Cells; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urokinase-Type Plasminogen Activator | 2013 |
Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Aspirin; Carcinoma, Pancreatic Ductal; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Forkhead Transcription Factors; Gemcitabine; Mice; Mice, Transgenic; Pancreatic Neoplasms; T-Lymphocytes, Regulatory | 2013 |
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays | 2013 |
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Crizotinib; Deoxycytidine; Female; Gemcitabine; Humans; Inactivation, Metabolic; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells.
Topics: 1-Methyl-3-isobutylxanthine; Amides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphodiesterase Inhibitors; Pyridines; Quinolones; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; rhoC GTP-Binding Protein; Vasodilator Agents | 2015 |
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gemcitabine; Glycoproteins; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Metalloproteases; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; RNA, Messenger; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells.
Topics: Aldehyde Dehydrogenase; Analysis of Variance; Animals; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disulfiram; Drug Delivery Systems; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction | 2013 |
Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperbaric Oxygenation; In Vitro Techniques; Pancreatic Neoplasms; Tumor Cells, Cultured | 2013 |
Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression; Glycoproteins; Humans; Immunophenotyping; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phenotype; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur; Tumor Microenvironment | 2014 |
MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Histones; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; ELAV Proteins; ELAV-Like Protein 1; Fluorouracil; Follow-Up Studies; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Protein Transport; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2014 |
CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Helicases; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Pancreatic Neoplasms; Proportional Hazards Models; Random Allocation; Survival Analysis; Xenograft Model Antitumor Assays | 2014 |
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Male; Middle Aged; Models, Statistical; Pancreatic Neoplasms; Platinum Compounds; Pulmonary Embolism; Retrospective Studies; Risk Assessment; Venous Thromboembolism; Venous Thrombosis | 2014 |
Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Communication; Cell Proliferation; Connexin 43; Deoxycytidine; Drug Resistance, Neoplasm; Gap Junctions; Gemcitabine; Humans; Immunoenzyme Techniques; Isothiocyanates; Microscopy, Electron; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering; Spheroids, Cellular; Sulfoxides; Tumor Cells, Cultured | 2014 |
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2014 |
Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Extracellular Matrix; Female; Gemcitabine; Glutathione; Humans; Hydrolysis; Lipid Bilayers; Lipopeptides; Matrix Metalloproteinase 9; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphatidylcholines; Polyethylene Glycols; Transport Vesicles | 2014 |
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Benzodiazepinones; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Checkpoint Kinase 1; Combined Modality Therapy; Deoxycytidine; DNA Damage; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Pyrazoles; Radioimmunotherapy; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Topics: Active Transport, Cell Nucleus; Animals; Antibiotics, Antineoplastic; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Smad4 Protein; Time Factors; Transfection; Up-Regulation | 2014 |
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Choline; Deoxycytidine; Diphosphates; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Genes, p53; Genes, ras; Homeodomain Proteins; Mice; Mice, Transgenic; NF-kappa B; Pancreatic Neoplasms; Pancreatitis, Chronic; Phosphorylation; STAT3 Transcription Factor; Systemic Inflammatory Response Syndrome; Trans-Activators; Treatment Outcome | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Diabetes Mellitus; Docetaxel; Fasting; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Paraneoplastic Syndromes; Retrospective Studies; Single-Blind Method; Taxoids; Treatment Outcome; Tumor Burden | 2014 |
Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Transgenic; Neoplastic Stem Cells; Nuclear Proteins; Pancreatic Neoplasms; Side-Population Cells; Transcription Factors | 2014 |
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Chick Embryo; Deoxycytidine; Female; Gemcitabine; Glucose; Glycolysis; Humans; Immunohistochemistry; Isoenzymes; L-Lactate Dehydrogenase; Mice, Inbred Strains; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyruvates; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Macrophage Colony-Stimulating Factor; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Random Allocation; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Cell Surface; Signal Transduction; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2014 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer.
Topics: Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mesoderm; MicroRNAs; Molecular Targeted Therapy; Neoplasm Proteins; Neuraminidase; Proto-Oncogene Proteins | 2014 |
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Disease Progression; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; RNA, Messenger; Survival Rate; Transcription Factor CHOP | 2014 |
A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Deoxycytidine; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Humans; Lysine; Mice; Pancreatic Neoplasms; Peptide Initiation Factors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridones; ras Proteins; RNA-Binding Proteins | 2014 |
Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Rabbits; Sensitivity and Specificity; Tissue Array Analysis | 2015 |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA, Small Interfering | 2015 |
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Regulation; Genetic Engineering; Herpesvirus 1, Human; Humans; Injections, Intralesional; Mice; Mice, Nude; Neoplasm Transplantation; Oncolytic Virotherapy; Pancreas; Pancreatic Neoplasms; Promoter Regions, Genetic; Trans-Activators; Tumor Burden; Viral Proteins | 2015 |
Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Splenic Artery; Splenic Vein | 2015 |
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Cyclin D1; Deoxycytidine; Disease Progression; Endothelial Cells; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lectins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; E2F1 Transcription Factor; Gemcitabine; Humans; Hydrolases; Mice, Nude; Pancreatic Neoplasms; Polyethylene Glycols; Ribonucleoside Diphosphate Reductase; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2014 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Matrix Metalloproteinase 13; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mucin-1; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2015 |
Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics | 2014 |
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weight; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate | 2015 |
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Indoles; Neoplasms, Experimental; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2015 |
Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutathione; Humans; Isothiocyanates; Mice; Mice, Inbred NOD; Mice, SCID; NF-E2-Related Factor 2; NF-kappa B; Oxidation-Reduction; Pancreatic Neoplasms; Reactive Oxygen Species; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; HMGB1 Protein; Hypoxia-Inducible Factor 1, alpha Subunit; Immunization; Mice, Inbred C57BL; Mice, Nude; Microscopy, Fluorescence; Mustard Compounds; Pancreatic Neoplasms; Phenylpropionates; Phosphorylation; Survival Analysis; T-Lymphocytes; Transcription Factors; Tumor Burden | 2015 |
Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Renal Insufficiency; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression; Genetic Variation; Hepatocyte Nuclear Factor 1-alpha; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomimetic Materials; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Saponins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; CD40 Antigens; Cell Line, Tumor; Combined Modality Therapy; CTLA-4 Antigen; Deoxycytidine; Female; Gemcitabine; Genetic Engineering; Humans; Immune Tolerance; Immunity, Cellular; Interferon-gamma; Lymphocyte Activation; Mice, Inbred C57BL; Pancreatic Neoplasms; T-Lymphocyte Subsets; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; CD47 Antigen; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Hybridomas; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Growth Processes; Deoxycytidine; Gemcitabine; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Xenograft Model Antitumor Assays | 2015 |
[Therapy in pancreatic cancer - and still it moves along!].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2015 |
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cells, Cultured; Deoxycytidine; Disease Models, Animal; Drug Resistance; Fibroblasts; Gemcitabine; Heterografts; Humans; Mice, Nude; Phosphoproteins; Somatostatin; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
p85α is a microRNA target and affects chemosensitivity in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2015 |
Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chick Embryo; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.
Topics: Animals; Carbon; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemoradiotherapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Heavy Ion Radiotherapy; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glycoproteins; Glycosylation; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polysaccharides; Prognosis; Retrospective Studies; Survival Analysis | 2015 |
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Topics: Activins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Self Renewal; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p57; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Nodal Protein; Pancreatic Neoplasms; RNA, Long Noncoding; Signal Transduction; T-Box Domain Proteins; Transcriptome; Transforming Growth Factor beta1 | 2015 |
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunohistochemistry; Immunotherapy; Macrophages; Mice; Pancreatic Neoplasms | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Lymphocyte Activation; MAP Kinase Signaling System; Monocytes; Myeloid Cells; NF-kappa B; Pancreatic Neoplasms; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2015 |
MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Gemcitabine; Genes, Tumor Suppressor; Humans; MicroRNAs; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Treatment Outcome | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane Permeability; Deoxycytidine; DNA Replication; Etoposide; Fluorouracil; Gemcitabine; Humans; Minichromosome Maintenance Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Treatment Outcome | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Specific Pathogen-Free Organisms; Warfarin; Xenograft Model Antitumor Assays | 2015 |
Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; I-kappa B Proteins; Male; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Pancreatic Neoplasms; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Pyruvate Kinase | 2016 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Collagen; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Molecular Targeted Therapy; Neoplasm Staging; Osteonectin; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; STAT3 Transcription Factor; Stromal Cells; Time Factors; Transcription Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Deoxycytidine; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Nestin; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2016 |
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2015 |
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biological Assay; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Genes, Reporter; Green Fluorescent Proteins; Humans; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; RGS Proteins | 2015 |
Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Melatonin; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Acetamides; Activating Transcription Factor 4; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cyclohexylamines; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice, Nude; Neoplasm Proteins; Oxidative Stress; Pancreatic Neoplasms; Protein Biosynthesis; Protein Phosphatase 1; Signal Transduction; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1alpha; Male; Mice; NF-kappa B; Pancreatic Neoplasms; Receptors, Interleukin-1; Xenograft Model Antitumor Assays | 2016 |
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Models, Biological; Mutation; Organoids; Pancreas; Pancreatic Neoplasms; Pluripotent Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; SOX9 Transcription Factor; Tissue Culture Techniques; Tumor Suppressor Protein p53 | 2015 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cluster Analysis; Computational Biology; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Genes, p53; Humans; MicroRNAs; Mutation; Pancreatic Neoplasms; Reproducibility of Results; RNA Interference; RNA, Messenger | 2015 |
EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Carriers; ErbB Receptors; Gemcitabine; Humans; Mice; Micelles; Pancreatic Neoplasms; Peptides; Polyesters; Polyethylene Glycols; Polymers | 2016 |
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Enzyme Activation; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Pancreatic Neoplasms; RNA Interference; RNA Processing, Post-Transcriptional; Transfection | 2015 |
HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice, Nude; Minor Histocompatibility Antigens; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphorylation; Random Allocation; Ribonucleosides; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2016 |
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Topics: Animals; Antigens, Surface; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2015 |
Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2015 |
MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; MicroRNAs; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Necrosis Factor alpha-Induced Protein 3 | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Hepatocyte Growth Factor; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2016 |
[A Case of Invasive Ductal Carcinoma in the Fat Replacement of the Pancreatic Body and Tail].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fats; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy | 2015 |
[The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Tegafur; Treatment Outcome | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Drug Combinations; Duodenum; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach; Tegafur | 2015 |
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; Time Factors; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2016 |
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sp Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2016 |
The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms | 2016 |
Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lumican; Mice; Microtubule-Associated Proteins; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heavy Ion Radiotherapy; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2016 |
Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Indoles; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases | 2016 |
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; S Phase; Thiophenes; Xenograft Model Antitumor Assays | 2016 |
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Autoantigens; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tumor Cells, Cultured | 2016 |
14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Phosphoproteins; Ribonucleotide Reductases; Transcription Factors; Transfection; Up-Regulation; YAP-Signaling Proteins | 2016 |
Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Immunohistochemistry; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Survival Analysis; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2016 |
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Situ Hybridization; Male; MicroRNAs; Middle Aged; Oligonucleotides; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2016 |
Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Conditioned; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inflammation; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2016 |
Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dodecanol; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Propane; Pyridines; Signal Transduction | 2016 |
Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, p53; Humans; Janus Kinase 2; Mice; Mutation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT3 Transcription Factor | 2016 |
Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Glaucarubin; Mice; Neoplasms, Experimental; Pancreatic Neoplasms | 2016 |
Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; bcl-X Protein; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Small Interfering; STAT5 Transcription Factor | 2016 |
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Immune Tolerance; Lectins, C-Type; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Necrosis; Pancreatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Up-Regulation | 2016 |
Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
Topics: Amino Acid Oxidoreductases; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Female; Fibrillar Collagens; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Tissue Distribution; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction | 2016 |
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; p21-Activated Kinases; Pancreatic Stellate Cells; Xenograft Model Antitumor Assays | 2016 |
Role of TFEB-driven autophagy regulation in pancreatic cancer treatment.
Topics: Animals; Apoptosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Lysosomes; Male; Mice; Proto-Oncogene Proteins p21(ras); RNA Interference | 2016 |
A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Mice; Mice, Knockout; MicroRNAs; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Receptors, Mineralocorticoid; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2016 |
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Topics: 3' Untranslated Regions; Acrylamides; Animals; Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Glycolysis; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; MicroRNAs; NAD; Nicotinamide Phosphoribosyltransferase; Pancreatic Neoplasms; Piperidines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hospitals, University; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Precision Medicine; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Tegafur | 2016 |
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Heterografts; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Retrospective Studies; Xenograft Model Antitumor Assays | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Tegafur; Treatment Outcome | 2017 |
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Receptors, Interleukin-8B; Signal Transduction; Small Molecule Libraries; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Isoforms; RNA, Small Interfering | 2016 |
Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Pancreatic Ductal; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Integrin beta1; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Cells, Cultured | 2016 |
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Topics: Albumins; Animals; Antibodies; Antigen-Presenting Cells; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Deoxycytidine; Gemcitabine; Immunity, Innate; Interferon-gamma; Lymphocyte Subsets; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2016 |
Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neuroendocrine Tumors; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Prognosis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Smoking; Stents; Young Adult | 2016 |
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Topics: Aminopyridines; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Fibrosis; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Immunotherapy; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Escape; Tumor Microenvironment | 2016 |
GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Kaplan-Meier Estimate; Male; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; PTEN Phosphohydrolase; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden | 2016 |
Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pancreatic Neoplasms | 2016 |
GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Topics: Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Binding; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53; Up-Regulation | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Invasiveness; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tissue Array Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period; Radiotherapy Dosage; Retrospective Studies; Tegafur | 2017 |
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Compassionate Use Trials; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Line, Tumor; Coculture Techniques; Cysteine-Rich Protein 61; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction; Statistics, Nonparametric; Survival Analysis; Transforming Growth Factor beta; Tumor Microenvironment | 2016 |
Survival variability of controls and definition of imaging endpoints for longitudinal follow-up of pancreatic ductal adenocarcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Follow-Up Studies; Gemcitabine; Longitudinal Studies; Male; Pancreatic Neoplasms; Rats, Inbred Lew; Survival Rate; X-Ray Microtomography | 2017 |
Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.
Topics: Autophagy; Autophagy-Related Proteins; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Membrane Proteins; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vesicular Transport Proteins | 2016 |
The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gemcitabine; Humans; Male; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Adhesion Molecules; Cell Cycle; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Intraoperative Care; Laparotomy; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Receptor, Notch1; Receptor, Notch3 | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Cytokines; Deoxycytidine; Disease Progression; Enzyme Activation; Enzyme Activators; Female; Fibrosis; Gemcitabine; Humans; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphorylation; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Complement Activation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Etanercept; Female; Gemcitabine; Humans; Infliximab; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proportional Hazards Models; Stromal Cells; Time Factors; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2016 |
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Connective Tissue Growth Factor; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Simvastatin; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Guanidines; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
Topics: Adenocarcinoma; Animals; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Models, Theoretical; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Transfection | 2017 |
MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Glycosylases; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Paclitaxel; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Hypoxia; Tumor Microenvironment; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Microbubbles; Pancreas; Pancreatic Neoplasms; Sonication; Ultrasonography | 2016 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires | 2016 |
MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Processing, Post-Transcriptional; RNA, Long Noncoding | 2017 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Topics: Acetylation; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 10; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
Topics: Aged; Apoptosis; Biopsy; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glucose Transporter Type 1; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphoproteins; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Messenger; Spheroids, Cellular; Tumor Cells, Cultured | 2017 |
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; p21-Activated Kinases; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Topics: 5'-Nucleotidase; Actins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Triphosphate; Deoxycytidine; Fibroblasts; Floxuridine; Gemcitabine; Humans; Liver; Liver Neoplasms; Mice; Pancreatic Neoplasms; Primary Cell Culture; Tumor Microenvironment | 2018 |
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells.
Topics: Activating Transcription Factor 4; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Gemcitabine; Glutathione Peroxidase; Heat-Shock Proteins; Humans; Lipid Peroxidation; Mice; Pancreatic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase | 2017 |
[Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; CD47 Antigen; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Gemcitabine; Humans; Magnetics; Magnetite Nanoparticles; Nanomedicine; Neoplastic Stem Cells; Pancreatic Neoplasms; Surface Properties; Tumor Cells, Cultured | 2017 |
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoplasmic Reticulum Stress; Female; Gemcitabine; Genes, myc; Genes, ras; Humans; Male; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mesoderm; Mice; Mosaicism; Oncogene Protein p55(v-myc); Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); SMARCB1 Protein; Transcriptome | 2017 |
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Microdissection; MicroRNAs; Pancreatic Neoplasms; Prognosis; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tumor Cells, Cultured; Up-Regulation | 2017 |
Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Mucin-4; Pancreas; Pancreatic Neoplasms; Survival Analysis; Sweden | 2017 |
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.
Topics: Adenocarcinoma; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Chickens; Chorioallantoic Membrane; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Drug Evaluation, Preclinical; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 6; Luminescent Measurements; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Sequence Analysis, DNA; SOX9 Transcription Factor; Tumor Cells, Cultured | 2017 |
Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Agents; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Meta-Analysis as Topic; Mucin-1; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Rate | 2008 |
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
Topics: Animals; Apoptosis; Azacitidine; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Nucleus; Coculture Techniques; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Etoposide; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; STAT1 Transcription Factor; Transfection | 2008 |
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2008 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gemcitabine; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Vaccines, Subunit | 2009 |
Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome | 2008 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Analysis | 2009 |
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Humans; Logistic Models; Male; Mass Spectrometry; Middle Aged; Neutropenia; Pancreatic Neoplasms; Phenotype; Thrombocytopenia | 2009 |
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Stromal Cells; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2009 |
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inactivation, Metabolic; Pancreatic Neoplasms; RNA-Binding Proteins; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2009 |
Cancer. Breaching the cancer fortress.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Fibroblasts; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Stromal Cells | 2009 |
[The inhibition of the Sonic Hedgehog (SHh) pathway improves the effects of chemotherapy in a model of ductal carcinoma of the pancreas in mice].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Hedgehog Proteins; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Veratrum Alkaloids | 2009 |
Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, Notch3; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction | 2010 |
HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prodrugs; RNA-Binding Proteins; Treatment Outcome | 2009 |
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Resveratrol; Stilbenes; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Treatment Outcome | 2010 |
EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Immunoenzyme Techniques; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; RNA-Binding Proteins; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Calibration; Carcinoma, Pancreatic Ductal; Deoxycytidine; Early Detection of Cancer; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2010 |
Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Topics: Aged; Algorithms; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Retrospective Studies; Survival Rate | 2010 |
Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Pneumonia; Radiography | 2010 |
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Biomimetic Materials; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Mice, Transgenic; Mitochondrial Proteins; Pancreatic Neoplasms; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; X-Linked Inhibitor of Apoptosis Protein | 2010 |
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-13; Interleukin-13 Receptor alpha2 Subunit; Mice; Mice, Nude; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cells, Cultured; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Survival Rate; Xenograft Model Antitumor Assays | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Neoplasm, Residual; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Pennsylvania; Polycomb Repressive Complex 2; Survival Rate; Transcription Factors | 2010 |
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2010 |
Finding the tumor copycat: approximating a human cancer.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Division; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Neoplasms | 2010 |
Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Homeodomain Proteins; Humans; Male; Pancreas; Pancreatic Neoplasms; Prognosis; RNA Interference | 2010 |
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Citrates; Deoxycytidine; Energy Metabolism; Female; Gemcitabine; Humans; Methotrexate; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Pancreatic Neoplasms; Thioctic Acid; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Collagen Type I; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Matrix; Gemcitabine; HMGA2 Protein; Humans; Matrix Metalloproteinase 14; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Messenger; Survival Analysis; Up-Regulation | 2011 |
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms | 2011 |
How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple liver and bone metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2011 |
Multidisciplinary approach and multimodal therapy in resected pancreatic cancer. Observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Colectomy; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Care Team; Prospective Studies; Stents; Survival Rate | 2011 |
MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2011 |
Metachronous multiple adenocarcinomas of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gastrectomy; Gemcitabine; Hepatitis C; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pancreatic Neoplasms | 2011 |
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; DNA Damage; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Uric Acid; Xanthine Dehydrogenase | 2011 |
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2011 |
Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Topics: AC133 Antigen; Antigens, CD; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Hyaluronan Receptors; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins; Pancreatic Neoplasms; Patched Receptors; Peptides; Receptors, Cell Surface; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Smoothened Receptor; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2011 |
Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Midkine; Pancreatic Neoplasms; Receptor, Notch2; RNA Interference; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2011 |
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Smad4 Protein; Transplantation, Heterologous; Treatment Outcome | 2011 |
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Heat-Shock Proteins; Heat-Shock Response; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Chaperones; Multivariate Analysis; Pancreas; Prognosis; Tissue Array Analysis | 2012 |
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Inhibitors; Female; Fibroblasts; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinolines; RNA-Binding Proteins; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases | 2012 |
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Cytokines; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Macrophages; Pancreatic Neoplasms; Phagocytosis; Phenylbutyrates | 2012 |
Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karyotype; Mice; Mice, SCID; Microsatellite Repeats; Neoplastic Stem Cells; Pancreatic Neoplasms; Transplantation, Heterologous | 2012 |
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Metformin; Pancreatic Neoplasms; Receptor, IGF Type 1; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2012 |
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinolines; Quinuclidines; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Gemcitabine; Humans; Hypoxia; Mice; Mice, Mutant Strains; Necrosis; Pancreatic Neoplasms; Protease Inhibitors; Receptors, Notch; Signal Transduction; Thiadiazoles; Translational Research, Biomedical | 2012 |
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Dipeptidases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; GPI-Linked Proteins; Humans; Male; MAP Kinase Signaling System; Maryland; Microtubule-Associated Proteins; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Reproducibility of Results; Treatment Outcome | 2012 |
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2012 |
Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2012 |
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Tumor Suppressor Proteins | 2012 |
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Drug Evaluation, Preclinical; Extracellular Fluid; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Microvessels; Pancreatic Neoplasms; Polyethylene Glycols; Stromal Cells; Tumor Microenvironment | 2012 |
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Pancreatic Neoplasms; Recombinant Proteins; Tissue Array Analysis; Treatment Outcome | 2013 |
Drug interactions: the importance of looking inside cancer cells.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Paclitaxel; Pancreatic Neoplasms | 2012 |
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2012 |
A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Fluorouracil; Gemcitabine; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Tumor Burden; Tumor Suppressor Protein p53 | 2012 |
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Topics: AC133 Antigen; Adenosine; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; Spheroids, Cellular; Tumor Cells, Cultured | 2012 |
High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemokine CX3CL1; Chemotherapy, Adjuvant; CX3C Chemokine Receptor 1; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Receptors, Chemokine; Retrospective Studies; Survival Analysis; Tissue Array Analysis; Up-Regulation | 2012 |
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Ohio; Pancreatectomy; Pancreatic Neoplasms; Paraffin Embedding; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Assessment; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome | 2012 |
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Biotransformation; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; France; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Multivariate Analysis; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Assessment; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Kaplan-Meier Estimate; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; RNA Splicing; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Signal Transduction | 2013 |
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Macrophage Migration-Inhibitory Factors; Male; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA Interference; Transplantation, Heterologous | 2013 |
Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pharmacogenetics | 2012 |
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2013 |
Cavitary pulmonary metastases of pancreas cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms | 2013 |
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Male; Mice; Mice, SCID; Middle Aged; Pancreatic Neoplasms; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lactoferrin; Neoplasm Proteins; Pancreatic Neoplasms; Proteomics; S100 Proteins; Transferrin | 2012 |
Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatography, Liquid; Crizotinib; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mass Spectrometry; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2013 |
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Progress in pancreatic cancer: moving beyond gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Pyrazoles; Random Allocation; Receptor, IGF Type 1; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2012 |
Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Lipocalins; Mice; Pancreatic Neoplasms | 2012 |
Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nicotine; Pancreatic Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Alleles; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Glycoproteins; GPI-Linked Proteins; Humans; Isoenzymes; Keratins; Male; Mesothelin; Mice; Middle Aged; Mutation; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Polyploidy; Retinal Dehydrogenase; Transplantation, Heterologous; Tumor Microenvironment | 2012 |
MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Kruppel-Like Transcription Factors; MAP Kinase Kinase Kinases; Nuclear Proteins; Pancreatic Neoplasms; Transcription Factors; Up-Regulation; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2013 |
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histone Acetyltransferases; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Origin Recognition Complex; Pancreatic Neoplasms; Phosphorylation; Polo-Like Kinase 1; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Pteridines; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2013 |
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Lymphocyte Count; Mice; Neoplasms, Experimental; Pancreatic Neoplasms; Survival Analysis; T-Lymphocytes, Regulatory | 2013 |
Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2013 |
Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Tracking; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Luciferases, Firefly; Mice; Pancreatic Neoplasms; Plasma Gases; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2012 |
ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.
Topics: ADAM Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Protein Structure, Tertiary; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2013 |
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gemcitabine; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2013 |
The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; MicroRNAs; Pancreatic Neoplasms; Proteome; Proteomics; Xenograft Model Antitumor Assays | 2013 |
[A case of liver metastasis of pancreatic duct carcinoma successfully treated with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quality of Life | 2003 |
[Pancreatic cancer--diagnostics and therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Neoadjuvant Therapy; Pancreatic Neoplasms | 2003 |
Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; gamma-Linolenic Acid; Gemcitabine; Pancreatic Neoplasms | 2003 |
Unusual liver abscess.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Abscess; Liver Neoplasms; Male; Pancreatic Neoplasms; Seminoma; Testicular Neoplasms; Tomography, X-Ray Computed | 2005 |
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinases; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2006 |
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; RNA Splicing; RNA, Messenger; RNA, Small Interfering; Transfection | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Survival Rate | 2006 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Time Factors | 2006 |
[Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Disease Progression; fas Receptor; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Remission Induction | 2006 |
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt | 2006 |
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; GTP-Binding Proteins; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Transglutaminases | 2006 |
[Pancreatic cancer].
Topics: Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Palliative Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Smad4 Protein; Tomography, X-Ray Computed; Tumor Suppressor Protein p53 | 2006 |
Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Lentivirus; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference | 2006 |
Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
Topics: Animals; Annexin A5; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2006 |
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
Topics: Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 8; Cell Communication; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gap Junctions; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Phenylbutyrates; Time Factors; Tumor Cells, Cultured | 2007 |
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Calcimycin; Calcium Channels; Carcinoma, Pancreatic Ductal; Cell Death; Cell Differentiation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Ionophores; Models, Biological; Pancreatic Neoplasms; Protein Glutamine gamma Glutamyltransferase 2; Transglutaminases; Tumor Cells, Cultured | 2007 |
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Deoxycytidine; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; p21-Activated Kinases; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Thyroid Hormone; Triiodothyronine | 2007 |
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2007 |
Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Wortmannin; Xenograft Model Antitumor Assays | 2007 |
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Green Fluorescent Proteins; Humans; Interleukin-4; Leukocidins; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Interleukin-4; Recombinant Fusion Proteins; Transfection; Xenograft Model Antitumor Assays | 2007 |
Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; fas Receptor; Gemcitabine; Humans; Indoles; Lymphatic Metastasis; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Phloroglucinol; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Gemcitabine resistance in pancreatic cancer: picking the key players.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms | 2008 |
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; HMGA1a Protein; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Tumor Cells, Cultured | 2008 |
Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Time Factors; Ultrasonography, Interventional | 2008 |
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lasers; Male; Microdissection; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Messenger; Tetrazolium Salts; Thiazoles | 2008 |